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  The	  sphingosine	  1-­‐phosphate	  receptor	  modulator	   fingolimod	  /	  Gilenya	  /	  FTY720	  has	   become	   an	   effective	   and	   commercially	   available	   therapeutic	   agent	   for	   the	  treatment	  of	  relapsing-­‐remitting	  multiple	  sclerosis.	  Fingolimod	  is	  phosphorylated	  by	   sphingosine	   kinase	   in	   vivo	   to	   the	   pharmacologically	   active	   S-­‐fingolimod	  phosphate.	   The	   original	   aim	   of	   the	   work	   was	   to	   synthesise	   novel	   phosphate	  delivery	   prodrug	   analogues	   of	   fingolimod	   and	   determine	   whether	   or	   not	   these	  novel	   analogues	   could	   provide	   an	   improved	   therapeutic	   profile.	   The	   principal	  phosphate	   delivery	   prodrug	   method	   to	   be	   investigated	   was	   phosphoramidate	  “ProTide”	  chemistry.	  	  ProTide	   fingolimod	   analogues	   were	   found	   to	   have	   a	   poor	   level	   of	   stability	   and	  readily	  degrade	   to	  unwanted	   cyclised	   structures	   at	   room	   temperature	  and	  when	  exposed	   to	   very	   mildly	   basic	   conditions.	   In	   order	   to	   mitigate	   the	   poor	   stability	  issues	  it	  was	  considered	  possible	  that	  forming	  ProTide	  analogues	  of	  mono-­‐alcohol	  S1P	   receptor	   modulators,	   as	   opposed	   to	   diol	   fingolimod,	   would	   lead	   to	   greater	  stability.	   The	   synthesis	   of	   mono-­‐alcohol	   S1P	   receptor	   modulator	   benzyl	   ether	  derivative	   analogues	   published	   by	   Tsuji	   et	   al	   was	   attempted	   and	   successfully	  achieved.	  	  Previously	   reported	   ProTide	   synthesis	   and	   in	   vitro	   testing	   methods	   were	  employed.	   Carboxypeptidase,	   human	   serum,	   base	   stability,	   acid	   stability	   and	   cell	  lysate	   processing	   experiments	   were	   conducted	   in	   the	   School	   of	   Pharmacy.	  Homology	  modelling	  was	  employed	  to	  determine	  S1P1	  selectivity	  of	  benzyl	  ether	  derivative	  analogues	  and	  novel	  structures.	  	  ProTide	  benzyl	  ether	  derivative	  analogues	  were	  found	  to	  have	  a	  far	  greater	  level	  of	  stability	   than	   ProTide	   fingolimod	   analogues	   and	   in	   vitro	   processing	   experiments	  showed	   that	   they	   are	   processed	   to	   the	   desired	   pharmacologically	   active	  monophosphate.	  The	  research	  signifies	  the	  development	  of	  an	  entirely	  new	  family	  of	  potential	  therapeutic	  agents.	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  UV	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Chapter	  1	  -­	  Introduction	  
	  
1.1	  Neurodegenerative	  Disease	  and	  Multiple	  Sclerosis	  
	  
1.1.1	  The	  Nervous	  System	  
	  The	  nervous	   system	   is	   the	  part	  of	   an	  animal’s	  body	   responsible	   for	   coordinating	  voluntary	  and	  involuntary	  actions	  and	  transmitting	  signals	  from	  one	  region	  of	  the	  body	  to	  another.	  The	  nervous	  system	  is	  comprised	  of	  the	  sensory	  organs,	  nervous	  tissue,	   spinal	   cord	   and	   the	   brain.	   In	   the	  majority	   of	   animal	   species	   the	   nervous	  system	  is	  subdivided	  into	  two	  further	  systems:	  the	  central	  nervous	  system	  (CNS)	  and	  the	  peripheral	  nervous	  system	  (PNS).	  The	  CNS	  consists	  of	  the	  brain	  and	  spinal	  cord	  whereas	  the	  PNS	  consists	  predominantly	  of	  nerves.1	  
	  1.1.1.1	  The	  Central	  Nervous	  System	  
	  The	  central	  nervous	  system	  (CNS)	  is	  comprised	  of	  the	  brain	  and	  spinal	  cord	  and	  is	  responsible	  for	  processing	  information,	  regulation	  of	  systems,	  performing	  actions	  and	  storing	  memories.	  The	  CNS	  contains	  both	  white	  matter	  and	  grey	  matter.	  White	  matter	   consists	   predominantly	   of	   myelinated	   axons	   and	   grey	   matter	   consists	  mainly	  of	  neuronal	   cell	   bodies.1	  Both	  white	  matter	   and	  grey	  matter	   contain	   glial	  cells,	   often	   referred	   to	   as	   supporting	   cells,	   which	   serve	   a	   variety	   of	   different	  functions	   including	   providing	   scaffold	   support	   for	   neurogenesis	   (generation	   of	  neurons	  from	  neural	  stem	  cells)	  and	  immunoregulation.2	  	  	  Axons	  are	  specialised	  projections	  from	  neurons	  (nerve	  cells).	  Their	   function	  is	  to	  conduct	   electrical	   impulses,	   also	   known	   as	   action	   potentials,	   from	   the	   neuron’s	  larger	   cell	   body	   to	   other	   neurons,	  muscles	   and	   glands.1	   Oligodendrocytes	   act	   to	  support	  and	  insulate	  axons	  by	  producing	  the	  electrically	  insulating	  myelin	  sheath	  thus	  enabling	  electrical	  conduction	  of	   the	  action	  potential	  along	  the	   length	  of	   the	  axon.	  3	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Figure	  1.1	  Neuron	  (Image:	  public	  domain.	  Produced	  by	  Mariana	  Ruiz	  Villarreal)	  	  	  
	  
Figure	  1.2	  Neuron	  with	  oligodendrocyte	  and	  myelin	   sheath	   (Image:	  public	  domain.	  Produced	  by	  Mariana	  Ruiz	  Villarreal)	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The	  human	  brain	  performs	  an	  enormous	  range	  of	  functions	  and	  has	  the	  capacity	  to	  consciously	   and	   unconsciously	   process	   information	   received	   from	   the	   PNS	   and	  take	  actions	  to	  ensure	  the	  continued	  survival	  of	  the	  organism.	  The	  brain	  is	  located	  in	  the	  head	  close	  to	  primary	  sensory	  organs	  responsible	  for	  vision	  (the	  eyes),	  taste	  (the	   tongue),	   smell	   (the	   nose),	   equilibrioception	   (the	   vestibular	   system)	   and	  hearing	  (the	  ears).1	  The	  brain	  is	  believed	  to	  be	  the	  organ	  of	  the	  body	  responsible	  for	   consciousness	   and	   the	   development	   of	   personality	   and	   character.	   It	   is	  considered	   to	   essentially	   define	   what	   makes	   a	   person	   who	   they	   are	   and	   any	  damage	  to	  the	  brain	  can	  cause	  considerable	  changes	  in	  character	  and	  personality.4	  	  
	  	  
Figure	  1.3	  Simplified	  model	  of	  the	  brain.	  Different	  regions	  of	  the	  brain	  and	  their	  functions	  (Image:	  Arizona	  State	  University	  School	  of	  Life	  Sciences	  website)	  	  1.1.1.2	  The	  Peripheral	  Nervous	  System	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1.1.1.3	  Neurodegenerative	  Disease	  
	  Neurodegenerative	  diseases	  are	  illnesses	  in	  which	  neurodegeneration	  is	  observed	  to	  occur.	  Neurodegeneration	  can	  be	  defined	  as	  the	  progressive	  loss	  of	  function	  and	  structure	   of	   neurons	   (nerve	   cells)	   and	   includes	   the	   death	   of	   neurons.	   Three	   of	  arguably	   the	   most	   well-­‐known	   neurodegenerative	   diseases	   include	   Alzheimer’s	  disease	   (the	   most	   common	   form	   of	   dementia),	   Parkinson’s	   disease	   and	  Huntington’s	  disease.5	  	  	   	  
1.1.2	  The	  Immune	  System	  
	  Organisms	  have	  their	  own	  systems	  to	  try	  to	  defend	  against	  infection	  and	  disease.	  In	  animals,	  such	  as	  humans,	  this	  system	  of	  defence	  is	  known	  as	  the	  immune	  system	  and	   is	   comprised	   of	   a	   complex	   network	   of	   defence	   mechanisms	   that	   work	   in	   a	  variety	  of	  ways.	  Unicellular	  organisms	  such	  as	  bacteria	  have	  their	  own	  versions	  of	  the	  immune	  system	  that	  typically	  include	  enzymes	  which	  protect	  against	  infection	  from	   viruses	   known	   as	   bacteriophages.	   In	   this	   document	   the	   human	   immune	  system	  will	  be	  the	  focus	  as	  it	  is	  relevant	  to	  the	  research	  described.	  	  In	   humans	   the	   immune	   system	   can	   be	   described	   as	   being	   comprised	   of	   two	  subsystems:	  the	  innate	  immune	  system	  (also	  found	  in	  all	  animals	  and	  plants)	  and	  the	  adaptive	  immune	  system	  (found	  in	  all	  jawed	  vertebrates).6,7	  
	  1.1.2.1	  Innate	  Immune	  System	  	  The	  innate	  immune	  system	  is	  an	  organism’s	  first	  line	  of	  defence	  and	  is	  different	  to	  the	   adaptive	   immune	   system	   in	   that	   the	   innate	   immune	   system	   doesn’t	   change	  with	  time	  and	  exposure	  to	  different	  pathogens.	  The	  innate	  immune	  system	  is	  non-­‐specific	  and	  consists	  of	  a	  variety	  of	  defensive	  measures	  including:	  	  
• Physical	  barriers	  such	  as	  the	  skin	  
• Enzymatic	  defence	  mechanisms	  such	  as	  antimicrobial	  lysozyme	  
• Anatomical	  traps	  such	  as	  the	  nasal	  cavity	  
• Mechanical	  cleansing	  mechanisms	  such	  as	  cilia	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• Phagocytes	  which	  ingest	  foreign	  entities	  such	  as	  bacteria	  and	  particles	  
• Reflexes	  such	  as	  coughing	  and	  sneezing6	  	  1.1.2.2	  Adaptive	  Immune	  System	  	  The	  adaptive	   immune	  system	   is	  also	  known	  as	   the	  acquired	   immune	  system	  and	  consists	  of	  specialised	  cells	  that	  destroy	  invading	  pathogens.	  The	  specialised	  cells	  of	   the	   adaptive	   immune	   system	   are	   known	   as	   lymphocytes	   and	   are	   a	   subset	   of	  leukocytes	  (white	  blood	  cells).	  The	  two	  major	  types	  of	  lymphocyte	  are	  known	  as	  B	  cells	  and	  T	  cells.	  Lymphocytes	  are	  located	  predominantly	  in	  the	  tissues	  and	  in	  the	  lymphatic	  system	  but	  also	  to	  a	  lesser	  extent	  in	  the	  circulatory	  system.6,7	  	  	  
	  	  
Figure	   1.4	   Scanning	   electron	   micrograph	   of	   a	   human	   T	   cell	   (Image	   courtesy	   of	   the	   National	  Institute	  of	  Allergy	  and	  Infectious	  Diseases)	  	  The	   adaptive	   immune	   system	   begins	   to	   target	   a	   pathogen	   if	   the	   pathogen	   has	  successfully	  evaded	  the	  innate	  immune	  system.	  The	  adaptive	  immune	  system	  will	  begin	   the	   process	   of	   neutralising	   the	   threat	   to	   the	   organism	   if	   the	   pathogen	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overcomes	   a	   threshold	   of	   accepted	   antigen	   concentration	   and	   activates	   antigen-­‐presenting	  dendritic	  cells.6,7	  	  	  The	   process	   of	   acquired	   immunity	   includes:	   the	   recognition	   of	   non-­‐self	   antigens	  during	   the	  dendritic	  process	  of	   antigen	  presentation,	   the	  generation	  of	   a	   specific	  response	   that	  has	  been	  adapted	  to	   the	  specific	  pathogen	  and	  the	  development	  of	  immunological	  memory.	  Immunological	  memory	  is	  the	  process	  of	  antibodies	  (also	  known	   as	   immunoglobulins)	   and	   memory	   cells	   developing	   ways	   to	   recognise	   a	  specific	  foreign	  antigen	  and	  then	  inducing	  an	  antigen-­‐specific	  response	  whenever	  the	  antigen	  is	  detected	  again.	  6,7	  	  The	  adaptive	  immune	  response	  predominantly	  takes	  place	  in	  the	  lymphoid	  tissues	  of	   the	   spleen,	   lymph	   nodes	   and	   bone	  marrow.	   Antibodies	   are	   produced	   in	   all	   of	  these	   tissues	   although	   the	   rate	   of	   antibody	   production	   is	   greater	   in	   the	   lymph	  nodes	  and	  spleen.	  The	  overall	  mass	  of	  antibody	  production	  is,	  however,	  greater	  in	  the	  bone	  marrow	  due	  to	  the	  comparatively	  greater	  mass	  of	  this	  tissue	  within	  the	  body.	  The	  lymph	  nodes,	  bone	  marrow,	  spleen	  and	  other	  lymphatic	  tissues	  that	  are	  involved	   in	   antibody	   production	   are	   collectively	   known	   as	   a	   vascular	   filtration	  system.6,7	  	  1.1.2.3	  Autoimmune	  Disease	  
	  Autoimmune	  diseases	  are	  caused	  by	  an	  abnormal	  immune	  response	  of	  the	  body	  to	  regions	  of	  the	  body	  normally	  present	  in	  a	  healthy	  organism.	  Autoimmune	  diseases	  occur	  when	   the	  body’s	  own	   immune	  system	  doesn’t	   recognise	   certain	   regions	  as	  native	   to	   the	   body	   and	   the	   immune	   system	   attacks	   these	   regions	   in	   the	   body	   it	  usually	   works	   to	   protect.	   Two	   of	   the	   more	   well	   known	   autoimmune	   disorders	  include	  rheumatoid	  arthritis	  and	  type	  I	  diabetes.8	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1.1.3	  Multiple	  Sclerosis	  
	  
“…the	   chief	   curse	  of	   the	   illness…	   I	  must	  ask	   constant	   services	   of	   people	   I	   love	  most	  
closely…	   it	   is	   an	   illness	   accompanied	   by	   frustration…	   it	   is	   an	   illness	   that	   inflicts	  
awareness	  of	  loss…	  sporadically	  it	  is,	  in	  its	  manifestations,	  a	  disgusting	  disease.”	  	  
-­	  Brigid	  Antonia	  Brophy	  (1929-­‐95)	  novelist	  and	  MS	  sufferer9	  	  Multiple	  sclerosis	  can	  reasonably	  be	  defined	  as	  both	  an	  autoimmune	  disease	  and	  a	  neurodegenerative	   disease.	   In	   the	   case	   of	  multiple	   sclerosis	   the	   immune	   system	  attacks	   the	   central	   nervous	   system	   causing	  myelin	   sheaths	   to	   become	   damaged	  and	  thus	  negatively	  impact	  nervous	  transmission.	  This	  neurodegeneration	  leads	  to	  varying	   severities	   of	   symptoms	   that	   can	   include	   but	   are	   not	   limited	   to:	   pain,	  fatigue,	   temperature	   sensitivity,	   constipation,	   erectile	   dysfunction,	   bladder	  dysfunction,	   stiffness,	   spasms,	  weakness,	   impaired	   speech,	   impaired	   swallowing,	  vertigo	  (dizziness),	  clumsiness,	  poor	  balance,	  tremor,	  loss	  of	  vision,	  depression	  and	  cognitive	  impairment.9,10	  	  
	  	  
Figure	  1.5	  The	  geography	  of	  MS:	  prevalence	  per	  100,000	  of	  the	  population11	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Figure	  1.6	  Multiple	  sclerosis	  sufferer	  Debbie	  Purdy	  outside	  the	  Royal	  Courts	  of	  Justice	  in	  London,	  UK.	  Debbie	  Purdy	  has	  campaigned	  to	  find	  out	  if	  her	  husband	  would	  be	  prosecuted	  if	  he	  were	  to	  help	  her	  to	  travel	  abroad	  to	  commit	  suicide.	  	  Multiple	   sclerosis	   is	   estimated	   to	   affect	   approximately	   2.5	   million	   people	  worldwide9	   and	   predominantly	   affects	   Caucasians	   in	   the	   developed	   world.	  Multiple	  sclerosis	  is	  approximately	  twice	  as	  common	  in	  women	  as	  in	  men11	  and	  in	  fact	  more	  recent	  data	  show	  proportionately	  more	  females	  are	  developing	  MS	  than	  men	  than	  was	  observed	  in	  earlier	  periods.12	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The	  disease	  appears	  to	  be	  caused	  by	  a	  variety	  of	  contributory	  environmental	  and	  genetic	  factors	  and	  follows	  four	  accepted	  clinical	  courses:	  	   1. Relapsing	  remitting	  2. Secondary	  progressive	  3. Primary	  progressive	  4. Progressive	  relapsing	  	  Relapsing	   remitting	  multiple	   sclerosis	   (RRMS)	   is	   the	  most	   common	   form	   of	   the	  disease	  and	  is	  observed	  in	  around	  85%	  of	  MS	  sufferers.11	  Relapsing	  remitting	  MS	  is	  characterised	   by	   attacks	   of	   neurological	   symptoms	   that	   are	   then	   followed	   by	  complete	   or	   incomplete	   recovery.	   These	   relapsing	   remitting	   symptoms	   typically	  last	  between	  a	  few	  days	  to	  several	  months	  and	  are	  experienced	  between	  phases	  of	  stable	   neurological	   condition	   without	   significant	   symptoms	   characteristic	   of	   the	  disease.	   Approximately	   10	   -­‐	   15%	   of	   MS	   sufferers	   exhibit	   symptoms	   of	   primary	  progressive	   multiple	   sclerosis	   (PPMS).	   PPMS	   is	   characterised	   by	   a	   progressive	  increase	  of	  neurological	  disability.	  A	  small	  number	  of	  patients	  exhibit	  symptoms	  of	  progressive	   relapsing	   multiple	   sclerosis	   (PRMS)	   and	   this	   disease	   course	   is	  characterised	  by	  superimposed	  relapses.	  After	  a	  number	  of	  years	  of	  RRMS	  many	  patients	   progress	   to	   secondary	   progressive	   multiple	   sclerosis	   (SPMS)	   and	   this	  clinical	  course	  features	  progressively	  accumulated	  neurological	  disability	  between	  or	  without	  additional	  relapses.11	  	  Multiple	  sclerosis	  is	  an	  inflammatory	  disease	  of	  the	  spinal	  cord	  and	  brain	  in	  which	  lymphocytes	   infiltrate	   the	   central	   nervous	   system	   and	   damage	   neuronal	   myelin	  sheaths	  and	  axons.	  The	  name	  multiple	  sclerosis	  refers	  to	  the	  scars	  (the	  sclerae)	  or	  lesions	   that	   are	   typically	   observed	   in	   regions	   of	   the	   central	   nervous	   system	   that	  are	   characteristic	   of	   the	   disease.	   It	   is	   widely	   held	   that	   these	   scars	   /	   lesions	   /	  plaques	  are	  caused	  by	  egress	  of	  T	  cells	  out	  of	  the	  lymph	  nodes	  which	  then	  cross	  the	  blood	  brain	  barrier	  and	  into	  the	  central	  nervous	  system;	  the	  T	  cells	  are	  believed	  to	  not	  recognise	  native	  neuronal	  antigens	  and	  begin	  to	  attack	  the	  myelin	  sheath	  as	  if	  it	   were	   a	   foreign	   entity.	   The	   damage	   caused	   to	   the	   neuronal	   axons	   by	   the	  demyelination	   leads	   to	   ineffectual	  saltatory	  conduction	  and	  a	  range	  of	  symptoms	  that	  get	  progressively	  worse	  over	  time.9	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As	  well	  as	  the	  physical	  symptoms	  associated	  with	  MS,	  people	  who	  suffer	  from	  MS	  are	  at	  a	  greater	  risk	  of	  suicide.	  This	  reflects	  an	  increased	  likelihood	  of	  depression	  of	   up	   to	   around	   50%	   according	   to	   some	   studies.	   The	   greater	   incidence	   of	  depression	  among	  MS	  sufferers	   is	  possibly	  due	  to	  cerebral	   inflammation	  or,	  as	   is	  probably	   more	   likely,	   it	   is	   a	   response	   to	   the	   uncertain	   future	   and	   physical	  restrictions	  that	  are	  symptomatic	  of	  steadily	  worsening	  disability.9	  	  Magnetic	  resonance	  imaging	  (MRI)	  is	  often	  used	  to	  assist	  in	  the	  diagnosis	  of	  MS.	  In	  figure	  1.7	  abnormalities	  of	  the	  brain	  can	  be	  seen	  as	  shown	  by	  MRI.	  The	  white	  spots	  that	   can	  be	   seen	  on	   the	   scan	  of	   the	  brain	  are	  what	  are	   referred	   to	  as	  plaques	  or	  lesions.	  Anomalies	  of	  this	  type	  observed	  on	  an	  MRI	  scan	  of	  the	  brain	  are	  indicative	  of	   a	   brain	   that	   displays	   characteristics	   that	   are	   commonly	   seen	   in	   the	  brain	   of	   a	  person	   suffering	   from	  multiple	   sclerosis.	   Figure	  1.8	   shows	   three	  different	   brains	  and	   two	   of	   which	   are	   brains	   of	   MS	   sufferers.	   Brain	   C	   is	   the	   brain	   of	   a	   person	  suffering	  from	  SPMS	  and	  when	  compared	  to	  the	  healthy	  brain	  labelled	  A	  the	  stark	  difference	  can	  be	  seen	  as	  caused	  by	  the	  high	  levels	  of	  demyelination.	  	  	  
	  
Figure	  1.7	  MRI	  scan	  showing	  lesions	  in	  the	  brain	  typical	  of	  MS10	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Figure	  1.8	  MRI	  scans	  of	  A-­‐	  normal	  brain,	  B-­‐	  RRMS	  brain	  and	  C-­‐	  SPMS	  brain13	  	  The	   exact	   causes	   of	   multiple	   sclerosis	   are	   complex	   and,	   at	   the	   time	   of	   writing,	  relatively	  poorly	  understood.	  Sunlight	  exposure,	  exposure	  to	  viruses	  and	  genetics	  are	   the	   most	   widely	   discussed	   causes	   of	   the	   disease	   but	   a	   myriad	   of	   other	  contributory	   factors	   such	   as	   dietary	   fat	   and	   cigarette	   smoking	   have	   been	  proposed.14	  What	  follows	  are	  summaries	  of	  some	  of	  these	  proposed	  contributory	  factors.	  	  1.1.3.1	  Genetics	  	  Looking	   at	   the	   distribution	   of	   multiple	   sclerosis	   around	   the	   world	   it	   has	   been	  suggested	  that	  MS	  is	  at	  least	  in	  part	  due	  to	  genetic	  defects	  of	  people	  who	  possess	  Scandinavian	   ancestry.	   The	   explanation	   for	   MS	   incidence	   in	   predominantly	  Caucasian	  populations	   is	   sometimes	  referred	   to	  as	   the	   “Viking	  Gene	  Hypothesis”.	  The	  theory	  claims	  that	  there	  was	  a	  mutation	  in	  the	  genetics	  of	  Scandinavian	  people	  that	   causes	   some	   of	   the	   population	   to	   develop	   multiple	   sclerosis.	   The	   Viking	  invasions	   of	   Great	   Britain	   and	   other	   places	   in	   Europe	   enabled	   these	   genes	   to	  spread	  and	  the	  later	  British	  Empire	  further	  caused	  these	  genes	  to	  be	  disseminated	  to	  the	  various	  places	  around	  the	  world	  where	  MS	  is	  most	  common.	  Nowadays	  MS	  is	  most	  highly	  prevalent	  in	  such	  countries	  as	  the	  United	  States,	  Canada,	  Australia,	  New	   Zealand,	   Norway,	   Iceland,	   Denmark	   and	   the	   United	   Kingdom.	  When	   taking	  these	  facts	  into	  account	  the	  Viking	  Gene	  Hypothesis	  is	  an	  attractive	  explanation	  for	  the	  occurrence	  of	  MS	  worldwide.	  	  	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
Trygve	   Holmøy,	   a	   researcher	   based	   in	   the	   neurology	   department	   at	   Ullevål	  University	  Hospital	  in	  Oslo,	  conducted	  an	  investigation	  of	  Norse	  literature	  to	  try	  to	  find	   descriptions	   of	  multiple	   sclerosis	   in	   Viking	   sagas,	   “however,	  most	   sagas	   are	  focused	   on	   feuds	   and	   struggles	   for	   power,	   and	   not	   so	   much	   is	   written	   about	  women’s	   health.”15	  Holmøy	   did	   not	   find	  many	   reports	   of	  MS	   in	   Viking	   literature	  although	  in	  one	  publication	  he	  describes	  the	  miraculous	  curing	  of	  a	  woman	  called	  Halldora	  who	  suffered	  occasional	  paralysis	  between	  1193	  and	  1198.15	  While	   this	  piece	  of	  evidence	  is	  far	  from	  being	  particularly	  convincing	  proof	  of	  the	  validity	  of	  the	  Viking	  Gene	  Hypothesis	   it	   does	   show	   that	  medieval	  Viking	  populations	  were	  aware	  of	  the	  existence	  of	  diseases	  that	  exhibit	  symptoms	  reminiscent	  of	  MS.	  	  However,	  while	  the	  Viking	  Gene	  Hypothesis	  is	  quite	  convincing,	  it	  can	  be	  said	  that,	  “genetic	  predisposition…	  cannot	  explain	  the	  remarkable	  differences	  in	  risk	  among	  people	  of	  common	  ancestry	  who	  migrate	  to	  areas	  of	  high	  or	  low	  MS	  prevalence.”12	  It	  therefore	  must	  be	  concluded	  that,	  while	  genetics	  probably	  do	  play	  a	  role	  in	  the	  development	   of	  MS,	   there	  must	   also	   be	   environmental	   factors	   that	   contribute	   to	  the	  likelihood	  of	  developing	  the	  disease.	  	  1.1.3.2	  Vitamin	  D	  	  One	  of	   the	  major	  points	  of	  discussion	  with	   regard	   to	   the	  causes	  of	   the	  disease	   is	  vitamin	  D.	  Vitamin	  D	   is	  synthesised	   in	   the	  skin	   from	  7-­‐dehydrocholesterol	   in	   the	  presence	   of	   UV	   radiation.	   One	   of	   the	  most	   common	   sources	   of	   UV	   radiation	   for	  humans	  is	  the	  sun.	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Figure	  1.9	  Prevalence	  of	  MS	  per	  every	  100,000	  people	  against	  latitude16	  	  Studies,	  such	  as	  the	  one	  shown	  in	  figure	  1.9,	  have	  found	  that	  people	  who	  are	  more	  frequently	   exposed	   to	   sunlight	   have	   a	   lower	   likelihood	   of	   developing	   multiple	  sclerosis.12,17	  The	  general	  trend,	  as	  shown	  in	  figure	  1.9,	  is	  that	  the	  further	  north	  the	  population	   is	   from	   the	   equator,	   the	   higher	   the	   incidence	   rate	   of	   MS.	   The	   total	  number	  of	  hours	  of	  darkness	  during	  the	  winter	  increases	  the	  further	  north	  a	  point	  on	   Earth	   is	   from	   the	   equator.	   Also	   at	   higher	   latitudes	   the	   temperatures	   are	  generally	  cooler	  than	  in	  more	  equatorial	  regions	  so	  people	  further	  north	  are	  more	  likely	  to	  wear	  more	  clothes	  in	  order	  to	  keep	  them	  warm	  which	  obscure	  their	  skin	  from	   the	   sun.	  This	   combination	  of	   cooler	   temperatures	   and	   longer	  nights	  during	  winter	   means	   that	   people	   living	   at	   higher	   latitudes	   have	   lower	   serum	   levels	   of	  vitamin	  D	  throughout	  the	  year	  than	  people	  living	  closer	  to	  the	  equator.14	  	  An	   unfortunate	   observation	   is	   that	  with	   increasing	   exposure	   to	   sunlight	   there	   is	  both	  a	  decreased	  risk	  of	  developing	  MS	  and	  an	   increased	  risk	  of	  developing	  skin	  cancer.	  In	  practice	  it	  would	  be	  very	  difficult	  for	  anyone	  to	  realistically	  balance	  the	  risks	  and	  benefits	  of	  sunlight	  by	  receiving	  a	  carefully	  calculated	  daily	  dosage	  of	  UV	  radiation	   from	   the	   sun.	   An	   alternative	   method	   of	   elevating	   the	   daily	   intake	   of	  vitamin	   D	   is	   through	   diet	   and	   some	   studies	   have	   shown	   that	   a	   daily	   intake	   of	  vitamin	  D	  supplements	  can	  reduce	  the	  risk	  of	  developing	  MS.14	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1.1.3.3	  Hygiene	  Hypothesis	  	  Another	   proposed	   contributory	   factor	   in	   the	   development	   of	   MS	   is	   personal	  hygiene.	   In	   fact,	   contrary	   to	   common	   wisdom,	   it	   has	   been	   proposed	   that	   an	  excessively	  hygienic	  childhood	  could	  lead	  to	  an	  increased	  likelihood	  of	  developing	  MS	   in	   later	   life.	   According	   to	   the	   hypothesis	   being	   exposed	   to	   a	   variety	   of	   viral	  pathogens	  in	  early	  development	  helps	  develop	  protection	  against	  developing	  MS	  in	  later	   life.12	   This	   idea	   does	   superficially	   seem	   to	   correspond	  with	  MS	   prevalence	  rates	   as	   MS	   is	   most	   prevalent	   in	   the	   developed	   world	   where	   cleanliness	   and	  personal	   hygiene	   is	   typically	   taken	   more	   seriously	   and	   is	   easier	   to	   achieve.	   In	  poorer	   parts	   of	   the	   world	   where	   high	   levels	   of	   personal	   hygiene	   are	   perhaps	  somewhat	  more	  difficult	   to	  maintain,	   such	  as	   subsaharan	  Africa,	   South	  East	  Asia	  and	   parts	   of	   Latin	   America,	   MS	   is	   far	   less	   prevalent;	   although,	   as	   previously	  highlighted,	   other	   factors	   appear	   to	   contribute	   to	   the	   lower	   prevalence	   rates	   in	  these	  parts	  of	  the	  world	  such	  as	  genetics	  and	  hours	  of	  sunlight	  per	  day.9,14	  	  1.1.3.4	  Epstein-­‐Barr	  Virus	  	  
	  
Figure	  1.10	  MS	  incidence	  rates	  against	  EBV	  infection	  and	  infectious	  mononucleosis12,18	  	  The	   Epstein-­‐Barr	   virus	   (EBV)	   has	   been	   suggested	   as	   a	   pathogen	   that	   directly	  affects	   the	   likelihood	   of	   developing	   MS	   but	   the	   evidence	   regarding	   this	   virus	  appears	   to	   contradict	   the	   hygiene	   hypothesis.	   There	   is	   a	   very	   low	   likelihood	   of	  developing	  MS	   for	   individuals	  who	   are	   seronegative	   for	   EBV	   but	   a	  much	   higher	  chance	  of	  developing	  MS	  in	  people	  who	  have	  at	  some	  point	  been	  infected	  by	  EBV.	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This	   apparent	   contradiction	   between	   the	   two	   hypotheses	   has	   been	   termed	   the	  Epstein-­‐Barr	  virus	  paradox.7	  There	  is	  a	  correlation	  between	  late	  EBV	  infection	  that	  exhibits	   infectious	   mononucleosis	   and	   the	   chances	   of	   developing	   MS	   as	   seen	   in	  figure	  1.10.	  	  1.1.3.5	  Treatments	  for	  Multiple	  Sclerosis	  
	  Multiple	   sclerosis	   is	   a	   disease	   that	   does	   not	   currently	   have	   a	   particularly	   broad	  range	  of	  effective	  treatments	  and	  many	  of	  the	  treatments	  are	  used	  to	  alleviate	  the	  symptoms	   of	   the	   disease	   rather	   than	   treat	   the	   underlying	   causes.	   Table	   1.1	   is	   a	  table	  of	  typical	  symptoms	  and	  treatments	  for	  multiple	  sclerosis.	  	  











Cerebrum	   Cognitive	  impairment	  	  	  	  Hemisensory	  and	  motor	  Affective	  (depression)	  Epilepsy	  (rare)	  Focal	  cortical	  deficits	  (rare)	  
Deficits	  in	  attention,	  reasoning,	  and	  executive	  function	  (early);	  dementia	  (late)	  Upper	  motor	  neuron	  sign	  	  
	  	  	  	  	  Antidepressant	  drugs	  Anticonvulsant	  drugs	  
Cognitive	  training	  
Optic	  nerve	  	   Unilateral	  painful	  loss	  of	  vision	   Scotoma,	  reduced	  visual	  acuity,	  colour	  vision	  and	  relative	  afferent	  pupillary	  defect	  
Low	  vision	  aids	   	  
Cerebellum	  and	  cerebellar	  pathways	  
Tremor	  	  	  	  	  	  Clumsiness	  and	  poor	  balance	  
Postural	  and	  action	  tremor,	  dysarthria	  	  	  	  	  	  Limb	  incoordination	  and	  gait	  ataxia	  
	   Wrist	  weights,	  carbamazepine,	  isoniazid,	  β	  blockers,	  clonazepam,	  thalamotomy	  and	  thalamic	  stimulation	  
Brainstem	   Diplopia,	  oscillopsia	  	  	  Vertigo	  	  Impaired	  swallowing	  Impaired	  speech	  and	  emotional	  lability	  
Nystagmus,	  internuclear	  and	  other	  complex	  opthalmoplegias	  	  	  Dysarthria	  Pseudobulbar	  palsy	  
	  	  	  Prochlorperazine,	  cinnarizine	  Anticholinergic	  drugs	  Tricyclic	  antidepressant	  drugs	  
Baclofen,	  gabapentin	  	  	  	  	  Speech	  therapy	  Speech	  therapy	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Paroxysmal	  symptoms	   Carbamazepine,	  gabapentin	  	  Spinal	  cord	   Weakness	  	  Stiffness	  and	  painful	  spasms	  	  	  	  Bladder	  dysfunction	  	  	  	  	  Erectile	  dysfunction	  Constipation	  
Upper	  motor	  neuron	  signs	  Spasticity	  	  	  	  	  
	  	  Tizanidine,	  baclofen,	  dantrolene,	  benzodiazepines,	  intrathecal	  baclofen,	  corticosteroids	  Anticholinergic	  drugs	  and/or	  intermittent	  self-­‐catheterisation,	  subrapubic	  catheterisation	  Sildenafil	  (Viagra)	  Bulk	  laxatives,	  enemas	  
	  	  Cannabinoids	  	  	  	  	  Abdominal	  vibration,	  cranberry	  juice	  
Other	   Pain	  	  Fatigue	  Temperature	  sensitivity	  and	  exercise	  intolerance	  
	   Carbamazepine,	  gabapentin	  Amantadine,	  modafanil	  
	  	  Premoline,	  fluoxetine	  Cooling	   suit,	   4-­‐aminopyridine	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1.2	  Fingolimod	  and	  S1P	  Receptors	  
	  Fingolimod	   is	   the	   first	   FDA	   approved	   oral	   treatment	   for	  RRMS.	   It	  was	  marketed	  under	   the	   name	   Gilenya	   by	   Novartis	   and	   is	   currently	   a	   “blockbuster”	   drug	  with	  annual	  sales	  in	  excess	  of	  $1	  billion.	  
	  
1.2.1	  Development	  of	  FTY720	  /	  Fingolimod	  /	  Gilenya	  	  Fingolimod	  was	  originally	  developed	  in	  Japan	  by	  a	  team	  comprised	  of	  individuals	  such	   as	   Kunitomo	   Adachi,	   Kenji	   Chiba	   and	   Tetsuro	   Fujita.	   Their	   work	   was	  conducted	   in	   several	   institutions	   and	   companies	   such	   as	   the	   Faculty	   of	  Pharmaceutical	   Sciences	  at	  Kyoto	  University	  and	  Yoshitomi	  Pharmaceuticals	  Ltd.	  The	  team	  used	  the	  chemical	  structure	  of	  an	  immunosuppressive	  compound	  known	  as	  myriocin	  (ISP-­‐I),19,20	  found	  in	  a	  Chinese	  eternal	  youth	  nostrum,	  as	  the	  basis	  for	  its	  development.	  	  	  The	  eternal	   youth	  elixir	   contains	   the	   fungus	   Isaria	   sinclairii	  and	   it	   is	   believed	  by	  some	  that	   ingesting	  a	  Chinese	  folk	  medicine	  containing	  this	   fungus	  can	  provide	  a	  wide	  range	  of	  health	  benefits.	  Modern	  analytical	  research	  techniques	  have	  indeed	  identified	   fungal	  metabolites	   such	   as	   cordycepin,	   an	   inhibitor	   of	   tumour	   growth,	  present	   in	   the	   fungus	   with	   beneficial	   biological	   properties	   in	   humans.	   Isaria	  
sinclairii	  is	  a	  species	  of	  entomopathogenic	  (parasitic)	  fungus	  that	  thrives	  on	  insects	  including	  the	  larvae	  of	  cicadas.	  Isaria	  sinclairii	  is	  the	  anamorph	  stage	  of	  the	  phyla	  
Ascomycota	   and	   belongs	   to	   the	   Cordyceps	   genus.	   Cordyceps	   fungi	   infect	   living	  insects	  and	  other	  arthropods,	  digest	  the	  internal	  organs	  of	  the	  host	  and	  eventually	  grow	  out	  of	  the	  dead	  host	  organism	  to	  form	  the	  fruiting	  body	  of	  the	  fungus.21	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Figure	  1.11	  Isaria	  sinclairii21	  	  	  	  
	  
Figure	  1.12	  The	  cordyceps	  genus	  of	   fungus	   forms	   the	  basis	   for	   the	  pathogen	  responsible	   for	   the	  fictitious	  2013	  outbreak	  of	  a	  devastating	  pandemic	  in	  the	  Playstation™	  game	  The	  Last	  of	  Us22	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Another	   family	   of	   natural	   products	   with	   similar	   pharmacological	   effects	   and	  chemical	   structures	   to	  myriocin,	   known	   as	   the	  mycestericins,	   was	   isolated	   from	  
Mycelia	  sterilia.23,24	   	  
	  
Figure	  1.13	  Myriocin	  (ISP-­‐1)	  
	  
Figure	  1.14	  Mycestericin	  C	  	  At	  nanomolar	  concentrations	  myriocin	  was	  observed	  to	  inhibit	  the	  proliferation	  of	  T	  cells	   in	  mouse	  allogeneic	  mixed	  lymphocyte	  reaction.20	  Chiba	  et	  al	  also	  showed	  that	  myriocin	   can	  be	  used	   to	  effectively	  prolong	   the	   survival	  of	   rat	   skin	  allograft	  although	   at	   higher	   doses	  myriocin	  was	   observed	   to	   induce	   significant	   toxicity	   in	  
vivo.	   Based	   on	   these	   preliminary	   results	   with	   myriocin	   the	   Japanese	   team	  optimised	  their	  lead	  compounds	  by	  screening	  them	  using	  in	  vitro	  mouse	  allogenic	  mixed	  lymphocyte	  reaction	  and	  in	  vivo	  rat	  skin	  allograft.	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activity	  of	  myriocin.	  Changing	  the	  carboxylic	  acid	  group	  to	  a	  hydroxymethyl	  group	  was	   found	   to	  be	   favourable	  as	   this	   reduced	   toxicity,	   increased	  desired	  activity	   in	  
vivo	   and	   presented	   less	   of	   a	   synthetic	   challenge	   by	   removing	   a	   chiral	   centre.24	  Further	  simplification	  eventually	   led	  to	  compounds	  such	  as	  ISP-­‐I-­‐36	  and	  ISP-­‐I-­‐55	  which	  have	  a	  2-­‐alkyl-­‐2-­‐aminopropane-­‐1,3-­‐diol	  framework.25	  Further	  modification	  of	  ISP-­‐I-­‐55	  by	  introducing	  a	  benzene	  ring	  within	  the	  side	  chain	  led	  to	  the	  eventual	  synthesis	   of	   FTY720	   (2-­‐amino-­‐2-­‐[2-­‐(4-­‐octylphenyl)ethyl]propane-­‐1,3-­‐diol	  hydrochloride)	  	  (fingolimod.HCl).25	  The	  synthesis	  of	  FTY720	  was	  first	  published	  in	  1995	   in	   a	   paper	  written	   by	   Adachi	   et	   al.26	   Fingolimod	   possesses	   a	  more	   potent	  immunosuppressive	  activity	  than	  ISP-­‐I-­‐55	  in	  vivo	  and	  the	  significant	  alterations	  of	  myriocin	   to	   yield	   FTY720	   effectively	   improved	   the	   immunosuppressive	   activity,	  toxicity	  and	  the	  physicochemical	  properties.	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  ISP-­‐I-­‐13	  	  	   	  
	  ISP-­‐I-­‐28	  	  	  	  
	  ISP-­‐I-­‐36	  	  	  	  
	  ISP-­‐I-­‐55	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The	   name	   FTY720	   is	   derived	   from	   the	   names	   of	   its	   discoverers:	   Fujita	   and	  colleagues	   at	   Kyoto	   University,	   Taito	   Company	   and	   Yoshitomi	   Pharmaceutical	  Industries.17	   The	   internationally	   recognised	   non-­‐proprietary	   name	   “fingolimod”	  was	  created	  from	  two	  words:	  “sphingosine”	  and	  “immunomodulator”.25	  	  	  Fingolimod	   was	   found	   to	   be	   effective	   in	   treating	   multiple	   sclerosis	   and	   other	  ailments	   such	   as	   Huntington’s	   disease	   and	   can	   improve	   upon	   skin	   allograft	  rejection	  problems.	  The	  pharmaceutical	  company	  Novartis	  entered	  into	  a	  licensing	  agreement	  with	  the	  original	  Japanese	  developers	  and	  in	  2010	  Fingolimod	  became	  an	   FDA	   approved	   drug	   and	   sold	   under	   the	   name	   Gilenya.	   Fingolimod	   has	   been	  approved	  by	  the	  Food	  and	  Drug	  Administration	  to	  treat	  RRMS.	  
	  
1.2.2	  S1P	  Receptors	  
	  Sphingosine	   1-­‐phosphate	   (S1P)	   receptors	   are	   G	   protein-­‐coupled	   receptors27	  expressed	  in	  a	  variety	  of	  tissues	  and	  cover	  a	  range	  of	  different	  functions.	  There	  are	  5	   types	   of	   S1P	   receptors	   referred	   to	   as	   the	   S1P1,	   S1P2,	   S1P3,	   S1P4	   and	   S1P5	  receptors.28	  The	  natural	  ligand	  is	  sphingosine-­‐1-­‐phosphate	  as	  shown	  in	  figure	  1.17	  which	  is	  the	  phosphorylated	  analogue	  of	  sphingosine	  as	  shown	  in	  figure	  1.16.29	  
	  
	  
Figure	  1.16	  Sphingosine	  
	  
	  
Figure	  1.17	  Sphingosine-­‐1-­‐phosphate	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are	   located	   in	   a	   broad	   range	   of	   different	   tissues	   including	   in	   the	   cardiovascular	  system,	   central	   nervous	   system	   and	   renal	   system.27	   The	   S1P1	   receptor	   has	   been	  implicated	   in	   lymphocyte	   egress	   from	   the	   lymph	   node	   and	   the	   down-­‐regulation	  and	   possibly	   reversal	   of	   demyelination	   in	   oligodendrocytes	   as	   shown	   in	   figures	  1.18	  and	  1.19.28	  	  	  	  
	  
Figure	  1.18	  S1P1	  receptors	  affect	  T	  cell	  egress	  from	  the	  lymph	  node28	  	  	  
	  
Figure	   1.19	   Oligodendrocytes	   express	   S1P5	   and	   S1P1	   receptors	   and	   play	   a	   role	   in	   regulating	  myelination28	  	  	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
1.2.3	  Mode	  of	  Action	  of	  Fingolimod	  
	  When	   ingested	   orally,	   fingolimod	   is	   absorbed	   by	   the	   digestive	   tract	   and	   is	  disseminated	   to	   different	   regions	   of	   the	   body	   including	   the	   blood	   stream,	  lymphatic	  system	  and	  the	  central	  nervous	  system.28	  Fingolimod	  is	  phosphorylated	  by	   sphingosine	   kinase	   to	   form	   fingolimod-­‐phosphate.24	   The	   active	   molecule	  fingolimod-­‐phosphate	   binds	   to	   sphingosine	   receptors	   and	   induces	   a	   range	   of	  biological	  responses.	  Fingolimod	  is	  known	  as	  a	  sphingosine	  receptor	  modulator	  as	  it	   binds	   to	   these	   receptors.	   Fingolimod	   is	   also	   known	   as	   an	   immunomodulator	  because	   it	  has	  a	   functional	  antagonistic	  effect	  on	   the	  S1P	  receptors	  and	  causes	  T	  cells	   to	   be	   sequestered	   in	   the	   lymph	   nodes	   and	   thus	   decreases	   lymphocyte	  concentration	  in	  the	  blood.29,33,34	  	  Fingolimod-­‐phosphate	  has	  similar	  effects	  to	  the	  naturally	  occurring	  sphingosine-­‐1-­‐phosphate	   and	   fingolimod-­‐phosphate	   interferes	   with	   the	   normal	   relationship	  between	  sphingosine-­‐1-­‐phosphate	  and	  the	  sphingosine	  receptors.29	  Of	  the	  5	  types	  of	   S1P	   receptors	   fingolimod-­‐phosphate	   is	   known	   to	   interact	  with	   the	   S1P1,	   S1P3,	  S1P4	   and	   S1P5	   receptors.	   Fingolimod	   in	   particular	   binds	   to	   the	   S1P1	   and	   S1P3	  receptors	  with	  high	  affinity.28	  	  	  
	  
Figure	  1.20	  Fingolimod	  (FTY720)29	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One	   of	   the	   principle	   effects	   of	   phosphorylated	   fingolimod	   binding	   to	   the	   S1P	  receptors	  is	  the	  sequestration	  of	  lymphocytes	  in	  the	  lymph	  nodes	  and	  thymus.34,35	  The	   sequestration	   of	   T	   cells	   causes	   fewer	   lymphocytes	   to	   cross	   the	   blood	   brain	  barrier	  and	  infiltrate	  the	  recently	  discovered36	  CNS	  lymphatic	  vessels.	  The	  reduced	  T	  cell	  entry	  to	  the	  central	  nervous	  system	  therefore	  leads	  to	  reduced	  degeneration	  of	  the	  myelin	  sheaths	  by	  the	  lymphocytes	  in	  individuals	  who	  suffer	  from	  MS	  and	  a	  reduction	  in	  the	  number	  of	  lesions	  detected	  by	  MRI.37	  	  Phosphorylated	  fingolimod	  has	  been	  referred	  to	  as	  a	  functional	  antagonist29	  of	  the	  S1P1	   receptor	   as	   binding	   to	   the	   S1P1	   receptor	   induces	   internalisation	   of	   the	  receptor.38	   The	   internalisation	   of	   the	   receptor	   reduces	   the	   probability	   of	   S1P	  binding	  to	  the	  S1P1	  receptors	  and	  inducing	  the	  usual	  biological	  responses	  such	  as	  T	  cell	  proliferation	  as	  shown	  in	  figures	  1.22	  and	  1.23.34	  	  
	  
Figure	  1.22	  Normal	  functioning	  of	  lymph	  node.	  Activated	  T	  cells	  egress	  from	  the	  lymph	  node	  along	  a	  sphingosine	  1-­‐phosphate	  –	  S1P	  receptor	  gradient34	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Figure	   1.23	   Phosphorylated	   fingolimod	   binds	   to	   and	   internalises	   S1P	   receptors	   causing	  lymphocyte	  sequestration34	   	  Additionally,	   fingolimod	  has	  been	  proposed	   to	   exhibit	   its	  neuroprotective	   effects	  by	  acting	  directly	  upon	  the	  CNS.33	  Some	  studies	  have	  suggested	  that	  in	  addition	  to	  reducing	   the	   rate	   of	   demyelination	   as	   observed	   in	   neurodegenerative	   disease,	  fingolimod	   is	   able	   to	   actively	   increase	   remyelination	   in	   CNS	   tissues.38,39,40	   The	  direct	   mode	   of	   action	   of	   the	   neuroprotective	   effects	   proposed	   in	   a	   number	   of	  studies	   involves	   the	   increased	   expression	   of	   brain-­‐derived	   neurotrophic	   factor	  (BDNF)	  in	  neurons.41,42,43	  BDNF	  release	  has	  been	  observed	  to	  up-­‐regulate	  neuronal	  generation	  and	  regeneration	  and	  deliberate	  modulation	  of	  this	  system	  could	  prove	  beneficial	   in	   ameliorating	   the	   symptoms	  of	   further	  neurological	  diseases	   such	  as	  Alzheimer’s42	   and	   Rett	   syndrome.41	   If	   both	   the	   proposed	   BDNF	   and	   lymphocyte	  sequestration	   modes	   of	   action	   are	   correct	   then	   fingolimod	   is	   able	   to	   decrease	  neurodegeneration	  by	  inhibiting	  the	  release	  of	  lymphocytes	  from	  lymph	  nodes	  and	  increase	  neural	  regeneration	  by	  up-­‐regulating	  BDNF	  release.	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Figure	  1.24	  Phospho-­‐fingolimod	  induces	  increased	  BDNF	  expression	  in	  cultured	  neurons41	  	  The	  inhibition	  of	  histone	  deacetylases	  (HDACs)	  by	  phosphorylated	  fingolimod	  also	  has	   further	   implications	   for	   the	  CNS	  processes	  of	  memory	  and	   learning.	  There	   is	  perhaps	   potential	   for	   future	   therapeutic	   applications	   of	   fingolimod	   or	   other	   S1P	  receptor	   modulators	   for	   disorders	   of	   psychological	   functions	   modulated	   by	  HDACs.44	  
	  
1.2.4	  Potential	  Therapeutic	  Uses	  of	  Fingolimod	  
	  Fingolimod	   has	   proven	   to	   be	   an	   effective	   treatment	   for	   RRMS	   and	   studies	   have	  shown	   potential	   uses	   in	   other	   diseases	   such	   as	   Huntington’s	   disease,45	   Rett	  syndrome,41	  PTSD,44	  cancer,46	  	  obesity,47	  ocular	  immune-­‐mediated	  inflammation,48	  Alzheimer’s	   disease,49	   diabetes,50	   autoimmune	   neuropathies,51	   	   stroke52	   and	  intracerebral	  hemorrhage.53	  	  
1.2.5	  Side	  Effects	  and	  Dangers	  of	  Fingolimod	  
	  A	  range	  of	  unwanted	  side	  effects	  have	  been	  observed	  in	  patients	  using	  fingolimod.	  Fingolimod	  is	  known	  to	  adversely	  affect	  the	  immune	  response	  to	  and	  clearance	  of	  enteric	   pathogen	   C.	   rodentium.54	   Fingolimod	   is	   known	   to	   induce	   transient	  bradycardia	   (decrease	   in	   heart	   rate)	   and	  other	   chronotropic	   effects55	   although	   a	  paper	  by	  Kovarik	  (of	  Novartis)	  published	  in	  2008	  states	  that	  atropine	  can	  reverse	  the	   chronotropic	   effect.56	   Fingolimod	   has	   also	   been	   observed	   to	   cause	   cancer	   in	  mice,	   increased	   likelihood	   of	   infection	   by	   viruses	   such	   as	   VZV,	   increased	   airway	  resistance,	  hepatotoxicity	  and	  macular	  edema.55,57,58	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1.2.6	  Fingolimod	  Analogues	  and	  Other	  S1P	  Receptor	  Modulators	  
	  The	  S1P	  receptors	  have	  been	  the	  recipients	  of	  a	  great	  amount	  of	  attention	  as	  of	  late	  and	  the	  broad	  range	  of	  recently	  developed	  S1P	  receptor	  modulators	  is	  a	  reflection	  of	  this	  fact.	  	  	  In	   order	   to	   try	   to	   reduce	   the	   bradycardia	   experienced	   by	   patients	   who	   take	  fingolimod,	  novel	  analogues	  have	  been	  developed	  which	  aim	  to	  reduce	  the	  amount	  of	  S1P3	  selectivity	  as	  S1P3	  receptors	  were	   found	  to	  have	  a	  greater	   influence	  over	  heart	   rate	   than	   S1P1	   receptors.59	  What	   follows	   are	   summaries	   of	   a	   few	   selected	  published	   S1P	   receptor	   modulators	   of	   which	   some	   may	   have	   the	   potential	   to	  replace	  fingolimod	  due	  to	  improved	  therapeutic	  profiles.	  	  The	  compound	  shown	  in	  figure	  1.25	  has	  been	  named	  AAL(R)	  in	  a	  2002	  paper60	  and	  was	   developed	   in	   the	   90s	   around	   the	   same	   time	   as	   fingolimod	   by	   the	   same	  Japanese	  team	  that	  developed	  FTY720.	  It	  has	  a	  similar	  pharmacological	  profile	  to	  FTY720	   and	   similar	   selectivity	   towards	   S1P1	   and	   S1P3	   receptors.	   According	   to	  Brinkmann	  et	  al	   in	   their	  2002	  paper	   the	  phosphorylated	  version	  of	   the	  drug	  has	  EC50	  values	  of:	  S1P1	  8.6	  nM	  and	  S1P3	  8.4	  nM.	  It	  is	  likely	  that	  the	  original	  Japanese	  team	   chose	   to	   further	   develop	   FTY720	   as	   AAL(R)	   has	   a	   chiral	   centre	   and	   large	  scale	  manufacture	  would	  presumably	  be	  more	  difficult	  and	  costly.	  	  
	  









Figure	  1.26	  KRP-­‐203	  	  CS-­‐0777	   as	   shown	   in	   figure	   1.27	   is	   currently	   in	   phase	   2	   clinical	   trials	   for	   the	  treatment	   of	   MS.59	   The	   phosphorylated	   version	   of	   the	   drug	   is	   reported	   to	   have	  EC50	  values	  of:	   S1P1	  1.1	  nM	  and	  S1P3	  350	  nM.	  CS-­‐077	   is	   the	  property	  of	  Daiichi	  Sankyo.	  	  
	  
Figure	  1.27	  CS-­‐0777	  	  GSK184279961	  has	  been	  chosen	  as	  a	  clinical	  candidate	  due	  to	  favourable	  biological	  activity.	  Of	  the	  other	  similar	  analogues	  developed	  this	  analogue	  is	  phosphorylated	  more	  efficiently	  by	  sphingosine	  kinase	   in	  vivo.	  The	  phosphorylated	  version	  of	  the	  drug	   is	   reported	   to	   have	   EC50	   values	   of:	   S1P1	   0.52	   nM	   and	   S1P3	   1,898	   nM.	  GSK1842799	  is	  the	  property	  of	  Praecis	  Pharma	  and	  GlaxoSmithKline.	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reported	  to	  have	  EC50	  values	  of:	  S1P1	  1.1	  nM	  and	  S1P3	  >10,000	  nM.	  PPI-­‐4955	  (6)	  is	  the	  property	  of	  Praecis	  Pharma.	  	  
	  
Figure	  1.29	  PPI-­‐4955	  (6)	  	  PPI-­‐495561	  was	  not	   chosen	   for	   clinical	   trials	  because	   the	  phosphorylation	  step	   is	  slow	   in	   vivo.	   The	   phosphorylated	   version	   of	   the	   drug	   is	   reported	   to	   have	   EC50	  values	  of:	  S1P1	  0.83	  nM	  and	  S1P3	  7,352	  nM	  which	  is	  an	  improvement	  of	  S1P1	  and	  S1P3	   selectivity	   when	   compared	  with	   GSK1842799.	   PPI-­‐4955	   is	   the	   property	   of	  Praecis	  Pharma.	  	  
	  


















Figure	  1.31	  2f	  (Tsuji	  2014)62	  	  The	  compound	  shown	  in	  figure	  1.32	  was	  labelled	  2h	  in	  Takashi	  Tsuji	  et	  al’s	  2014	  paper.62	  The	  phosphorylated	  version	  of	  the	  drug	  is	  reported	  to	  have	  EC50	  values	  of:	   S1P1	  6.5	  nM	  and	  S1P3	  >20,000	  nM.	  The	  compound	   in	  question	   is	  presumably	  the	   property	   of	  Daiichi	   Sankyo	   and	   has	   excellent	   S1P1	   selectivity	   over	   S1P3.	   The	  overall	   potency	   of	   the	   drug	   is	   greatly	   reduced	   by	   the	   rate	   of	   the	   in	   vivo	  phosphorylation	  step.	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1.3	  The	  Pharmacology	  of	  Drug	  Action:	  Opportunities	  for	  Prodrugs	  
	  Christopher	  Lipinski	  developed	  the	   ‘rule	  of	  5’	  and	  it	   is	  used	  as	  a	  general	  guide	  to	  determine	  whether	   a	   potential	   therapeutic	   compound	  will	   be	   orally	   active.	   “The	  rule	  of	  5	  states	  that:	  poor	  absorption	  or	  permeation	  are	  more	  likely	  when:	  	  
• There	  are	  more	   than	  5	  H-­‐bond	  donors	   (expressed	  as	   the	   sum	  of	  OHs	  and	  NHs)	  
• The	  molecular	  weight	  is	  over	  500	  
• The	  Log	  P	  is	  over	  5	  (or	  MLog	  P	  is	  over	  4.15)	  
• There	  are	  more	  than	  10	  H-­‐bond	  acceptors	  (expressed	  as	  the	  sum	  of	  Ns	  and	  Os)	  
• Compound	   classes	   that	   are	   substrates	   for	   biological	   transporters	   are	  exceptions	  to	  the	  rule”64	  	  When	   developing	   novel	   small	   molecule	   therapeutics	   it	   is	   prudent	   to	   keep	   these	  rules	   in	   mind	   however	   there	   are	   FDA	   approved	   drugs	   that	   do	   not	   meet	   the	  requirements	  of	  every	  one	  of	  the	  five	  rules.	  A	  number	  of	  antibiotics	  and	  antifungal	  compounds,	  in	  particular,	  are	  known	  to	  be	  orally	  active	  despite	  not	  adhering	  to	  the	  rule	  of	  5.	  64	  
	  
1.3.1	  CNS	  Acting	  Drugs	  	  
	  When	   developing	   therapeutics	   which	   are	   designed	   to	   be	   active	   in	   the	   central	  nervous	   system	   there	   is	   an	   even	   lower	   likelihood	   that	   any	   novel	   compound	  will	  effectively	  migrate	   to	   the	  desired	  CNS	  tissues.	  The	  blood-­‐brain	  barrier	  (BBB)	  has	  evolved	   to	   protect	   the	   central	   nervous	   system	   from	   devastating	   invasion	   by	  unwanted	   toxins	   and	   pathogens.	   However,	   the	   BBB	   poses	   a	   serious	   obstacle	   to	  drug	  developers	  who	  wish	  to	  develop	  agents	  that	  are	  active	  in	  the	  CNS.	  	  	  Lipinski	   developed	   another	   set	   of	   rules65	   which	   can	   be	   applied	   to	   a	   compound	  when	  considering	  its	  potential	  to	  cross	  the	  BBB:	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• Molecular	  weight	  ≤	  400	  g/mol	  
• LogP	  ≤	  5	  
• Hydrogen	  bond	  donors	  ≤	  3	  
• Hydrogen	  bond	  acceptors	  ≤	  7	  
	  The	  majority	   of	   drugs	  which	   cross	   the	   BBB	   do	   so	   via	   passive	   diffusion	   although	  some	   compounds	   such	   as	   gabapentin	   and	   L-­‐DOPA	   are	   transported	   across	   the	  epithelial	  cell	  barrier	  via	  active	  transport.	  Gabapentin	  and	  L-­‐DOPA	  are	  transported	  into	  the	  CNS	  by	  L-­‐type	  amino	  acid	  transporter-­‐1	  (LAT1).66	  	  
	  
Figure	  1.34	  Diazepam	  (Valium)	  	  Diazepam	   is	   a	   benzodiazepine	   CNS-­‐acting	   pharmaceutical	   product	   and	   has	   a	  molecular	  weight	  of	  284.7	  g/mol,	  a	  logP	  of	  2.74,	  3	  hydrogen	  bond	  acceptors	  and	  0	  hydrogen	  bond	  donors.	  Diazepam	  conforms	  to	  all	  of	  Lipinski’s	  rules	  of	  the	  CNS.	  	  
1.3.2	  Prodrugs	  
	  Prodrugs	  can	  be	  described	  as	  pharmacologically	   inactive	  or	   less	   than	   fully	  active	  derivatives	  of	  active	  drugs	  that	  are	  converted	  into	  the	  active	  drug	  within	  the	  body	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The	  prodrug	  approach	  can	  be	  preferable	  to	  administering	  the	  active	  molecule	  itself	  due	   to	   improvements	   in	   ADME	   properties	   (absorption,	   distribution,	  metabolism	  and	  excretion).69	  A	  fuller	   list	  of	   improvements	  the	  prodrug	  approach	  can	  provide	  includes	  improvements	  in:	  	  
• Patient	  acceptance	  i.e.	  taste/odour	  
• Selectivity	  and	  reduced	  toxicity	  
• Stability	  and/or	  prolonged	  release	  
• Absorption	  and	  distribution	  
• Physicochemical	  properties	  i.e.	  solubility	  and	  LogP	  
• Site-­‐specific	  delivery68,69	  	  Two	   comparatively	  well-­‐known	   prodrugs	   include	   the	   painkiller	   codeine	   and	   the	  psychopharmacologically	   active	   compound	   psilocybin.	   Codeine	   has	   a	   very	   close	  structural	  similarity	  to	  morphine	  but	  contains	  a	  methyl	  ether	  group	  rather	  than	  an	  alcohol	  group.	  The	  cytochrome	  P450	  enzyme	  CYP2D6	  converts	  the	  ether	  group	  to	  an	  alcohol	  group	  in	  the	  liver	  yielding	  morphine.69	  Psilocybin	  on	  the	  other	  hand	  is	  metabolised	  to	  the	  active	  molecule	  psilocin	  by	  dephosphorylating	  enzymes	  known	  as	  alkaline	  phosphatases.70	  	  
	  
	  




















Scheme	  1.3	  Metabolism	  of	  psilocybin	  to	  the	  active	  molecule70	  	  Fingolimod	   is	   in	   fact	   a	   prodrug	   as	   fingolimod	   itself	   is	   not	   the	   pharmacologically	  active	   molecule.	   The	   phosphorylation	   step	   is	   essential	   to	   induce	   the	   desired	  biological	  activity	  as	  it	  is	  fingolimod-­‐phosphate	  that	  binds	  to	  the	  S1P	  receptors	  and	  induces	  the	  immunomodulatory	  effects.30	  
	  
1.3.3	  Phosphate	  Delivery	  Prodrugs	  	  A	  large	  number	  of	  different	  types	  of	  phosphate	  prodrug	  have	  been	  developed	  and	  publicised.	  Some	  examples	  of	  phosphorus	  prodrug	  technologies	  include:71,72	  	  
• Bis(pivaloyloxymethyl)	  (POM)	  prodrugs	  
• Bis(isopropyloxymethyl)	  carbonate	  (POC)	  prodrugs	  
• S-­‐acyl-­‐2-­‐thioethyl	  (SATE)	  prodrugs	  
• Cyclosal	  prodrugs	  
• HepDirect	  prodrugs	  
• Ether	  lipid	  ester	  (Hostetler)	  prodrugs	  




















Figure	  1.35	  Adefovir	  dipivoxil	  contains	  a	  bis	  POM	  phosphate	  delivery	  motif71	  	  Adefovir	   dipivoxil	   is	   FDA	   approved	   to	   treat	   infections	   of	   the	   hepatitis	  B	   virus.	   It	  was	  originally	  developed	  to	  treat	  HIV	  but	  it	  was	  found	  that	  kidney	  toxicity	  was	  too	  much	  of	  an	  issue	  for	  that	  application.71	  
	  






























Figure	  1.37	  Analogue	  of	  azidothymidine	  containing	  aryl	  SATE	  phosphate	  delivery	  motif71	  	  	  
	  
Figure	  1.38	  Analogue	  of	  azidothymidine	  containing	  CycloSal	  phosphate	  delivery	  motif71	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1.3.4	  Phosphoramidate	  (ProTide)	  Prodrugs	  
	  Phosphoramidate	   “ProTides”	   have	   been	   developed,	   synthesised	   and	   patented	   by	  Prof.	  Chris	  McGuigan	  and	  his	  researchers	  for	  over	  a	  decade.	  They	  act	  as	  a	  form	  of	  prodrug	   that	  can	  have	  much	  greater	  potencies	   than	   the	  original	  drug	  molecule.73	  Typically	  the	  ProTide	  method	  is	  applied	  to	  nucleosides.74	  	  Nucleosides	  consist	  of	  a	  DNA-­‐type	  base	  such	  as	  guanine	  or	  cytosine,	  or	  analogues	  thereof,	  and	  a	  sugar.	  The	  image	  below	  depicts	  gemcitabine.	  Gemcitabine	  is	  an	  FDA	  approved	  drug	  that	  is	  currently	  used	  to	  treat	  a	  range	  of	  types	  of	  cancer	  including	  breast	  cancer,	  pancreatic	  cancer	  and	  lung	  cancer.75	  	  
	  















Figure	  1.41	  Acelarin	  based	  on	  gemcitabine76	  	  Another	  drug,	  developed	  by	  the	  pharmaceutical	  company	  Gilead,	  which	  makes	  use	  of	   phosphoramidate	   technology	   is	   sofosbuvir.77	  The	  FDA	  approved	  Sofosbuvir	   in	  2013	   for	   treatment	   of	   the	   hepatitis	   C	   virus	   in	   combination	   with	   ribavirin.	  Sofosbuvir’s	  mode	  of	  action	  involves	  the	  inhibition	  of	  the	  RNA	  polymerase	  used	  by	  the	  virus	  to	  replicate	  the	  viral	  RNA.	  Sofosbuvir	  has	  generated	  in	  excess	  of	  $1	  billion	  in	   revenue	   since	   its	   approval	   and	   continues	   to	   be	   a	   very	   financially	   successful	  treatment	  for	  the	  hepatitis	  C	  virus.	  	  
	  
Figure	  1.42	  Sofosbuvir	  
	  Other	  ProTide	  nucleosides	  which	  have	  been	  in	  clinical	  trials	  include:	  	  	  

























	   	   	  
	  
Confidential	  
• GS-­‐9131,	   containing	   an	   L-­‐alaninyl	   ethyl	   ester	   ProTide	   moiety,	   for	   HIV	  treatment71	  
• INX-­‐08189,	   containing	   an	   L-­‐alaninyl	   neopentyl	   ester	   ProTide	  moiety,	   for	  HCV	  treatment71	  
• Thymectacin,	   containing	   an	   L-­‐alaninyl	   methyl	   ester	   ProTide	   moiety,	   for	  cancer	  treatment71	  
	  
1.3.5	  Mode	  of	  Action	  of	  Phosphoramidates	  
	  Nucleosides	   possessing	   phosphoramidate	   structures	   are	   believed	   to	   diffuse	  through	   the	   cell	   membrane	   via	   passive	   diffusion.	   	   The	   lipophilic	   nature	   of	   the	  phosphoramidate	  moiety	   is	   believed	   to	   facilitate	   this	   process	   and	   in	   the	   case	   of	  nucleosides	  this	  is	  beneficial	  as	  the	  polar	  nature	  of	  the	  monophosphate	  nucleoside	  does	   not	   facilitate	   diffusion	   across	   the	   cell	   membrane	   (see	   scheme	   1.4).	   When	  inside	   the	   cell	   the	   ProTide	   is	   processed	   by	   enzymes	   such	   as	   cathepsine	   A78,	  carboxypeptidases	   and	   phosphoramidases	   such	   as	   Hint	   enzyme79	   to	   form	   the	  nucleoside-­‐phosphate	  molecule	  (as	  shown	  in	  scheme	  1.5).	  	  	  
	  


























Scheme	  1.5	  Proposed	  intracellular	  enzymatic	  processing	  of	  ProTides73	  	  	  In	  the	  case	  of	  nucleosides	  the	  monophosphate	  is	  often	  further	  phosphorylated	  by	  kinases	   to	   form	   a	   triphosphate	   active	   molecule	   that	   is	   then	   processed	   and	  incorporated	  into	  the	  host	  DNA/RNA.	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1.4	  Aim	  of	  Work:	  Phosphoramidate	  Fingolimod	  Analogues	  
	  The	   original	   aim	   of	   the	   research	   project	   described	   was	   to	   produce	   kinase-­‐independent	   second	   generation	   ProTide	   fingolimod	   analogues	   and	   to	   allow	   the	  project	  to	  evolve	  depending	  on	  experimental	  results	  and	  extensive	  searching	  of	  the	  available	  literature.	  	  
	  










	   	   	  
	  
Confidential	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chapter	  1	  




	  1. Carpenter	  M.	  Human	  Neuroanatomy.	  Seventh	  edition.	  1976.	  2. Villegas	  S,	  Poletta	  F,	  Carri	  N.	  GLIA:	  A	  reassessment	  based	  on	  novel	  data	  on	  the	  developing	   and	  mature	   central	   nervous	   system.	  Cell	   Biol.	   Int.	  2003,	   27,	   599-­‐609.	  3. Rosenberg	  S,	  Chan	  J.	  Modulating	  myelination:	  knowing	  when	  to	  say	  Wnt.	  Genes	  
Dev.	  2009,	  23,	  1487-­‐1493.	  4. Brooks	  D,	  McKinlay	  W.	  Personality	  and	  behavioural	  change	  after	  severe	  blunt	  head	   injury-­‐	   a	   relative’s	   view.	   J	   Neurol	   Neurosurg	   Psychiatry.	  1983,	   46,	   336-­‐344.	  5. Friedlander	  R.	  Apoptosis	  and	  caspases	  in	  neurodegenerative	  diseases.	  N.	  Engl.	  
J.	  Med.	  2003,	  348,	  1365-­‐1375.	  6. Weir	  D	  M.	  Immunology.	  Fifth	  edition.	  Churchill	  Livingston	  Medical	  Text,	  1983.	  7. Chaplin	  D.	   Overview	   of	   the	   immune	   response.	   J.	   Allergy	   Clin.	   Immunol.	  2010,	  125,	  1-­‐29.	  	  8. Zhang	   Q,	   Vignali	   D.	   Co-­‐stimulatory	   and	   co-­‐inhibitory	   pathways	   in	  autoimmunity.	  Immunity.	  2016,	  44,	  1034-­‐1051.	  9. Compston	  A,	  Coles	  A.	  Multiple	  sclerosis.	  Lancet.	  2008,	  372,	  1502-­‐17.	  10. Compston	  A,	  Coles	  A.	  Multiple	  sclerosis.	  Lancet.	  2002,	  359,	  1221-­‐31.	  11. Milo	   R,	   Kahana	   E.	   Multiple	   sclerosis:	   Geoepidemiology,	   genetics	   and	   the	  environment.	  Autoimmun.	  Rev.	  2010,	  9,	  A387-­‐A394.	  12. Ascherio	  A,	  Munger	  K.	  Environmental	  risk	  factors	  for	  multiple	  sclerosis.	  Part	  I:	  The	  role	  of	  infection.	  Ann.	  Neurol.	  2007,	  61,	  288-­‐299.	  13. Trapp	   B,	   Nave	   K.	   Multiple	   sclerosis:	   an	   immune	   or	   neurodegenerative	  disorder?	  Annu.	  Rev.	  Neurosci.	  2008,	  31,	  247-­‐269.	  14. Ascherio	  A,	  Munger	  K.	  Environmental	  risk	  factors	  for	  multiple	  sclerosis.	  Part	  II:	  Noninfectious	  factors.	  Ann.	  Neurol.	  2007,	  61,	  504-­‐513.	  15. Holmøy	   T.	   A	   Norse	   contribution	   to	   the	   history	   of	   neurological	   diseases.	  Eur.	  
Neurol.	  2006,	  55,	  57-­‐58.	  16. Simpson	  S,	  Blizzard	  L,	  Otahal	  P,	  Van	  der	  Mei	  I,	  Taylor	  B.	  Latitude	  is	  significantly	  associated	  with	  the	  prevalence	  of	  multiple	  sclerosis:	  a	  meta-­‐analysis.	  J.	  Neurol.	  
Neurosurg.	  Psychiatry.	  2011,	  82,	  1132-­‐1141.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
17. Simpson	  S,	  Taylor	  B,	  Blizzard	  L,	  Ponsonby	  A,	  Pittas	  F,	  Tremlett	  H,	  Dwyer	  T,	  Gies	  P,	  Van	  der	  Mei	  I.	  Higher	  25-­‐hydroxyvitamin	  D	  is	  associated	  with	  lower	  relapse	  risk	  in	  multiple	  sclerosis.	  Ann.	  Neurol.	  2010,	  68,	  193-­‐203.	  18. Thacker	   E,	   Mirzaei	   F,	   Ascherio	   A.	   Infectious	   mononucleosis	   and	   risk	   for	  multiple	  sclerosis:	  a	  meta-­‐analysis.	  Ann.	  Neurol.	  2006,	  59,	  499-­‐503.	  19. Fujita	  T,	  Inoue	  K,	  Yamamoto	  S,	  Ikumoto	  T,	  Sasaki	  S,	  Toyama	  R,	  Yoneta	  M,	  Chiba	  K,	   Hoshino	   Y,	   Okumoto	   T.	   Fungal	   metabolites.	   Part	   11.	   A	   potent	  immunosuppressive	   activity	   found	   in	   Isaria	   sinclairii	   metabolite.	   J.	   Antibiot.	  
1994,	  47,	  208-­‐215.	  20. Fujita	  T,	  Inoue	  K,	  Yamamoto	  S,	  Ikumoto	  T,	  Sasaki	  S,	  Toyama	  R,	  Yoneta	  M,	  Chiba	  K,	   Hoshino	   Y,	   Okumoto	   T.	   Fungal	   metabolites.	   Part	   12.	   Potent	  immunosuppressant,	   14-­‐deoxomyriocin,	   (2S,	   3R,	   4R)-­‐(E)-­‐2-­‐amino-­‐3,4-­‐dihyroxy-­‐2-­‐hydroxymethyleicos-­‐6-­‐enoic	   acid	   and	   structure-­‐activity	  relationships	  of	  myriocin	  derivatives.	  J.	  Antibiot.	  1994,	  47,	  216-­‐224.	  21. Chun	   J,	   Brinkmann	  V.	   A	  mechanistically	   novel,	   first	   oral	   therapy	   for	  multiple	  sclerosis:	  the	  development	  of	  fingolimod	  (FTY720,	  Gilenya).	  Discov.	  Med.	  2011,	  12,	  213-­‐228.	  22. http://thelastofus.wikia.com/wiki/The_Infected	  23. Sasaki	   S,	   Hashimoto	   R,	   Kiuchi	   M,	   Inoue	   K,	   Ikumoto	   T,	   Hirose	   R,	   Chiba	   K,	  Hoshino	   Y,	   Okumoto	   T,	   Fujita	   T.	   Fungal	   metabolites.	   Part	   14.	   Novel	   potent	  immunosuppressants,	  mycestericins,	   produced	  by	  Mycelia	   sterilia.	   	   J.	   Antibiot.	  
1994,	  47,	  420-­‐433.	  24. Fujita	   T,	   Hamamichi	   N,	   Kiuchi	   M,	   Matsuzaki	   T,	   Kitao	   Y,	   Inoue	   K,	   Hirose	   R,	  Yoneta	   M,	   Sasaki	   S,	   Chiba	   K.	   Determination	   of	   absolute	   configuration	   and	  biological	  activity	  of	  new	  immunosuppressants,	  mycestericins	  D,	  E,	  F	  and	  G.	   J.	  
Antibiot.	  1996,	  49,	  846-­‐853	  25. Chiba	   K,	   Adachi	   K.	   Discovery	   of	   fingolimod,	   the	   sphingosine	   1-­‐phosphate	  receptor	   modulator	   and	   its	   application	   for	   the	   therapy	   of	   multiple	   sclerosis.	  
Future	  Med.	  Chem.	  2012,	  4,	  771-­‐781.	  26. Adachi	  K,	   Kohara	  T,	  Nakao	  N,	  Arita	  M,	   Chiba	  K,	  Mishina	  T,	   Sasaki	   S,	   Fujita	   T.	  Design,	   synthesis,	   and	   structure-­‐activity	   relationships	   of	   2-­‐substituted-­‐2-­‐amino-­‐1,3-­‐propanediols:	   Discovery	   of	   a	   novel	   immunosuppressant,	   FTY720.	  
Bioorg.	  Med.	  Chem.	  Lett.	  1995,	  8,	  853-­‐856.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
27. Oldstone	  M,	  Rosen	  H.	  Sphingosine-­‐1-­‐phosphate	  signalling	   in	   immunology	  and	  infectious	  diseases.	  Microbiol.	  Immunol.	  2014,	  378,	  1-­‐183.	  28. Blaho	  V,	  Hla	  T.	  An	  update	  on	  the	  biology	  of	  sphingosine	  1-­‐phosphate	  receptors.	  
J.	  Lipd	  Res.	  2014,	  55,	  1596-­‐1608.	  29. Brinkmann	   V,	   Billich	   A,	   Baumruker	   T,	   Heining	   P,	   Schmouder	   R,	   Francis	   G,	  Aradhye	   S,	   Burtin	   P.	   Fingolimod	   (FTY720):	   discovery	   and	  development	   of	   an	  oral	  drug	  to	  treat	  multiple	  sclerosis.	  Nat.	  Rev.	  Drug	  Discov.	  2010,	  9,	  883-­‐897.	  30. Chun	  J,	  Hartung	  H.	  Mechanism	  of	  action	  of	  oral	  fingolimod	  (FTY720)	  in	  multiple	  sclerosis.	  Clin.	  Neuropharmacol.	  2010,	  33,	  91-­‐101.	  31. Massberg	  S,	  Andrian	  U.	  Fingolimod	  and	  sphingosine-­‐1-­‐phosphate	  –	  Modifiers	  of	  lymphocyte	  migration.	  N.	  Engl.	  J.	  Med.	  2006,	  355,	  1088-­‐1091.	  32. Prager	  B,	  Spampinato	  S,	  Ransohoff	  R.	  Sphingosine	  1-­‐phosphate	  signalling	  at	  the	  blood-­‐brain	  barrier.	  Trends	  Mol.	  Med.	  2015,	  21,	  354-­‐363.	  33. Miron	  V,	  Schubart	  A,	  Antel	  J.	  Central	  nervous	  system-­‐directed	  effects	  of	  FTY720	  (fingolimod).	  J.	  Neurol.	  Sci.	  2008,	  274,	  13-­‐17.	  34. Pelletier	  D,	  Hafler	  D.	   Fingolimod	   for	  multiple	   sclerosis.	  N.	   Engl.	   J.	  Med.	  2012,	  366,	  339-­‐47.	  35. Sensken	  S,	  Bode	  C,	  Gräler	  M.	  Accumulation	  of	  fingolimod	  (FTY720)	  in	  lymphoid	  tissues	   contributes	   to	   prolonged	   efficacy.	   J.	   Pharmacol.	   Exp.	   Ther.	  2008,	   328,	  963-­‐969.	  36. Louveau	  A,	  Smirnov	  I,	  Keyes	  T,	  Eccles	  J,	  Rouhani	  S,	  Peske	  J,	  Derecki	  N,	  Castle	  D,	  Mandell	   J,	   Lee	   K,	   Harris	   T,	   Kipnis	   J.	   Structural	   and	   functional	   features	   of	   the	  central	  nervous	  lymphatic	  vessels.	  Nature.	  2015,	  523,	  337-­‐341.	  37. Kappos	  L,	  Antel	  J,	  Comi	  G,	  Montalban	  X,	  O’Connor	  P,	  Polman	  C,	  Haas	  T,	  Korn	  A,	  Karlsson	  G,	  Radue	  E.	  Oral	  fingolimod	  (FTY720)	  for	  relapsing	  multiple	  sclerosis.	  
N.	  Engl.	  J.	  Med.	  2006,	  355,	  1124-­‐1140.	  38. Mullerhausen	   F,	   Zecri	   F,	   Cetin	   C,	   Billich	   A,	   Guerini	   D,	   Seuwen	   K.	   Persisten	  signalling	   induced	   by	   FTY720-­‐phosphate	   is	   mediated	   by	   internalized	   S1P1	  receptors.	  Nat.	  Chem.	  Biol.	  2009,	  5,	  428-­‐434.	  39. Miron	   V,	   Ludwin	   S,	   Darlington	   P,	   Jarjour	   A,	   Soliven	   B,	   Kennedy	   T,	   Antel	   J.	  Fingolimod	   (FTY720)	   enhances	   remyelination	   following	   demyelination	   of	  organotypic	  cerebellar	  slices.	  Am.	  J.	  Pathol.	  2010,	  176,	  2682-­‐2694.	  40. Jackson	  S,	  Giovannoni	  G,	  Baker	  D.	  Fingolimod	  modulates	  microglial	  activation	  to	  augment	  markers	  of	  remyelination.	  J.	  Neuroinflammation.	  2011,	  8,	  1-­‐12.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
41. Deogracias	   R,	   Yazdani	   M,	   Dekkers	   M,	   Guy	   J,	   Ionescu	   M,	   Vogt	   K,	   Barde	   Y.	  Fingolimod,	   a	   sphingosine-­‐1	   phosphate	   receptor	   modulator,	   increases	   BDNF	  levels	   and	   improves	   symptoms	   of	   a	   mouse	   model	   of	   Rett	   syndrome.	   PNAS.	  
2012,	  109,	  14230-­‐14235.	  42. Fukumoto	   K,	   Mizoguchi	   H,	   Takeuchi	   H,	   Horiuchi	   H,	   Kawanokuchi	   J,	   Jin	   S,	  Mizuno	  T,	  Suzumura	  A.	  Fingolimod	  increases	  brain-­‐derived	  neurotrophic	  factor	  levels	   and	   ameliorates	   amyloid	   β-­‐induced	  memory	   impairment.	  Behav.	   Brain	  
Res.	  2014,	  268,	  88-­‐93.	  43. Doi	  Y,	  Takeuchi	  H,	  Horiuchi	  H,	  Hanyu	  T,	  Kawanokuchi	  J,	  Jin	  S,	  Parajuli	  B,	  Sonobe	  Y,	  Mizuno	  T,	  Suzumura	  A.	  Fingolimod	  phosphate	  attenuates	  oligomeric	  amyloid	  β-­‐induced	   neurotoxicity	   via	   increased	   brain-­‐derived	   neurotrophic	   factor	  expression	  in	  neurons.	  PLOS	  ONE.	  2013,	  8,	  1-­‐10.	  44. Hait	  N,	  Wise	  L,	  Allegood	   J,	  O’Brien	  M,	  Avni	  D,	  Reeves	  T,	  Knapp	  P,	  Lu	   J,	  Luo	  C,	  Miles	  M,	  Milstien	   S,	   Lichtman	   A,	   Spiegel	   S.	   Active	   phosphorylated	   fingolimod	  inhibits	   histone	   deacetylases	   and	   facilitates	   fear	   extinction	   memory.	   Nat.	  
Neurosci.	  2014,	  17,	  971-­‐980.	  45. Pardo	  A,	  Amico	  E,	  Favellato	  M,	  Castrataro	  R,	  Fucile	  S,	   Squitieri	  F,	  Maglione	  V.	  FTY720	   (fingolimod)	   is	   a	   neuroprotective	   and	   disease-­‐modifying	   agent	   in	  cellular	   and	   mouse	   models	   of	   Huntington	   disease.	  Hum.	   Mol.	   Gen.	   2014,	   23,	  2251-­‐2265.	  46. Liao	  A,	  Broeg	  K,	  Fox	  T,	  Tan	  S,	  Watters	  R,	  Shah	  M,	  Zhang	  L,	  Li	  Y,	  Ryland	  L,	  Yang	  J,	  Aliaga	  C,	  Dewey	  A,	  Rogers	  A,	  Loughran	  K,	  Hirsch	  L,	  Jarbadan	  N,	  Baab	  K,	  Liao	  J,	  Wang	  H,	  Kester	  M,	  Desal	  D,	  Amin	  S,	  Loughran	  T,	  Liu	  X.	  Therapeutic	  efficacy	  of	  FTY720	  in	  a	  rat	  model	  of	  NK-­‐cell	  leukemia.	  Blood.	  2011,	  118,	  2793-­‐2800.	  47. Moon	  M,	   Jeong	   J,	   Lee	   J,	   Park	  Y,	   Lee	   Y,	   Seol	   J,	   Park	   S.	   Antiobesity	   activity	   of	   a	  sphingosine	  1-­‐phosphate	  analogue	  FTY720	  observed	   in	  adipocytes	  and	  obese	  mouse	  model.	  Exp.	  Mol.	  Med.	  2012,	  44,	  603-­‐614.	  48. Copland	  D,	   Liu	   J,	   Schewitz-­‐Bowers	  L,	  Brinkmann	  V,	  Anderson	  K,	  Nicholson	  L,	  Dick	   A.	   Therapeutic	   dosing	   of	   fingolimod	   (FTY720)	   prevents	   cell	   infiltration,	  rapidly	   suppresses	   ocular	   inflammation,	   and	   maintains	   the	   blood-­‐ocular	  barrier.	  AJP.	  2012,	  180,	  672-­‐681.	  49. Hemmati	  F,	  Dargahi	  L,	  Nasoohi	  S,	  Omidbaksh	  R,	  Mohamed	  Z,	  Chik	  Z,	  Naidu	  M,	  Ahmadiani	  A.	  Neurorestorative	  effect	  of	  FTY720	  in	  a	  rat	  model	  of	  Alzheimer’s	  disease:	  comparison	  with	  memantine.	  Behav.	  Brain	  Res.	  2013,	  252,	  415-­‐421.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
50. Moon	  H,	  Chon	  J,	  Joo	  J,	  Kim	  D,	  In	  J,	  Lee	  H,	  Park	  J,	  Choi	  J.	  FTY720	  preserved	  islet	  β-­‐cell	   mass	   by	   inhibiting	   apoptosis	   and	   increasing	   survival	   of	   β-­‐cells	   in	   db/db	  mice.	  Diabetes	  Metab.	  Res.	  Rev.	  2013,	  29,	  19-­‐24.	  51. Kim	  H,	  Jung	  C,	  Dukala	  D,	  Bae	  H,	  Kakazu	  R,	  Wollmann	  R,	  Soliven	  B.	  Fingolimod	  and	   related	   compounds	   in	   a	   spontaneous	   autoimmune	   polyneuropathy.	   J.	  
Neuroimmunol.	  2009,	  214,	  93-­‐100.	  52. Brunkhorst	  R,	  Kanaan	  N,	  Koch	  A,	  Ferreiros	  N,	  Mirceska	  A,	  Zeiner	  P,	  Mittelbronn	  M,	  Derouiche	  A,	  Steinmetz	  H,	  Foerch	  C,	  Pfeilschifter	   J,	  Pfeilschifter	  W.	  FTY720	  treatment	   in	   the	   convalescence	   period	   improves	   functional	   recovery	   and	  reduces	  reactive	  astrogliosis	  in	  photothrombotic	  stroke.	  PLOS	  ONE.	  2013,	  8,	  1-­‐9.	  53. Rolland	  W,	   Lekic	   T,	   Krafft	   P,	   Hasegawa	   Y,	   Altay	   O,	   Hartman	   R,	   Ostrowski	   R,	  Manaenko	   A,	   Tang	   J,	   Zhang	   J.	   Fingolimod	   reduces	   cerebral	   lymphocyte	  infiltration	   in	   experimental	  models	   of	   rodent	   intracerebral	   hemorrhage.	  Exp.	  
Neurol.	  2013,	  241,	  45-­‐55.	  54. Murphy	  C,	  Hall	  L,	  Huley	  G,	  Quinlan	  A,	  MacSharry	  J,	  Shanahan	  F,	  Nally	  K,	  Melgar	  S.	   The	   sphingosine-­‐1-­‐phosphate	   analogue	   FTY720	   impairs	  mucosal	   immunity	  and	  clearance	  of	  enteric	  pathogen	  citrobacter	  rodentium.	  Infect.	  Immun.	  2012,	  80,	  2712-­‐2723.	  55. Cohen	   J,	   Chun	   J.	   Mechanisms	   of	   fingolimod’s	   efficacy	   and	   adverse	   effects	   in	  multiple	  sclerosis.	  Ann.	  Neurol.	  2011,	  69,	  759-­‐777.	  56. Kovarik	   J,	   Slade	  A,	  Riviere	  G,	  Neddermann	  D,	  Maton	  S,	  Hunt	  T,	   Schmouder	  R.	  The	  ability	  of	  atropine	  to	  prevent	  and	  reverse	  the	  negative	  chronotropic	  effect	  of	  fingolimod	  in	  healthy	  subjects.	  Br.	  J.	  Clin.	  Pharmacol.	  2008,	  66,	  199-­‐206.	  57. Gross	  C,	  Baumgartner	  A,	  Rauer	  S,	  Stich	  O.	  Multiple	  sclerosis	  rebound	  following	  herpes	   zoster	   infection	   and	   suspension	   of	   fingolimod.	   Neurology.	   2012,	   79,	  1942-­‐1943.	  58. Gasperini	  C,	  Ruggieri	  S.	  Development	  of	  oral	  agent	  in	  the	  treatment	  of	  multiple	  sclerosis:	   how	   the	   first	   available	   oral	   therapy,	   fingolimod	   will	   change	  therapeutic	  paradigm	  approach.	  Drug	  Des.	  Dev.	  Ther.	  2012,	  6,	  175-­‐186.	  59. Bigaud	  M,	   Guerini	   D,	   Billich	   A,	   Bassilana	   F,	   Brinkmann	   V.	   Second	   generation	  S1P	   pathway	   modulators:	   Research	   strategies	   and	   clinical	   developments.	  	  
Biochim.	  Biophys.	  Acta.	  2014,	  1841,	  745-­‐758.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
60. Brinkmann	  V,	  Davis	  M,	  Heise	  C,	  Albert	  R,	  Cottens	  S,	  Hof	  R,	  Bruns	  C,	  Prieschl	  E,	  Baumruker	   T,	   Hiestand	   P,	   Foster	   C,	   Zollinger	   M,	   Lynch	   K.	   The	   immune	  modulator	   FTY720	   targets	   sphingosine	   1-­‐phosphate	   receptors.	   J.	   Biol.	   Chem.	  
2002,	  277,	  21453-­‐21457.	  61. Deng	   H,	   Bernier	   S,	   Doyle	   E,	   Lorusso	   J,	   Morgan	   B,	   Westlin	   W,	   Evindar	   G.	  Discovery	   of	   clinical	   candidate	   GSK1842799	   as	   a	   selective	   S1P1	   receptor	  agonist	  (prodrug)	  for	  multiple	  sclerosis.	  ACS	  Med.	  Chem.	  Lett.	  2013,	  4,	  942-­‐947.	  62. Tsuji	   T,	   Suzuki	   K,	   Nakamura	   T,	   Goto	   T,	   Sekiguchi	   Y,	   Ikeda	   T,	   Fukuda	   T,	  Takemoto	   T,	   Mizuno	   Y,	   Kimura	   T,	   Kawase	   Y,	   Nara	   F,	   Kagari	   T,	   Shimozato	   T,	  Yahara	   C,	   Inaba	   S,	   Honda	   T,	   Izumi	   T,	   Tamura	  M,	   Nishi	   T.	   Synthesis	   and	   SAR	  studies	  of	  benzyl	  ether	  derivatives	  as	  potent	  orally	  active	  S1P1	  agonists.	  Bioorg.	  
Med.	  Chem.	  2014,	  22,	  4246-­‐4256.	  63. Hamada	  M,	  Nakamura	  M,	  Kiuchi	  M,	  Marukawa	  K,	  Omatsu	  A,	  Shimano	  K,	  Sato	  N,	  Sugahara	   K,	   Asayama	   M,	   Takagi	   K,	   Adachi	   K.	   Removal	   of	   sphingosine	   1-­‐phosphate	   receptor-­‐3	   (S1P3)	   agonism	   is	   essential,	   but	   inadequate	   to	   obtain	  immunomodulating	   2-­‐aminopropane-­‐1,3-­‐diol	   S1P1	   agonists	   with	   reduced	  effect	  on	  heart	  rate.	  J.	  Med.	  Chem.	  2010,	  53,	  3154-­‐3168.	  64. Lipinski	  C,	  Lombardo	  F,	  Dominy	  B,	  Feeney	  P.	  Experimental	  and	  computational	  approaches	   to	   estimate	   solubility	   and	   permeability	   in	   drug	   discovery	   and	  development	  settings.	  Adv.	  Drug	  Deliv.	  Rev.	  2001,	  46,	  3-­‐26.	  65. Pajouhesh	   H,	   Lenz	   G.	   Medicinal	   chemical	   properties	   of	   successful	   central	  nervous	  system	  drugs.	  NeuroRx.	  2005,	  2,	  541-­‐553.	  66. Rankovic	  Z.	  CNS	  drug	  design:	  balancing	  physicochemical	  properties	  for	  optimal	  brain	  exposure.	  J.	  Med.	  Chem.	  2015,	  58,	  2584-­‐2608.	  67. Rautio	  J,	  Kumpulainen	  H,	  Heimbach	  T,	  Oliyai	  R,	  Oh	  D,	  Järvinen	  T,	  Savolainen	  J.	  Prodrugs:	  design	  and	  clinical	  applications.	  Nat.	  Rev.	  Drug	  Discov.	  2008,	  7,	  255-­‐270.	  68. Stanczak	  A,	  Ferra	  A.	  Prodrugs	  and	  soft	  drugs.	  Pharmacol.	  Rep.	  2006,	  58,	  599-­‐613.	  69. Huttunen	  K,	  Raunio	  H,	  Rautio	   J.	  Prodrugs-­‐from	  serendipity	   to	  rational	  design.	  
Pharmacol.	  Rev.	  2011,	  63,	  750-­‐771.	  70. Passie	   T,	   Seifert	   J,	   Schneider	   U,	   Emrich	   H.	   The	   pharmacology	   of	   psilocybin.	  
Addict.	  Biol.	  2002,	  7,	  357-­‐364.	  
Chapter	  1	  
	   	   	  
	  
Confidential	  
71. Pradere	   U,	   Garnier-­‐Amblard	   E,	   Coats	   S,	   Amblard	   F,	   Schinazi	   R.	   Synthesis	   of	  nucleoside	  phosphate	  and	  phosphonate	  prodrugs.	  Chem.	  Rev.	  2014,	  114,	  9154-­‐9218.	  72. Hartline	  C,	  Gustin	  K,	  Wan	  W,	  Ciesla	  S,	  Beadle	  J,	  Hostetler	  K,	  Kern	  E.	  Ether	  lipid-­‐ester	  prodrugs	  of	  acyclic	  nucleoside	  phosphonates:	  activity	  against	  adenovirus	  replication	  in	  vitro.	  J.	  Infect.	  Dis.	  2005,	  191,	  396-­‐9.	  73. McGuigan	  C,	  Murziani	  P,	  Slusarczyk	  M,	  Gonczy	  B,	  Voorde	  J,	  Liekens	  S,	  Balzarini	  J.	  Phosphoramidate	  ProTides	  of	  the	  anticancer	  agent	  FUDR	  successfully	  deliver	  the	  preformed	  bioactive	  monophosphate	  in	  cells	  and	  confer	  advantage	  over	  the	  parent	  nucleoside.	  J.	  Med.	  Chem.	  2011,	  54,	  7247-­‐7258.	  74. Mehellou	   Y,	   Balzarini	   J,	   McGuigan	   C.	   Aryloxy	   phosphoramidate	   triesters:	   a	  technology	   for	   delivering	   monophosphorylated	   nucleosides	   and	   sugars	   into	  cells.	  ChemMedChem.	  2009,	  4,	  1779-­‐1791.	  75. Toschi	   L,	   Finocchiaro	   G,	   Bartolini	   S,	   Gioia	   V,	   Cappuzzo	   F.	   The	   role	   of	  gemcitabine	  in	  cancer	  therapy.	  Future	  Oncol.	  2005,	  1,	  7-­‐17.	  76. Slusarczyk	  M,	  Lopez	  M,	  Balzarini	  J,	  Mason	  M,	  Jiang	  W,	  Blagden	  S,	  Thompson	  E,	  Ghazaly	   E,	   McGuigan	   C.	   Application	   of	   ProTide	   technology	   to	   gemcitabine:	   a	  successful	  approach	  to	  overcome	  the	  key	  cancer	  resistance	  mechanisms	  leads	  to	   a	   new	   agent	   (NUC-­‐1031)	   in	   clinical	   development.	   J.	   Med.	   Chem.	  2014,	   57,	  1531-­‐1542.	  77. Sofia	  M,	  Bao	  D,	  Chang	  W,	  Du	  J,	  Nagarathnam	  D,	  Rachakonda	  S,	  Redyy	  P,	  Ross	  B,	  Wang	  P,	  Zhang	  H,	  Bansal	  S,	  Espiritu	  C,	  Keilman	  M,	  Lam	  A,	  Micolochick	  H,	  Niu	  C,	  Otto	   M,	   Furman	   P.	   Discovery	   of	   a	   β-­‐D-­‐2’-­‐deoxy-­‐2’-­‐α-­‐fluoro-­‐2’-­‐β-­‐C-­‐methyluridine	  nucleotide	  prodrug	   (PSI-­‐7977)	   for	   the	   treatment	  of	  hepatitis	  C	  virus.	  J.	  Med.	  Chem.	  2010,	  53,	  7202-­‐7218.	  78. Birkus	  G,	  Wang	  R,	  Liu	  X,	  Kutty	  N,	  MacArthur	  H,	  Cohlar	  T,	  Gibbs	  C,	  Swaminathan	  S,	   Lee	   W,	   McDermott	   M.	   Cathepsin	   A	   Is	   the	   Major	   Hydrolase	   Catalyzing	   the	  Intracellular	   Hydrolysis	   of	   the	   Antiretroviral	   Nucleotide	   Phosphonoamidate	  Prodrugs	  GS-­‐730	  and	  GS-­‐9131.	  Antimicrob.	  Agents	  Chemother.	  2007,	   51,	  543-­‐550.	  79. Zhou	   X,	   Chou	   T,	   Aubol	   B,	   Park	   C,	   Wolfenden	   R,	   Adams	   J,	   Wagner	   C.	   Kinetic	  Mechanism	   of	   Human	   Histidine	   Triad	   Nucleotide	   Binding	   Protein	   1.	  
Biochemistry.	  2012,	  52,	  3588-­‐3600.	  	  
Chapter	  1	  
	   	   	  
	  
Confidential	  






2.1.1	  The	  Synthetic	  Challenge	  	  In	   order	   to	   produce	   novel	   phosphoramidate	   prodrugs	   of	   fingolimod	   a	   synthesis	  route	  needs	  to	  be	  developed.	  As	  the	  synthesis	  of	  these	  compounds	  has	  never	  been	  previously	   performed,	   and	   literature	   searching	   provides	   no	   synthesis	   routes	   to	  produce	  the	  desired	  compounds,	  the	  method	  needs	  to	  be	  discovered.	  	  
	  






































Figure	  2.1	  Desired	  S-­‐isomer	  of	  ProTide	  Fingolimod	  	  
	  
Figure	  2.2	  Likely	  bis-­‐product	  which	  is	  not	  expected	  to	  have	  favourable	  biological	  activity	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The	  first	  problem	  to	  tackle	  regarding	  this	  synthetic	  challenge	  was	  to	  try	  to	  find	  a	  reaction	  system	  that	  would	  cause	  a	  phosphorochloridate	  to	  selectively	  bind	  to	  the	  OH	  group	  rather	  than	  the	  NH2	  group.	  NH2	  groups	  are	  significantly	  more	  basic	  than	  OH	  groups	  and	  the	  OH	  groups	  on	  fingolimod	  have	  a	  pKa	  value	  of	  approximately	  16	  whereas	  the	  amine	  has	  a	  pKa	  value	  of	  around	  30	  and	  it	  is	  logical	  to	  expect	  that	  the	  NH2	   group	   will	   nucleophilically	   attack	   the	   phosphorus	   atom	   of	   the	  phosphorochloridate	  more	   readily	   than	  an	  OH	  group.2	   In	  order	   to	   find	  a	  method	  that	  would	   lead	   to	  O-­‐bound	  phosphoramidate	  an	  alternative	  molecule	   that	   could	  act	   as	   a	  model	   for	   fingolimod	  was	  used.	   It	  was	  decided	   that	  3-­‐amino-­‐1-­‐propanol	  would	   make	   a	   good	   model	   as	   it	   possesses	   an	   OH	   group	   and	   a	   NH2	   group.	   The	  simplicity	  of	  the	  molecule	  should	  also	  make	  interpretation	  of	  the	  data	  easier	  than	  it	  would	  be	  if	  a	  more	  complex	  model	  were	  used.	  	   	  
Figure	  2.4	  3-­‐amino-­‐1-­‐propanol	  	  
2.1.2	   Phosphorochloridate	  Chemistry	  	  The	   first	   step	   of	   a	   standard	   phosphoramidate	   synthesis	   is	   to	   synthesise	   a	  phosphorochloridate.1,3,4	   It	   was	   decided	   that	   phenyl-­‐(benzyloxy-­‐L-­‐alaninyl)	  phosphorochloridate	   would	   be	   an	   adequate	   starting	   phosphorochloridate	   as	  ProTides	  synthesised	  with	  this	  phosphorochloridate	  are	  often	  found	  to	  have	  more	  favourable	  biological	  activity.	  	  	  
	  











































































Figure	  2.6	  31P	  NMR	  of	  Ph-­‐LAla-­‐OBzl	  PCl	  	  	  	  	  	  	  	  	  	  	  
Chapter	  2	  





Figure	  2.7	  Structure	  and	  1H	  NMR	  spectrum	  of	  Ph-­‐Gly-­‐OMe	  PCl	  
A	  =	  7.2	  –	  7.5	  ppm	  (5H),	  B	  =	  3.95	  ppm	  (2H),	  C	  =	  3.8	  ppm	  (3H),	  D	  =	  4.5	  ppm	  (1H)	  	  	  

























NAME        CM-EL-131.2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150401
Time              11.13
INSTRUM       Avance500
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                   16
DS                    2
SWH           10330.578 Hz
FIDRES         0.157632 Hz
AQ            3.1719425 sec
RG                  144
DW               48.400 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        500.1330885 MHz
NUC1                 1H
P1                11.50 usec
PLW1        11.37600040 W
F2 - Processing parameters
SI                32768
SF          500.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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product	   of	   this	   reaction	   was	   observed	   to	   be	   the	   unwanted	   N-­‐bound	  phosphoramidate	  with	  no	  O-­‐bound	  phosphoramidate	  observed.	  	  
	  
Scheme	  2.4	  3-­‐amino-­‐1-­‐propanol	  phosphoramidate	  synthesis	  using	  NaH	  	  
	  











































PC                 1.40
GB                    0
LB                 1.00 Hz
SSB                   0
WDW                  EM
SF          202.4563350 MHz
SI                32768
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PL13W        0.00000000 W
PL12W        0.29600734 W
PL2W        14.33185768 W
PL13             120.00 dB
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======== CHANNEL f2 ========
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======== CHANNEL f1 ========
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D11          0.03000000 sec
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TD                16384
PULPROG          zgpg30
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Date_          20140131
PROCNO                1
EXPNO                 2
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phosphoramidate	   can	   be	   seen	   further	   downfield	   at	   10.65	   ppm	   and	   10.38	   ppm.	  These	   chemical	   shifts	   are	   indicative	   of	   the	   N-­‐bound	   product	   as	   N-­‐bound	  phosphoramidates	  usually	  have	  a	  chemical	   shift	  of	  between	  10	  and	  11	  ppm.	  The	  two	   peaks	   observed	   for	   the	   product	   correspond	   to	   the	   two	   expected	  diastereoisomers.	  	  
	  
Figure	  2.9	  The	  two	  N-­‐bound	  diastereoisomers	  formed	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2.1.4	   Phosphoramidate	  Synthesis	  Using	  a	  NMI	  Base	  	  The	   next	   reaction	   conditions	   tested	   involved	   using	   N-­‐methylimidazole	   base	   in	  anhydrous	   tetrahydrofuran	   solvent.	   The	   reaction	   was	   begun	   at	   0	   °C	   but	   then	  allowed	  to	  warm	  to	  room	  temperature.	  The	  reaction	  mixture	  was	  left	  to	  stir	  over	  the	  weekend.	  These	  reaction	  conditions	  have	  previously	  proven	  to	  be	  effective	  in	  synthesising	  novel	  phosphoramidates.	  1,4,6,7,8	  	  
	  




















Figure	  2.10	  31P	  NMR	  of	  phosphoramidate	  product	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2.1.5	   Phosphoramidate	  Synthesis	  Using	  a	  NaOMe	  Base	  	  Other	   reaction	   conditions	   tested	   involved	   using	   sodium	   methoxide	   base	   in	  anhydrous	   dichloromethane	   solvent.	   The	   reaction	  was	   begun	   at	   -­‐78	   °C	   and	   then	  allowed	  to	  warm	  to	  room	  temperature.	  The	  reaction	  mixture	  was	  left	  to	  stir	  for	  1.5	  hours.	  Again	  the	  major	  product	  of	  the	  reaction	  was	  the	  N-­‐bound	  phosphoramidate	  and	  no	  O-­‐bound	  product	  was	  observed.	  	  	  
	  
Scheme	  2.8	  3-­‐amino-­‐1-­‐propanol	  phosphoramidate	  synthesis	  using	  NaOMe	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2.1.6	   Phosphoramidate	  Synthesis	  Using	  a	  tBuMgCl	  Base	  	  However	   it	   was	   found	   that	   when	   using	   tertiary-­‐butylmagnesium	   chloride	  (tBuMgCl)	  in	  anhydrous	  tetrahydrofuran	  solvent	  at	  room	  temperature1,3,4,5,6,7,9	  for	  24	  hours	  the	  phosphorochloridate	  bound	  to	  both	  the	  OH	  group	  and	  the	  NH2	  group:	  	  
	  























Figure	  2.12	  31P	  NMR	  of	  phosphoramidate	  product	  using	  tBuMgCl	  	  The	  4	  major	  peaks	  observed	  at	  3.96,	  3.92,	  3.64	  and	  3.61	  ppm	  were	  considered	  to	  likely	  be	  indicative	  of	  an	  O-­‐bound	  phosphoramidate.	  To	  be	  sure	  that	  the	  new	  peaks	  further	  upfield	  were	  not	  unreacted	  phosphorochloridate	  the	  product	  was	  “spiked”	  with	   phosphorochloridate	   starting	   material.	   Figure	   2.13	   shows	   the	   31P	   NMR	  spectrum	  obtained	  when	  the	  product	  of	  the	  tBuMgCl	  synthesis	  was	  spiked	  with	  the	  phosphorochloridate.	  The	  peaks	  which	  correspond	  to	  the	  N-­‐bound	  phosphorus	  on	  the	   3-­‐amino-­‐1-­‐propanol	   can	   be	   seen	   at	   11.75,	   11.44	   and	   11.38	   ppm.	   The	   peaks	  which	  correspond	  to	  the	  O-­‐bound	  phosphorus	  on	  the	  3-­‐amino-­‐1-­‐propanol	  can	  be	  seen	  at	  3.95,	  3.92,	  3.63	  and	  3.60	  ppm.	  The	  spiked	  phosphorochloridate	  peaks	  can	  be	  seen	  at	  5.04	  and	  4.81	  ppm.	  The	  phosphorochloridate	  peaks	  are	  further	  upfield	  in	   this	   spectrum	   compared	   to	   the	   earlier	   spectra	   shown	   (figures	   2.6	   and	   2.8)	  because	   this	   particular	  NMR	   experiment	  was	   conducted	   in	  MeOD	   as	   opposed	   to	  CDCl3	  and	  different	  solvents	  can	  cause	  the	  chemical	  shifts	  to	  be	  different	  when	  run	  in	  NMR.	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Figure	   2.13	   31P	   NMR	   of	   phosphoramidate	   product	   ‘spiked’	   with	   phosphorochloridate	   starting	  material	  	  After	  establishing	  that	  the	  new	  peaks	  seen	  between	  3	  –	  4	  ppm	  do	  correspond	  to	  O-­‐bound	   phosphoramidate	   it	   was	   considered	   that	   the	   data	   may	   be	   spectra	   of	   a	  mixture	  of	  O-­‐bound	  and	  N-­‐bound	  phosphoramidates.	  Mass	  spectrometry	  showed	  that	   it	   is	   just	   one	   product:	   3-­‐amino-­‐1-­‐propanol	   with	   phosphoramidate	   moieties	  bound	  at	  both	  the	  N-­‐terminal	  and	  the	  O-­‐terminal.	  The	  predicted	  mass	  of	  this	  bis-­‐product	   is	   709.2	   g/mol	   and	   the	   observed	   mass	   is	   710.3	   m/z	   (M+H+).	   Further	  evidence	  to	  prove	  that	   it	   is	   just	  one	  compound	  rather	  than	  a	  mixture	   include	  the	  fact	  that	  the	  product	  was	  observed	  just	  as	  one	  spot	  on	  thin	  layer	  chromatography	  (TLC)	   and	   the	   presence	   of	   4	   peaks	   at	   both	   the	   O	   and	  N	   regions	   of	   the	   31P	  NMR	  spectrum.	  The	  8	  major	  peaks	  observed	   in	  the	  31P	  NMR	  spectrum	  are	  presumably	  due	  to	  the	  4	  different	  diastereoisomers	  that	  are	  formed	  by	  this	  synthesis	  as	  shown	  in	  figure	  2.14.	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As	   the	   NH2	   group	   in	   fingolimod	   is	   far	   more	   sterically	   hindered	   than	   the	   NH2	  present	   in	   3-­‐amino-­‐1-­‐propanol	   it	  was	   hypothesised	   that	   the	   bulky	   tertiary	   butyl	  group	   of	   tBuMgCl	  would	   not	   be	   able	   to	   easily	   deprotonate	   the	   amine	   group	   and	  thus	  the	  amine	  group	  would	  not	  bind	  to	  the	  phosphorochloridate.	   It	  was	  decided	  that	   another	   model	   would	   be	   used	   which	   more	   accurately	   represents	   the	  functional	   characteristics	   of	   fingolimod.	   This	   time	   2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol	  was	   used	   as	   it	   has	   a	   primary	   alcohol	   group	   and	   a	   NH2	   group	   attached	   to	   a	  quaternary	  carbon	  thus	  putting	  the	  NH2	  group	  in	  a	  much	  more	  sterically	  hindered	  position.	  For	   the	  purposes	  of	   the	   regioselective	  questions	   trying	   to	  be	  addressed	  this	  molecule	  is	  a	  more	  accurate	  model	  of	  fingolimod.	  	  
	  
Scheme	  2.12	  Phosphoramidate	  formation	  using	  tBuMgCl	  and	  2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol	  	  	  
	  























Figure	   2.15	   31P	   NMR	   of	   phosphoramidate	   product	   using	   tBuMgCl	   and	   2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol	   	  The	  31P	  NMR	  spectrum	  of	  the	  yielded	  product	  shown	  in	  figure	  2.15	  clearly	  shows	  the	   desired	   2	   major	   peaks	   between	   2	   and	   4	   ppm	   that	   correspond	   to	   O-­‐bound	  phosphoramidate	   and	   no	   peaks	   between	   10	   and	   12	   ppm	   that	   would	   imply	   the	  phosphoramidate	   bound	   to	   the	   NH2	   amine	   group.	   	   Mass	   spectrometry	   further	  confirmed	   the	   synthesis	   as	   the	   predicted	  mass	   is	   330.1	   g/mol	   and	   the	   observed	  mass	  is	  331.1	  m/z.	  This	  represented	  a	  breakthrough	  in	  this	  project	  and	  removed	  a	  significant	  synthetic	  hurdle.	  	  
	  
Figure	  2.16	  The	   two	  products	  of	   the	   reaction	   that	  give	   the	   two	  major	  peaks	  observed	   in	   the	   31P	  NMR	  spectrum	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Following	   the	   success	   of	   the	   phosphoramidate	   2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol	  synthesis	   it	  was	  concluded	  that	   there	  was	  enough	  evidence	   to	  suggest	   that	   those	  reaction	   conditions	   used	   could	   be	   used	   to	   synthesise	   novel	   ProTide	   fingolimod	  analogues.	   The	   lead	   reaction	   conditions	   devised	   after	   conducting	   these	  experiments	  are:	  	  	  
tBuMgCl	   (1	   equivalent)	   is	   added	   dropwise	   to	   a	   solution	   of	   primary	   alcohol	   (e.g.	  
fingolimod	  hydrochloride)	  (1	  equivalent)	  in	  anhydrous	  THF	  (7	  ml)	  under	  anhydrous	  
conditions.	  The	  mixture	  is	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  
the	  phosphorochloridate	  (1	  equivalent)	   in	  anhydrous	  THF	  (2	  ml)	   is	  added	  dropwise	  
to	   the	   stirring	   reaction	  mixture.	   The	   reaction	   is	   left	   to	   stir	   for	   24	   hours.	   After	   24	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Chapter	  3	  -­	  Synthesis	  of	  ProTide	  Fingolimod	  Analogues	  
	  
	  
3.1	  Phosphoramidate	  Fingolimod	  Synthesis	  
	  Using	   the	   reaction	   conditions	   that	   were	   developed	   to	   yield	   the	   bis	   3-­‐amino-­‐1-­‐propanol	   phosphoramidate	   and	  O-­‐bound	   phosphoramidate	   2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol,	  a	  reaction	  with	   the	  aim	  of	  synthesising	  a	  phosphoramidate	  by	  reacting	  fingolimod	  hydrochloride	  with	  a	  phosphorochloridate	  was	  attempted.	  	  	  	   	  The	   phosphorochloridate	   that	   was	   initially	   synthesised	   in	   preparation	   for	   the	  reaction	   was	   phenyl-­‐(methoxy-­‐L-­‐alaninyl)	   phosphorochloridate	   as	   shown	   in	  scheme	  3.1.	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unwanted	   bis	   product	   or	   a	   mixture	   of	   different	   products.	   Inevitably	   if	   this	  synthesis	  were	  to	  go	  as	  well	  as	  realistically	  possible,	  such	  as	  100%	  yield	  of	  mono	  phosphoramidate	   fingolimod	  with	   the	   4	   likely	   diastereoisomers	   yielded	   in	   equal	  proportions	   of	   25%	   of	   the	   overall	   yield,	   some	   form	   of	   separation	   would	   be	  necessary	  in	  order	  to	  isolate	  the	  desired	  S-­‐isomer.	  	  
	  
Scheme	   3.2	   Ideal	   (although	   highly	   improbable)	   result	   of	   the	   reaction	   yielding	   the	   S-­‐isomer	   of	  fingolimod	  phosphoramidate	   	  The	   reaction	  was	   conducted	  as	  described	  at	   the	  end	  of	   the	  Discussion	   section	  of	  Chapter	   2.	   The	   reaction	   was	   left	   overnight	   and	   the	   process	   of	   analysing	   the	  reaction	  mixture	  and	  separating	  the	  products	  began	  the	  next	  day.	  TLC	  showed	  that	  there	  were	  more	  products	  or	  by-­‐products	   from	  this	  reaction	  than	  were	  observed	  when	   conducting	   phosphoramidate	   syntheses	   with	   3-­‐amino-­‐1-­‐propanol	   or	   2-­‐amino-­‐2-­‐methyl-­‐1-­‐propanol.	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The	   spots	   on	   the	   TLC	   were	   visible	   using	   UV	   light	   and	   were	   also	   visible	   when	  stained	  with	  KMnO4.	   It	  was	  decided	  that	  running	  column	  chromatography	  on	  the	  reaction	   mixture	   in	   an	   eluent	   system	   using	   dichloromethane	   and	   progressively	  increasing	   percentages	   of	   methanol	   would	   be	   a	   sensible	   method	   of	   trying	   to	  separate	  the	  different	  compounds	  observed	  using	  TLC.	  	  After	   running	   the	   column	   a	   small	   sample	   of	   each	   of	   the	   fractions	   collected	   was	  spotted	  onto	  TLC	  paper	  and	  then	  held	  under	  UV	  light	  to	  see	  in	  which	  fractions	  the	  compounds	  of	  interest	  had	  eluted.	  	  UV	  activity	  was	  observed	  in:	  	  
• Fractions	  16	  –	  20	  
• Fractions	  26	  –	  29	  
• Fractions	  32	  –	  40	  	  It	   is	  believed	   that	   the	  UV	  activity	  observed	   in	   these	   fractions	   corresponds	   to	   the	  three	  areas	  of	  UV	  activity	  seen	  when	  conducting	  TLC	  on	  the	  crude	  reaction	  mixture	  in	  10%	  MeOH	  and	  90%	  AcOEt	  as	  shown	  in	  figures	  3.1	  and	  3.2.	  The	  three	  groups	  of	  fractions	  were	  collected	  separately	  and	  the	  solvents	  were	  removed	  in	  vacuo.	  	  	  
	  	  
Figure	  3.2	  The	  spots	  observed	  via	  TLC	  (MeOH	  10	  %	  /	  AcOEt	  90%)	  and	  the	  fractions	  to	  which	  they	  correspond	   	  	  	  
Fractions 16 - 20
Fractions 26 - 29
Fractions 32 - 40
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3.1.1	  Fractions	  16	  -­	  20	  	  The	  product	  of	  fractions	  16	  -­‐	  20	  was	  observed	  to	  be	  a	  clear	  oil	  with	  a	  mass	  of	  290	  mg	   after	   commencing	   the	   experiment	  with	   500	  mg	   fingolimod	   HCl	   and	   403	  mg	  phosphorichloridate.	   	   31P	   NMR	   (as	   shown	   in	   figure	   3.3)	   and	   1H	   NMR	   were	  conducted.	  Analysis	  of	  these	  spectra	  and	  later	  mass	  spectroscopic	  analysis	  showed	  that	  the	  mixture	  of	  compounds	  yielded	  in	  fractions	  16	  -­‐	  20	  are	  4	  different	  isomers	  (figures	  3.3	  and	  3.4)	  of	  the	  expected	  bis	  fingolimod	  phosphoramidate.	  Eight	  major	  peaks	   are	   seen	   in	   the	   31P	  NMR	  spectrum	   (as	   shown	   in	   figure	  3.3)	   as	   there	   are	  4	  different	  isomers	  and	  2	  phosphorus	  atoms	  thus	  making	  the	  number	  of	  peaks	  4	  x	  2	  =	  8	  peaks.	  The	  predicted	  mass	  of	  the	  bis	  product	  is	  789.4	  g/mol	  and	  the	  main	  peak	  observed	  using	  mass	   spectrometry	  has	   a	  mass	  of	  790.4	  m/z.	  The	   integrations	  of	  the	  peaks	  in	  the	  aromatic	  region	  of	  the	  1H	  NMR	  spectrum	  are	  also	  highly	  indicative	  of	  the	  expected	  bis	  product.	  	   	  	  	  
	  
Figure	  3.3	  31P	  NMR	  of	  the	  product	  yielded	  in	  fractions	  16	  –	  20	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Figure	  3.4	  The	  suggested	  products	  collected	  in	  fractions	  16	  –	  20	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observed	  mass	  was	  549.3	  m/z.	  A	  yield	  of	  350	  mg	  of	  the	  desired	  product	  (ignoring	  isomer	  issues)	  is	  a	  satisfying	  yield	  of	  44%.	  It	  was	  concluded	  that,	  barring	  the	  issues	  of	   having	   to	   still	   separate	   the	   different	   diastereoisomers,	   the	   synthesis	   and	  purification	   route	   devised	   is	   perfectly	   acceptable	   for	   small	   scale	   laboratory	  synthesis	  of	  ProTide	  fingolimod	  analogues.	  	  
	  
Figure	  3.5	  31P	  NMR	  of	  the	  product	  yielded	  in	  fractions	  26	  –	  29	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Figure	  3.6	  The	  four	  different	  diastereoisomers	  of	  mono	  ProTide	  fingolimod	  formed	  by	  the	  reaction	  with	  the	  desired	  S-­‐Ph-­‐LAla-­‐OMe-­‐F	  analogues	  above	  and	  the	  undesired	  R-­‐Ph-­‐LAla-­‐OMe-­‐F	  analogues	  below	   	  











































Figure	   3.7	   An	   unwanted	   by-­‐product	   of	   the	   reaction	   that	   is	   possibly	   responsible	   for	   the	   peak	  observed	  in	  the	  PNMR	  spectrum	  of	  the	  product	  obtained	  in	  fractions	  32	  –	  40	  	  
	  








	   	   	  
	  
Confidential	  
3.1.4	   NMR	   Analyses	   of	   Phenyl-­(Methyloxy-­L-­Alaninyl)	   Phosphoramidate	  
Fingolimod	  	  The	  mixture	   of	   bis	   isomers	   obtained	   from	   fractions	   16	   –	   20	   and	   the	  mixture	   of	  mono	  isomers	  obtained	  from	  fractions	  26	  –	  29	  were	  placed	  under	  high	  vacuum	  to	  try	  to	  remove	  remaining	  solvents	  such	  as	  dichloromethane	  and	  methanol.	  Solvent	  peaks	  are	  easily	  visible	   in	  the	  original	  1H	  NMR	  spectra	  and	  removal	  of	  remaining	  solvent	   from	   the	   product	   leads	   to	   improved	   1H	   NMR	   results.	   After	   placing	   the	  mono	   ProTide	   fingolimod	   (named	   unofficially	   as	   Ph-­‐LAla-­‐OMe-­‐F)	  mixture	   under	  high	   vacuum	   31P	   NMR,	   1H	   NMR,	   13C	   NMR,	   COSY	   and	   HSQC	   nuclear	   magnetic	  resonance	  experiments	  were	  conducted.	  	  
	  
Figure	   3.9	   31P	   NMR	   spectrum	   of	   Ph-­‐LAla-­‐OMe-­‐F	   showing	   no	   unwanted	   impurities	   or	   N-­‐bound	  phosphoramidate	  moiety	  as	  would	  be	  seen	  at	  around	  11	  ppm	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Figure	   3.10	   Ph-­‐LAla-­‐OMe-­‐F	   (1),	   letters	   A	   –	   N	   correspond	   to	   the	   peaks	   labelled	   in	   the	   1H	   NMR	  spectrum	  in	  figure	  3.11	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Figure	   3.12	   The	   doubled-­‐headed	   arrows	   signify	   regions	   on	   the	   chemical	   structure	   and	   1H	  NMR	  spectrum	  which	  correspond	  as	  shown	  in	  the	  COSY	  experiment	  (figure	  3.13)	  and	  are	  therefore	  close	  to	  each	  other	  in	  3D	  space.	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Figure	   3.14	   Ph-­‐LAla-­‐OMe-­‐F	   (1),	   letters	   A	   –	   O	   correspond	   to	   the	   peaks	   labelled	   in	   the	   13C	   NMR	  spectrum	  (figure	  3.15)	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Figure	  3.16	  HSQC	  experiment	  of	  Ph-­‐LAla-­‐OMe-­‐F	  (1)	  that	  shows	  how	  the	  peaks	  in	  the	  1H	  NMR	  and	  13C	  NMR	  spectra	  correlate	  with	  each	  other	  	  A	   comparison	   of	   the	   1H	   NMR	   and	   13C	   NMR	   spectra	   with	   the	   HSQC	   experiment	  above	   (figure	   3.16)	   confirms	   that	   the	   protons	   and	   carbons	   of	   the	  molecule	   have	  been	  correctly	  correlated	  with	  each	  other.	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3.2	  Further	  Syntheses	  
	  After	   the	   confirmed	   successful	   synthesis	   of	   phenyl-­‐(methoxy-­‐L-­‐alaninyl)	  phosphoramidate	   fingolimod	   (1)	   an	   additional	   ten	   analogues	   were	   synthesised.	  The	  syntheses	  generally	  followed	  the	  same	  pattern	  of	  products	  and	  by-­‐products	  as	  described	  in	  similar	  ratios	  and	  therefore	  the	  obtained	  data	  for	  these	  experiments	  will	  not	  be	  discussed	  in	  detail.	  	  	  
Phenyl-­(benzyloxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (2)	  
	  
Scheme	  3.3	  Ph-­‐LAla-­‐OBzl-­‐F	  was	  successfully	  synthesised	  as	  a	  mixture	  of	  4	  diastereoisomers	  with	  a	  yield	  of	  22%	  
	  
	  
Phenyl-­(benzyloxy-­glycinyl)	  phosphoramidate	  fingolimod	  (3)	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Phenyl-­(benzyloxy-­L-­leucinyl)	  phosphoramidate	  fingolimod	  (4)	  
	  
Scheme	  3.5	  Ph-­‐Leu-­‐OBzl-­‐F	  was	  successfully	  synthesised	  as	  a	  mixture	  of	  4	  diastereoisomers	  with	  a	  yield	  of	  23%	  
	  
	  
Phenyl-­(benzyloxy-­L-­prolinyl)	  phosphoramidate	  fingolimod	  (5)	  
	  
Scheme	  3.6	   Ph-­‐Pro-­‐OBzl-­‐F	  was	   successfully	   synthesised	  as	   a	  mixture	  of	  diastereoisomers	  with	  a	  yield	  of	  20%	  
	  
	  
Phenyl-­(ethoxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (6)	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Naphthyl-­(ethoxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (7)	  
	  
Scheme	  3.8	   Naphth-­‐LAla-­‐OEt-­‐F	  was	   successfully	   synthesised	   as	   a	  mixture	   of	   4	   diastereoisomers	  with	  a	  yield	  of	  23%	  
	  
	  
Phenyl-­(methoxy-­glycinyl)	  phosphoramidate	  fingolimod	  (8)	  
	  
Scheme	  3.9	  Ph-­‐Gly-­‐OMe-­‐F	  was	  successfully	  synthesised	  as	  a	  mixture	  of	  4	  diastereoisomers	  with	  a	  yield	  of	  33%	   	  	  
Phenyl-­(ethoxy-­glycinyl)	  phosphoramidate	  fingolimod	  (9)	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Phenyl-­(pentoxy-­L-­phenylalanyl)	  phosphoramidate	  fingolimod	  (10)	  
	  
Scheme	  3.11	  Ph-­‐Phe-­‐OPe-­‐F	  was	  successfully	  synthesised	  as	  a	  mixture	  of	  4	  diastereoisomers	  with	  a	  yield	  of	  10%	  	  	  
Phenyl-­(methoxy-­L-­isoleucinyl)	  phosphoramidate	  fingolimod	  (11)	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Compound	   Ar	   AA	   R	   %	  Yield	   31P	  NMR	  δ 	  (ppm)	  
1	   Ph	   L-­‐Ala	   Me	   44	   3.60,	  3.47,	  3.14,	  3.06	  
2	   Ph	   L-­‐Ala	   Bzl	   22	   3.58,	  3.22,	  3.11	  
3	   Ph	   Gly	   Bzl	   17	   4.27,	  3.99	  
4	   Ph	   Leu	   Bzl	   23	   4.66,	  4.46,	  4.20,	  3.95	  
5	   Ph	   Pro	   Bzl	   20	   2.99,	  2.94	  
6	   Ph	   L-­‐Ala	   Et	   20	   4.05,	  3.84,	  3.73,	  3.59	  
7	   Naphth	   L-­‐Ala	   Et	   23	   4.90,	  4.70,	  4.42,	  3.55	  
8	   Ph	   Gly	   Me	   33	   3.62,	  3.00	  
9	   Ph	   Gly	   Et	   39	   4.48	  
10	   Ph	   Phe	   Pe	   10	   4.11,	  3.95,	  3.11	  
11	   Ph	   Ile	   Me	   38	   4.30,	  4.25,	  3.65,	  3.60	  	  
Table	  3.1	  ProTide	  Fingolimod	  analogues	  synthesised	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4.1.1	  Review	  of	  the	  Chiral	  Synthetic	  Challenge	  and	  Available	  Literature	  
	  The	  synthetic	  procedure	  developed	  and	  detailed	  in	  chapters	  2	  and	  3	  overcomes	  all	  but	  one	  of	  the	  primary	  synthetic	  challenges	  involved	  in	  the	  production	  of	  ProTide	  fingolimod	   analogues.	   The	   final	   problem	   is	   the	   issue	   of	   chirality.	   As	   previously	  explained,	   it	   is	   S-­‐monophosphate	   fingolimod	  which	   is	   the	   active	   compound.	   The	  syntheses	   detailed	   in	   the	   previous	   chapters	   yield	   a	   mixture	   of	   S	   and	  R	   ProTide	  fingolimod	  as	  shown	  in	  figures	  4.1	  and	  4.2	  below.	  
	  
	  
Figure	  4.1	  Undesired	  R-­‐isomer	  of	  ProTide	  Fingolimod	  	  	  	  Figure	  4.2	  S-­‐isomer	  of	  ProTide	  Fingolimod	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After	  several	  attempts	  to	  separate	  the	  different	  diastereoisomers	  using	  HPLC	  were	  attempted	  (data	  not	  shown),	  but	  showed	  no	  potential	  for	  being	  a	  viable	  method	  of	  isolating	   the	   desired	   S-­‐isomers,	   a	   paper	   was	   chosen	   which	   details	   the	   chiral	  synthesis	   of	   S-­‐monophosphate	   fingolimod	   as	   a	   basis	   for	   developing	   the	   chiral	  synthesis	  of	  ProTide	   fingolimod.2	  The	  general	  method	  detailed	   in	  Kiuchi’s	  paper2	  showed	   potential	   as	   being	   relatively	   simple,	   cheap	   and	   high	   yielding	   when	  compared	  with	  the	  other	  papers	  reviewed.	  	  Kyle	  Coppola’s	  2014	  paper3	  details	  a	  method	  devised	  to	  synthesise	  phosphorylated	  diols	  using	  titanium	  alkoxide	  catalysts	  as	  shown	  in	  scheme	  4.1.	  In	  their	  paper	  they	  state	   that	   the	   aim	   of	   their	  work	   is	   to	   design	   a	  method	   that	   can	   be	   used	   for	   the	  phosphorylation	  of	  fingolimod	  but	  when	  looking	  at	  their	  results	  it	  seems	  unlikely	  that	  their	  method	  could	  be	  used	  to	  achieve	  enantioselectivity.	  Another	  detracting	  factor	   was	   that	   they	   had	   not	   tested	   their	  method	   on	   fingolimod	   itself.	   Certainly	  when	  compared	  with	  the	  other	  literature	  available	  the	  application	  of	  their	  work	  to	  the	  chiral	  synthetic	  problem	  was	  inevitably	  going	  to	  be	  far	  more	  experimental	  and	  potentially	   difficult	   than	   the	   other	   applicable	   routes.	   If	   one	   were	   to	   use	   their	  method	   then	   the	   use	   of	   chiral	  HPLC	   to	   separate	   the	  S	   and	  R	   enantiomers	  would	  probably	   be	   essential.	   It	   is	   also	   highly	   unlikely	   that	   one	   could	   replace	   the	  tetrabenzyl	  pyrophosphate	  used	  in	  their	  reaction	  for	  a	  phosphorochloridate	  or	  any	  other	   phosphorus	   compound	   that	   could	   be	   converted	   into	   a	   ProTide	   post-­‐phosphorylation.	  For	  numerous	  reasons	   this	   route	  was	  considered	  a	  poor	  choice	  for	  chiral	  ProTide	  fingolimod	  synthesis.	  	  
	  
Scheme	   4.1	   The	   chemistry	   detailed	   was	   considered	   a	   poor	   starting	   point	   for	   chiral	   ProTide	  fingolimod	  synthesis3	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column,	  which	  was	  not	   immediately	  available,	  and	   is	  generally	  only	  applicable	  to	  smaller	  laboratory	  scales.	  For	  the	  purposes	  of	  the	  research	  described	  preparative	  chiral	   HPLC	   can	   be	   done	   on	   an	   acceptable	   scale	   but	   if	   ever	   the	   chiral	   synthesis	  were	   to	   be	   scaled	   up	   for	   industrial	   applications	   then	   an	   alternative	   route	  would	  need	   to	  be	  devised.	  A	   further	   likely	  problem	  of	   relying	  on	  chiral	  HPLC	   is	   that	  all	  ProTide	   fingolimod	   analogues	   contain	   at	   least	   2	   chiral	   centres	   (a	   carbon	   chiral	  centre	  and	  a	  phosphorus	  chiral	  centre).	  The	  potential	  synthetic	  strategy	  shown	  in	  scheme	  4.3	   requires	   the	   separation	   of	   compounds	   containing	  3	   chiral	   centres	   as	  opposed	  to	  one.	  This	  would	  almost	  certainly	   lead	  to	  an	  even	  greater	  challenge	   in	  obtaining	   the	   desired	   compounds	   via	   the	   use	   of	   a	   chiral	   column.	   It	  was	   decided	  that	  a	  route	  that	  does	  not	  require	  the	  use	  of	  chiral	  HPLC	  would	  be	  preferable.	  	  
	  























































































Figure	  4.4	  The	  three	  chiral	  centres	  which	  would	  likely	  make	  any	  attempted	  chiral	  HPLC	  separation	  extremely	  challenging	  if	  not	  impossible	  	  The	   paper	  which	   appeared	   to	   show	   the	  most	   promise2	   reports	   the	   use	   of	   lipase	  enzymes	  to	  selectively	  protect	  one	  OH	  group	  with	  a	  reported	  enantiomeric	  purity	  of	  99%.	  No	  chiral	  HPLC	  separation	  is	  necessary	  and	  the	  chemistry	  involved,	  for	  the	  most	  part,	   is	  already	  established	  as	  being	  reliable,	  effective	  and	  cheap.	  The	  paper	  describes	   the	   enantioselective	   synthesis	   of	   fingolimod	   phosphate	   and	   it	   was	  considered	  that	  the	  chemistry	  described	  could	  be	  applied	  to	  the	  chiral	  synthesis	  of	  phosphoramidate	   fingolimod.	  An	   initial	  best-­‐case	   scenario	   synthesis	  was	  devised	  as	  shown	  in	  scheme	  4.4.	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4.1.2	  Development	  of	  the	  Chiral	  Synthetic	  Procedure	  
	  The	   first	   attempted	   experiment,	   as	   shown	   in	   scheme	   4.5,	   was	   ineffective.	   The	  experimental	   procedure	   as	   described	   in	   the	   relevant	   paper1	   was	   followed	  carefully.	   The	   lipase	   used,	   Lipase	   from	   Porcine	   Pancreas	   Type	   II,	   was	   cheap	   and	  easily	   obtained	   from	   Sigma	   Aldrich.	   However,	   the	   paper	   clearly	   states	   that	   a	  number	  of	  different	  enzymes	  were	   trialled	  and	  that,	  “…some	  other	   lipases	   (Lipase	  
AS,	   PS,	   AK,	   M10,	   F-­AP15,	   AYS,	   and	   G50)	   and	   PPL	   (porcine	   pancreas	   lipase)	   were	  
ineffective	  like	  Lipase	  SL,	  our	  successive	  screening	  of	  lipase	  revealed	  that	  immobilized	  
lipase	   (Toyobo	   Co.)	   and	   Novozyme	   435	   had	   excellent	   catalytic	   activities.”2	   It	  therefore	  came	  as	  little	  surprise	  that	  the	  first	  experiment	  as	  shown	  in	  scheme	  4.5	  was	  not	  successful.	  
	  
	  
Scheme	  4.5	  First	  attempted	  enzymatic	  enantioselective	  protection	  of	  fingolimod	  hydrochloride	  
	  Following	   section	   5.3	   of	   the	   paper,	   protection	   of	   the	   free	   amine	   was	   attempted	  using	  acetic	  anhydride	  and	  sodium	  bicarbonate	  as	  shown	  in	  scheme	  4.6.	  However,	  unexpectedly,	  after	  initially	  assuming	  that	  the	  yielded	  compound	  was	  the	  desired	  product	   (mass	  of	  350.3	  m/z	  observed)	  after	   further	  analysis	   it	  became	  apparent	  that	  the	  primary	  product	  was	  actually	  O-­‐protected	  fingolimod	  with	  an	  assumed	  0%	  of	   enantioselectivity.	   The	   broad	   peak	   at	   around	   4.4	   ppm	   in	   figure	   4.5	   has	   an	  integration	  of	  2	  and	  is	  typical	  of	  a	  free	  amine.	  	  
	  


































Figure	  4.5	  1H	  NMR	  spectrum	  of	  product	  with	  clear	  broad	  free	  amine	  peak	  at	  around	  4.4	  ppm	  	  
	  
Figure	  4.6	  Main	  product	  of	  reaction	  described	  in	  scheme	  4.6	  	  In	  order	  to	   improve	  the	   likelihood	  of	  effective	  N-­‐protection	  a	  simple	  yet	  effective	  procedure	   to	   form	   the	   freebase	  was	   developed	   as	   described	   in	   scheme	   4.7.	   The	  procedure,	  after	  a	  little	  experimentation,	  gives	  a	  yield	  of	  around	  100%.	  	  	  
	  
Scheme	  4.7	  Synthesis	  of	  freebase	  fingolimod	  from	  fingolimod	  hydrochloride	  (100%	  yield)	  	  As	   described	   in	   the	   paper2	   the	   use	   of	   benzyl	   chloroformate	   as	   an	  N-­‐protecting	  agent	   was	   investigated	   as	   it	   was	   considered	   possible	   that	   it	   would	   be	   more	  N-­‐selective	  than	  acetic	  anhydride.	  A	  test	  reaction	  was	  attempted	  as	  shown	  in	  scheme	  4.8	   and	   then	   the	   conditions	   were	   applied	   to	   freebase	   fingolimod	   as	   shown	   in	  scheme	  4.9.	  The	  products	  of	  both	  reactions	  contained	  a	  mixture	  of	  N-­‐protected	  and	  O-­‐protected	  compounds	  but	  these	  were	  separable	  via	  column	  chromatography	  to	  the	  desired	   compound	  as	   shown	   in	   scheme	  4.9	  with	   an	   initial	   yield	  of	   78%.	  The	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second	  attempt	  of	   the	   reaction	  described	   in	   scheme	  4.9	   gave	   the	  product	  with	   a	  satisfying	  yield	  of	  95%.	  	  
	  
Scheme	  4.8	  Test	  of	  the	  reaction	  conditions	  was	  conducted	  using	  3-­‐amino-­‐1-­‐propanol	  
	  
	  
Scheme	   4.9	   N-­‐protection	   of	   freebase	   fingolimod	   using	   benzyl	   chloroformate	   and	   sodium	  bicarbonate	  (95%	  yield)	  
	  Once	   the	   lipase	   enzyme,	   derived	   from	   gram-­‐negative	   pseudomonas	   bacteria7,	  described	   as	   being	   the	   most	   effective	   and	   enantioselective	   in	   the	   lead	   paper2	  arrived	   from	   the	   Japanese	  producers	  an	  O-­‐protection	  experiment	  was	   conducted	  on	  N-­‐protected	  fingolimod,	  as	  shown	  in	  scheme	  4.10.	  The	  reaction	  gave	  the	  desired	  product	  with	  a	  yield	  of	  78%.	   	  
	  
Scheme	   4.10	   Successful	   enantioselective	   O-­‐protection	   of	   N-­‐protected	   fingolimod	   using	  Immobilized	  Lipase	  (LIP-­‐301)	  (78%	  yield)	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hypothesis	  is	  that	  the	  NH3+Cl-­‐	  or	  free	  NH2	  interact	  with	  the	  enzyme	  in	  a	  way	  as	  to	  prevent	  ease	  of	  access	  of	  the	  free	  OH	  to	  the	  active	  site	  of	  the	  enzyme.	  	  
	  
Scheme	  4.11	  Unsuccessful	  enantioselective	  O-­‐protection	  of	  fingolimod	  HCl	  	  Scheme	  4.12	  shows	  the	  successful	  synthesis	  of	  a	  phosphoramidate	  of	  the	  product	  of	  the	  reaction	  shown	  in	  scheme	  4.10.	  However,	  when	  considering	  that	  the	  harsh	  conditions	   that	   would	   be	   required	   to	   deprotect	   the	   alcohol	   (such	   as	   pH	   2	  conditions)	   would	   likely	   cause	   an	   unwanted	   decomposition	   of	   the	   ester	  component	   of	   the	   phosphoramidate	   (by	   acid	   catalysed	   ester	   hydrolysis1),	   it	  was	  decided	  that	  a	  more	  labile	  OH	  protecting	  group	  would	  be	  used.	  	  
	  
Scheme	  4.12	  Phosphoramidate	  synthesis	  of	  N	  and	  O	  protected	  fingolimod	  (77%	  yield)	  
	  The	   alternative	   to	   an	   acetyl	   protecting	   group	   described	   in	   the	   lead	   paper2	   is	   a	  benzyloxycarbonyl	  protecting	  group	  derived	   from	  benzyl	  vinyl	  carbonate.	  Benzyl	  vinyl	   carbonate	   is	   not	   readily	   commercially	   available	   and	   was	   therefore	  synthesised	  following	  a	  published	  procedure.8	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The	   first	   attempted	   O-­‐protection	   of	   N-­‐protected	   fingolimod	   using	   benzyl	   vinyl	  carbonate,	   as	   shown	   in	   scheme	   4.14,	   was	   successful	   but	   the	   product	   was	   only	  obtained	   in	  a	  disappointing	  141	  mg	  yield	  of	  18%.	  This	   is	   in	  contrast	   to	   the	  same	  reaction	  conducted	  using	  vinyl	  acetate	  as	  shown	  in	  scheme	  4.10	  that	  gave	  a	  yield	  of	  78%	   and	   in	   stark	   contrast	   to	   the	   reported	   yield	   of	   99%.	   The	   reaction	   was	  attempted	  again	  this	  time	  at	  a	  higher	  temperature	  of	  35	  °C	  for	  2	  days	  but	  this	  time	  the	  yield	  was	  an	  even	  more	  disappointing	  7%.	  	  
	  
Scheme	  4.14	  Enantioselective	  O-­‐protection	  of	  N-­‐protected	  fingolimod	  (18%	  yield)	  
	  A	   search	   of	   the	   relevant	   literature	   provided	   two	   papers	   which	   suggested	   that	  changing	   the	   solvent	   from	   THF	   to	   diisopropyl	   ether	   and	   increasing	   the	  temperature	  to	  40	  °C	  could	  give	  more	  favourable	  results.9,10	  Fortunately	  changing	  the	  reaction	  conditions	  as	  previously	  described	  gave	  an	  improved	  583	  mg	  yield	  of	  54%.	  A	  polarimetry	  experiment	  was	  run	  on	  the	  product	  giving	  an	  optical	  rotation	  value	   of	   [α]	   =	   -­‐56.59	   	   ([α]D24	   =	   -­‐1.2)	   	   suggesting	   a	   non-­‐racemic	   mixture.	  Enantiomeric	   excess	   would	   need	   to	   be	   determined	   by	   further	   work	   such	   as	   by	  chiral	  HPLC.	  	  
	  
Scheme	   4.15	   Enantioselective	   benzyloxycarbonyl	   O-­‐protection	   of	   N-­‐protected	   fingolimod	   (54%	  yield)	  	  Now	  a	  phosphoramidate	  synthesis	  was	  attempted	  with	  benzyloxycarbonyl	  N	  and	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be	   less	   likely	   to	   be	   cleaved	   when	   removal	   of	   the	   benzyloxycarbonyl	   protecting	  groups	   was	   attempted.	   The	   31P	   NMR	   spectrum	   of	   the	   product	   of	   the	   reaction	  shown	  in	  scheme	  4.16	  can	  be	  seen	  in	  figure	  4.7.	  There	  are	  clearly	  2	  peaks	  at	  3.67	  ppm	  and	  3.53	  ppm	  which	   correspond	   to	   the	  2	  diastereoisomers	   shown	   in	   figure	  4.8.	  Enantiomeric	  excess	  would	  need	  to	  be	  determined	  via	  chiral	  HPLC.	  	  
	  
Scheme	   4.16	   Phosphoramidate	   synthesis	   of	   benzyloxycarbonyl	   N	   and	   O-­‐protected	   fingolimod	  (23%	  yield)	  
	  
Figure	  4.7	  31P	  NMR	  spectrum	  of	  product	  of	  reaction	  shown	  in	  scheme	  4.16	  	  	  
	  




























































	   	   	  
	  
Confidential	  
Finally,	   cleavage	   of	   the	   protecting	   groups	  was	   successfully	   achieved	   on	   the	   first	  attempt	  following	  a	  procedure	  described	  in	  the	  lead	  paper.2	  The	  use	  of	  a	  palladium	  catalyst	  was	  employed	  in	  a	  hydrogen	  rich	  environment	  as	  shown	  in	  schemes	  4.17	  and	  4.18.	  	  
	  
Scheme	  4.17	  Successful	  cleavage	  of	  the	  protecting	  groups	  yielding	  the	  final	  target	  compound	  (59%	  yield)	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Unfortunately,	   however,	   a	   major	   by-­‐product	   of	   the	   reaction	   was	   the	   cyclised	  structure	  shown	  in	  figure	  4.9.	  The	  exact	  mass	  of	  the	  cyclised	  compound	  is	  440.24	  g/mol	  and	  a	  mass	  of	  441.2	  m/z	  was	  detected	   in	   the	  mass	  spectrometric	  analysis	  which	   almost	   certainly	   corresponds	   to	   the	   unwanted	   cyclised	   product	   shown	  below.	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Chapter	   5	   –	   Biochemical	   Processing	   of	   ProTide	  
Fingolimod	  Analogues	  
	  In	   order	   to	   assess	   the	   viability	   of	   ProTide	   fingolimod	   analogues	   as	   potentially	  efficacious	   therapeutics	  different	   types	  of	   in	   vitro	   testing	   such	  as	   stability	   assays	  and	  enzymatic	  processing	  experiments	  need	  to	  be	  conducted.	  	  	  
5.1	  Stability	  Assays	  
	  It	  is	  important	  to	  find	  out	  if	  the	  ProTide	  fingolimod	  analogues	  are	  stable	  and	  do	  not	  decompose	   when	   exposed	   to	   environmental	   conditions	   typical	   of	   an	   effective	  orally-­‐acting	  medication.	  	  
5.1.1	  Acid	  Stability	  Test	  
	  Oral	   medication	   (medicine	   taken	   as	   a	   pill)	   needs	   to	   be	   stable	   in	   the	   acidic	  conditions	   of	   the	   stomach	   for	   at	   least	   an	   hour	   before	   it	   is	   transferred	   to	   the	  digestive	  tract	  where	  it	  can	  be	  absorbed	  by	  the	  lumen	  and	  enter	  the	  bloodstream.	  The	  stomach	  is	  a	  highly	  acidic	  environment	  of	  between	  pH	  1	  -­‐	  2.	  	  In	  order	  to	  determine	  the	  viability	  of	  ProTide	  fingolimod	  analogues	  as	  orally	  active	  drugs	   capable	   of	  withstanding	   the	   conditions	   of	   the	   stomach	   Ph-­‐Gly-­‐OBzl-­‐F	  was	  subjected	  to	  a	  pH	  1.5	  buffer	   for	  12	  hours.	  Figure	  5.1	  shows	  the	  change	  in	  the	  31P	  NMR	  spectrum	  of	  the	  pH	  1.5	  Ph-­‐Gly-­‐OBzl-­‐F	  solution	  over	  12	  hours.	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Figure	  5.1	  Stacked	  31P	  NMR	  spectra	  of	  Ph-­‐Gly-­‐OBzl-­‐F	  stability	  test	  over	  12	  hours	  in	  the	  presence	  of	  pH	  1.5	  buffer	  	  It	  can	  be	  clearly	  seen	  that	  the	  peak	  indicative	  of	  Ph-­‐Gly-­‐OBzl-­‐F	  does	  not	  decrease	  in	  height	  and	  that	  no	  new	  peaks	  are	  formed.	  This	  is	  a	  favourable	  result	  as	  it	  implies	  that	  ProTide	  fingolimod	  analogues	  will	  not	  be	  degraded	  in	  the	  stomach	  and	  will	  be	  intact	  by	  the	  time	  they	  reach	  the	  small	  intestine.	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5.1.2	  Base	  Stability	  Test	  
	  A	   pH	   8	   buffer	   was	   made	   using	   carefully	   measured	   amounts	   of	   HCl	   and	   tris	  (hydroxymethyl)	  aminomethane.	  Ph-­‐Gly-­‐OBzl-­‐F	  was	  subjected	  to	  pH	  8	  conditions	  for	   13	   hours	   at	   room	   temperature.	   Figure	   5.2	   shows	   the	   change	   in	   the	   31P	  NMR	  spectra	   of	   the	   pH	   8	   Ph-­‐Gly-­‐OBzl-­‐F	   solution	   over	   13	   hours.	   Significant	   levels	   of	  degradation	  can	  be	  seen.	  The	  half-­‐life	  of	  Ph-­‐Gly-­‐OBzl-­‐F	  has	  been	  calculated	   to	  be	  approximately	   13	   hours	   as	   during	   a	   period	   of	   around	   13	   hours	   the	   parent	   peak	  was	  reduced	  to	  a	  relative	  integration	  of	  50%.	  	  Although	   the	   stomach	  does	   reach	  pH	  between	  1	   -­‐	   2	   and	   the	   acid	   stability	   test	   is	  very	  relevant	  to	  determining	  if	  a	  compound	  could	  be	  an	  effective	  oral	  medication,	  no	  area	  of	   the	  human	  body	  reaches	  a	  basicity	  equal	   to	  or	  greater	   than	  pH	  8.	  The	  results	  of	   the	  pH	  8	  base	   test	  prove	   that	  additional	  chemical	  reactions	  or	  analysis	  should	  not	  be	  conducted	  in	  pH	  8	  or	  above	  as	  degradation	  is	  a	  likely	  consequence.	  	  	  
	  
Figure	  5.2	  Stacked	  31P	  NMR	  spectra	  of	  Ph-­‐Gly-­‐OBzl-­‐F	  stability	  test	  over	  13	  hours	  in	  the	  presence	  of	  pH	  8	  buffer	  














Scheme	   5.2	   Probable	   base-­‐induced	   degradation	   of	   ProTide	   fingolimod	   to	   unwanted	   cyclised	  product	  
	  
5.1.3	  DMSO	  Freeze	  Thaw	  Stability	  Tests	  

























Figure	  5.3	   Stacked	  31P	  NMR	  spectra	  of	   freeze-­‐thaw	  experiment	  of	  Ph-­‐Gly-­‐OBzl-­‐F	   in	  DMSO	  over	  5	  days	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Figure	  5.5	  Stacked	  31P	  NMR	  spectra	  of	  freeze-­‐thaw	  experiment	  of	  Ph-­‐LAla-­‐OMe-­‐F	  in	  DMSO	  over	  5	  days	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5.2	  Enzymatic	  and	  Human	  Serum	  Assays	  
	  Established	   ProTides,	   such	   as	   sofosbuvir,	   are	   processed	   by	   naturally	   occurring	  enzymes	  in	  the	  human	  body	  to	  the	  monophosphate	  form	  (as	  shown	  in	  scheme	  5.3	  below).	   31P	   NMR	   enzymatic	   assays	   have	   been	   developed	   to	   assess	   previously	  synthesised	   ProTides	   for	   their	   capacity	   to	   be	   processed	   by	   enzymes	   such	   as	  carboxypeptidase	  and	  porcine	  liver	  esterase.	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5.2.1	  Ph-­LAla-­OEt-­F	  Carboxypeptidase	  Experiment	  	  
	  



























Figure	   5.7	   Stacked	   31P	   NMR	   spectra	   of	   Ph-­‐LAla-­‐OEt-­‐F	   processing	   by	   carboxypeptidase	   over	   12	  hours	   	  Mass	  spectrometric	  analysis	  of	  the	  products	  of	  the	  Ph-­‐LAla-­‐OEt-­‐F	  experiment	  did	  not	   show	   the	  presence	   of	   a	   product	   that	  would	   typically	   be	   expected	   to	   be	   seen	  after	  conducting	  an	  enzymatic	  experiment.	  The	  most	  significant	  observed	  masses	  in	  positive	  mode	  after	  conducting	  the	  experiment	  were:	  	  
• 336.3	  m/z	  
• 395.2	  m/z	  
• 469.3	  m/z	  













Figure	  5.8	  Parent	  compound	  Ph-­‐LAla-­‐OEt-­‐F	  (562.3	  g/mol)	  	  
	  
Figure	   5.9	   Possible	   initial	   product	   of	   processing	   of	   Ph-­‐LAla-­‐OEt-­‐F	   by	   carboxypeptidase	   (534.3	  g/mol)	  
	  
	  






























Figure	  5.11	  Possible	  product	  of	  processing	  of	  Ph-­‐LAla-­‐OEt-­‐F	  by	  carboxypeptidase	  (387.2	  g/mol)	  
	  No	   masses	   corresponding	   to	   the	   expected	   products	   of	   carboxypeptidase	  processing	   were	   observed.	   The	   most	   significant	   non-­‐parent	   peak	   in	   the	   mass	  spectrum	   is	   the	   peak	   of	   469.3	   m/z.	   It	   is	   currently	   understood	   that	   this	   is	   the	  primary	   degradation	   product	   of	   the	   enzymatic	   experiment	   and	   it	   is	   the	   mildly	  basic	   conditions	   (pH	   7.6)	   that	   catalyse	   an	   unwanted	   cyclisation	   of	   the	   parent	  compound	   to	   the	   product	   shown	   in	   figure	   5.12.	   	   The	   predicted	   mass	   of	   the	  cyclisation	  product	   is	  468.28	  g/mol	   so	   it	   therefore	  appears	  highly	   likely	   that	   the	  mass	   peak	   observed	   as	   469.3	   m/z	   corresponds	   to	   this	   unwanted	   cyclised	  compound.	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5.2.2	  Ph-­Gly-­OBzl-­F	  Carboxypeptidase	  Experiment	  	  
	  
Scheme	  5.5	  Ph-­‐Gly-­‐OBzl-­‐F	  carboxypeptidase	  processing	  experiment	  	  An	   identical	   experiment	   (ignoring	   unintentional	   differences	   in	   the	   amount	   of	  enzyme	  used)	  was	   conducted	  with	  Ph-­‐Gly-­‐OBzl-­‐F.	  The	   results	  of	   this	   experiment	  can	   be	   seen	   in	   figure	   5.13.	   There	   was	   an	   apparently	   slightly	   slower	  processing/degradation	   of	   this	   phosphoramidate	   fingolimod	   analogue	   than	   was	  observed	  with	  Ph-­‐LAla-­‐OEt-­‐F.	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In	   this	   case	   another	   NMR	   tube	   containing	   the	   same	   ratios	   of	   acetone,	   starting	  material	   and	   Trizma	   buffer	   but	   without	   the	   enzyme	   was	   used	   as	   a	   control	  experiment	   and	   the	  phosphorus	  NMR	   spectrum	   run	   the	  next	   day	   can	  be	   seen	   in	  figure	   5.14.	   It	   can	   be	   clearly	   seen	   that	   the	   degradation	   pattern	   observed	   in	   the	  control	   experiment	   without	   the	   enzyme	   is	   very	   similar	   to	   the	   degradation	  observed	  in	  the	  presence	  of	  enzyme	  so	  it	  can	  be	  concluded	  that	  the	  environmental	  conditions	  of	   the	  enzymatic	   experiment	  e.g.	  pH	  and	   solvent	   system	  are	  partly	  or	  perhaps	   completely	   responsible	   for	   the	   degradation	   observed.	   No	   mass	  spectrometric	   analysis	   was	   conducted	   on	   the	   products	   of	   this	   experiment	   but	  considering	   the	   results	   of	   the	   Ph-­‐LAla-­‐OEt-­‐F	   experiment	   it	   seems	   likely	   that	   the	  major	   product	   as	   seen	   at	   2.8	   ppm	   in	   figure	   5.13	   is	   another	   cyclised	   product	   as	  shown	  in	  scheme	  5.5.	  The	  slightly	  different	  chemical	  shifts	  observed	  in	  figures	  5.13	  and	  5.14	  are	  due	  to	  the	   incorrect	   input	  of	   the	  solvent	  being	  MeOD	  as	  opposed	  to	  deuterated	  acetone.	  
	  
Figure	   5.14	   31P	   NMR	   Ph-­‐Gly-­‐OBzl-­‐F	   control	   experiment	   (all	   the	   same	   reagents	   and	   reaction	  conditions	  but	  without	  the	  carboxypeptidase	  enzyme)	  spectrum	  at	  11am	  the	  next	  day	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5.2.3	  Ph-­LAla-­OEt-­F	  Porcine	  Liver	  Esterase	  Experiment	  	  
	  
Scheme	  5.6	  Ph-­‐LAla-­‐OEt-­‐F	  porcine	  liver	  esterase	  processing	  experiment	  	  A	   larger	   scale	   enzymatic	   experiment,	   this	   time	   using	   porcine	   liver	   esterase	   as	  opposed	   to	   carboxypeptidase,	   was	   conducted	   on	   Ph-­‐LAla-­‐OEt-­‐F	   using	   a	   method	  adapted	  from	  a	  published	  paper.2	  In	  this	  experiment	  30	  mg	  starting	  material	  was	  stirred	  in	  1	  ml	  Trizma	  buffer	  and	  2	  ml	  acetone	  and	  was	  monitored	  via	  TLC	  over	  2	  days.	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The	  major	  peaks	  observed	  in	  the	  mass	  spectrum	  of	  the	  organic	  extract	  were:	  	  
• 330.3	  m/z	  
• 469.3	  m/z	  
• 563.3	  m/z	  	  All	   three	   of	   these	  peaks	   can	  be	   assigned.	   The	  peak	   of	   330.3	  m/z	   corresponds	   to	  fingolimod+Na,	  469.3	  m/z	  corresponds	  to	  the	  same	  unwanted	  cyclisation	  product	  as	   shown	   in	   figure	   5.12	   and	   scheme	   5.6	   and	   563.3	  m/z	   is	   the	   unreacted	   parent	  ProTide	  fingolimod	  compound.	  	  	  
5.2.4	  Initial	  Conclusions	  	  In	   both	   the	   carboxypeptidase	   experiment	   and	   the	   porcine	   liver	   esterase	  experiment	   with	   Ph-­‐LAla-­‐OEt-­‐F	   none	   of	   the	   desired	   products	   of	   enzymatic	  processing	  were	  observed.	  The	  human	  small	  intestine	  has	  been	  measured	  to	  reach	  pH	  7.5,3	  a	  pH	  that	  is	  essentially	  identical	  to	  Trizma	  buffer	  (published	  to	  be	  pH	  7.6),	  so	   it	   appears	   likely	   that	   Ph-­‐LAla-­‐OEt-­‐F	   is	   not	   a	   viable	   fingolimod	   phosphorus	  prodrug	   to	   be	   used	   in	   humans	   as	   a	   therapeutically	   active	   compound.	   Base	  catalysed	   degradation	   to	   the	   unwanted	   cyclised	   product	   was	   experimentally	  observed	  to	  occur	  and	  enzymatic	  processing	  was	  not.	  	  After	   analysis	   of	   the	   data	   obtained	   from	   the	   basic	   and	   enzymatic	   experiments	  previously	  described	  it	  was	  concluded	  that	  all	  ProTide	  fingolimod	  analogues	  are	  
likely	   to	   be	   too	   unstable	   to	   be	   therapeutically	   viable	   compounds.	   The	   base-­‐induced	   degradation	   pattern	   of	   Ph-­‐Gly-­‐OBzl-­‐F	   as	   shown	   in	   figure	   5.2	   is	   almost	  identical	  to	  the	  degradation	  pattern	  observed	  in	  the	  carboxypeptidase	  experiment	  of	  the	  same	  compound	  as	  shown	  in	  figure	  5.13.	  When	  compared	  with	  the	  spectra	  obtained	   for	   the	   Ph-­‐LAla-­‐OEt-­‐F	   experiments	   it	   seems	   that	   it	   is	   the	   mildly	   basic	  environment	   that	   is	   responsible	   for	   the	   degradation	   rather	   than	   the	   enzyme.	   A	  putative	  mechanism	  of	  degradation	   is	  shown	  in	  scheme	  5.7.	  Further	  experiments	  were	  conducted	  to	  ascertain	  whether	  this	  is	  indeed	  the	  case.	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Scheme	  5.7	  Proposed	  mechanism	  of	  Trizma	  catalysed	  cyclisation	  of	  ProTide	  fingolimod	  
	  
5.2.5	  Ph-­LAla-­OBzl-­F	  Carboxypeptidase	  Experiment	  
	  
	  


























































Figure	  5.16	  Stacked	   31P	  NMR	  spectra	  of	  Ph-­‐LAla-­‐OBzl-­‐F	  processing	  by	  carboxypeptidase	  over	  13	  hours	   	  
5.2.6	  Ph-­Leu-­OBzl-­F	  Porcine	  Liver	  Esterase	  Experiment	  	  
	  
Scheme	  5.9	  Ph-­‐Leu-­‐OBzl-­‐F	  carboxypeptidase	  processing	  experiment	  	  A	  larger	  scale	  porcine	  liver	  esterase	  experiment	  was	  conducted	  on	  Ph-­‐Leu-­‐OBzl-­‐F	  and	  monitored	   via	   TLC	   as	   previously	   described.2	   Again	   the	  main	   product	   of	   the	  reaction	  was	  the,	  now	  expected,	  cyclisation	  product	  as	  shown	  in	  scheme	  5.9.	  The	  predicted	   mass	   is	   572.34	   g/mol	   and	   the	   observed	   mass	   of	   the	   product	   of	   the	  reaction	  is	  573.35	  m/z.	  
	  


































Figure	   5.17	   31P	   NMR	   spectrum	   of	   organic	   extract	   of	   Ph-­‐Leu-­‐OBzl-­‐F	   large	   scale	   enzymatic	  experiment	  with	  porcine	  liver	  esterase	  	  
	  
5.2.7	  Naphth-­LAla-­OEt-­F	  Porcine	  Liver	  Esterase	  Experiment	  	  
	  
Scheme	  5.10	  Unwanted	  cyclisation	  of	  Naphth-­‐LAla-­‐OEt-­‐F	  to	  compound	  of	  observed	  mass	  of	  469.3	  m/z	  
	  Another	  porcine	   liver	  esterase	  experiment	  was	  conducted	  on	  Naphth-­‐LAla-­‐OEt-­‐F.	  This	   experiment	   is	   an	   adequate	   test	   of	   the	   hypothesis	   that	   the	  major	   product	   of	  these	  enzymatic	  reactions	   is	   the	  cyclisation	  product	  as	  previously	  described.	  The	  only	   difference	   between	   Ph-­‐LAla-­‐OEt-­‐F	   and	   Naphth-­‐LAla-­‐OEt-­‐F	   is	   that	   one	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compound	  contains	  a	  phenol	  attached	  to	  the	  phosphorus	  and	  the	  other	  compound	  contains	   a	   naphthol	   attached	   to	   the	   phosphorus.	   If	   the	   cyclisation	   hypothesis	   is	  correct	   then	   the	  major	   degradation	   product	   of	   both	   Ph-­‐LAla-­‐OEt-­‐F	   and	   Naphth-­‐LAla-­‐OEt-­‐F	   should	   be	   the	   same	   compound	   with	   an	   identical	   chemical	   shift	   as	  observed	   by	   31P	   NMR	   and	   identical	   mass	   as	   observed	   by	   mass	   spectrometry.	  Indeed	  the	  major	  degradation	  product	  has	  a	  mass	  peak	  ion	  of	  469.3	  m/z	  which	  is	  identical	   to	   the	   mass	   observed	   for	   both	   porcine	   liver	   esterase	   and	  carboxypeptidase	  processing	  experiments	  with	  Ph-­‐LAla-­‐OEt-­‐F.	  
	  
Figure	   5.18	   31P	   NMR	   spectrum	   of	   organic	   extract	   of	   Naphth-­‐LAla-­‐OEt-­‐F	   large	   scale	   enzymatic	  experiment	  with	  porcine	  liver	  esterase	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Figure	  5.19	  31P	  NMR	  spectrum	  of	  Ph-­‐LAla-­‐OBzl-­‐F	  control	  with	  no	  enzyme	  in	  acetone	  and	  Trizma	  after	  24	  h	  	  	   	  
	  
Figure	  5.20	   31P	  NMR	   spectrum	  of	   Ph-­‐LAla-­‐OBzl-­‐F	  with	   carboxypeptidase	   in	   acetone	   and	  Trizma	  after	  24	  h	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5.2.9	  Ph-­LAla-­OBzl-­F	  Human	  Serum	  Experiment	  
	  
	  
Scheme	  5.12	  Ph-­‐LAla-­‐OBzl-­‐F	  human	  serum	  processing	  experiment	  	  A	  stability	  study	  of	  Ph-­‐LAla-­‐OBzl-­‐F	  in	  human	  serum	  was	  also	  conducted	  following	  a	   previously	   reported	   procedure.1	   It	   appears	   that,	   as	   with	   the	   enzymatic	  experiments,	  the	  major	  product	  is	  likely	  to	  be	  the	  same	  unwanted	  cyclised	  product.	  The	  parent	  peak	  in	  this	  case	  is	  not	  observed	  as	  it	  is	  not	  significantly	  soluble	  in	  the	  D2O,	  serum	  and	  DMSO	  environment.	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The	  major	  peaks	  observed	  in	  the	  positive	  mode	  mass	  spectrum	  were:	  	  
• 380.07	  m/z	  
• 438.03	  m/z	  
• 464.12	  m/z	  
• 532.28	  m/z	  	   	  The	  exact	  mass	  of	  the	  cyclised	  structure	  is	  530.29	  g/mol	  so	  in	  this	  case	  none	  of	  the	  observed	   peaks	   correspond	   exactly	   to	   the	   cyclised	   compound.	   The	   peak	   with	   a	  mass	  of	  532.28	  m/z	  is	  clearly	  very	  similar	  to	  the	  mass	  of	  the	  cyclised	  product	  but	  unlike	  with	  the	  carboxypeptidase	  experiments	  no	  peak	  that	  corresponds	  exactly	  to	  the	   [M+H+]	   cyclised	   compound	   peak	   is	   observed.	   During	   the	   time	   in	   which	   this	  mass	   spectrometric	   analysis	  was	   conducted	   the	  MS	   device	   used	   repeatedly	   gave	  results	   in	  which	   the	  peak	   corresponding	   to	   the	   expected	  product	  had	   a	  mass	  +1	  that	  would	   be	   expected.	   This	   occurred	  with	   numerous	   samples	   and	   so	   the	  most	  likely	  explanation	  for	  the	  532.28	  m/z	  peak	  is	  that	  it	  is	  in	  fact	  the	  cyclised	  structure	  expected	  and	  the	  +1	  mass	  observed	  is	  an	  artefact	  of	  a	  slightly	  malfunctioning	  mass	  spectrometer.	  	  The	  major	  peaks	  observed	  in	  the	  negative	  mode	  mass	  spectrum	  were:	  	  
• 334.07	  m/z	  
• 392.04	  m/z	  
• 450.01	  m/z	  
• 507.98	  m/z	  
• 565.95	  m/z	  
• 567.94	  m/z	  
• 623.91	  m/z	  	  The	  exact	  mass	  of	  the	  parent	  Ph-­‐LAla-­‐OBzl-­‐F	  molecule	  is	  624.33	  g/mol	  so	  possibly	  the	   peak	   of	   623.91	   m/z	   [M-­‐H]	   corresponds	   to	   that.	   The	   mass	   of	   the	   desired	  monophosphate	   is	   387.22	   g/mol	   and	   none	   of	   the	   peaks	   observed	   correspond	   to	  that.	  The	  peak	  at	  334.07	  m/z	  in	  the	  negative	  mode	  analysis	  is	  perhaps	  due	  to	  the	  cleaved	  ProTide	  moiety	  as	  shown	  in	  figure	  5.22	  [M-­‐H].	  The	  mass	  data	  obtained	  was	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thoroughly	   compared	   with	   published	   fingolimod	   degradation	   mass	   data4,	   with	  modifications	  of	  the	  structures	  to	  include	  likely	  ProTide	  degradation	  products	  but	  no	  other	  proposed	  structures	  appear	  to	  correlate	  with	  the	  mass	  data	  observed	  for	  the	  human	  serum	  degradation	  products.	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5.3	  Final	  Conclusions	  
	  The	   enzymatic	   processing	   experimental	   data	   have	   repeatedly	   shown	   that	   all	  ProTide	  fingolimod	  analogues	  tested	  are	  not	  processed	  as	  initially	  expected	  to	  any	  of	  the	  desired	  compounds	  as	  shown	  in	  scheme	  5.3.	  It	  seems	  that	  the	  adjacent	  free	  OH	   on	   the	   fingolimod	   parent	   molecule	   gives	   rise	   to	   an	   unacceptable	   level	   of	  instability	   and	   lack	   of	   effective	   processing	   to	   the	   final	   pharmacologically	   active	  monophosphate	  or	  expected	  intermediates.	  The	  logical	  conclusion	  to	  mitigate	  this	  problem,	   if	   one	   still	   wishes	   to	   develop	   novel	   phosphoramidate	   S1P	   receptor	  modulator	  compounds,	  is	  to	  synthesise	  S1P	  receptor	  modulator	  parent	  molecules	  which	   only	   contain	   one	   OH	   group	   and	   convert	   them	   to	   phosphoramidates	   as	  shown	  in	  figure	  5.23.	  	  
	  A	   	   	   	   	   	   	   B	  
Figure	   5.23	   The	   enzymatic	   and	   stability	   studies	   of	   ProTide	   fingolimod	   analogues	   yielded	   data	  which	  suggest	  that	  compound	  B	  above	  is	  likely	  to	  be	  far	  more	  stable	  than	  compound	  A	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fingolimod	  analogues	  at	  room	  temperature	  has	  led	  to	  degradation	  and	  therefore	  it	  appears	  unlikely	  that	  ProTide	  fingolimod	  analogues	  present	  a	  realistic	  therapeutic	  opportunity.	  	  	  A	   method	   of	   mitigating	   the	   unwanted	   cyclisation	   issue	   was	   investigated	   by	   Dr	  Fabrizio	   Pertusati.	   The	   structure	   shown	   in	   figure	   5.24	   possesses	   a	   p-­‐methoxy	  group	  on	  the	  phenyl	  component	  of	  the	  phosphoramidate.	  While	  this	  structure	  may	  improve	   stability	   (unpublished	   results)	   it	   is	   unlikely	   to	   completely	   mitigate	   the	  unwanted	   cyclisation	   issue	  and	   the	   cyclisation	  will	  presumably	   just	  proceed	  at	   a	  slower	   rate.	   The	   synthesis	   of	   the	   p-­‐methoxy	   analogue	   still	   leaves	   the	   unwanted	  diasteroisomer	  issue	  unaddressed	  and	  stability	  is	  likely	  to	  be	  too	  much	  of	  an	  issue	  for	  FDA	  approval.	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Chapter	  6	  –	  Benzyl	  Ether	  Derivative	  “Tsuji”	  Compounds	  
	  
	  
6.1	   Rationale	   for	   Selection	   of	   BED	   Family	   of	   Compounds	   for	  
Phosphorus	  Prodrug	  Synthesis	  	  After	   the	   initial	   stability	   and	   enzymatic	   studies	   on	   ProTide	   fingolimod	   did	   not	  appear	   to	   give	   favourable	   results	   it	   was	   decided	   that	   it	   would	   be	   better	   to	  synthesise	  phosphorus	  prodrugs	  of	  chiral	  parent	  molecules	  which	  only	  contain	  one	  OH	  group.	  The	  rationale	  for	  this	  can	  be	  summarised	  as	  follows:	  	   1. Improved	   stability	   (removes	   possibility	   of	   cyclisation	   by	   the	   free	  adjacent	  OH	  group)	  2. Removes	  issues	  of	  unwanted	  diastereoisomers	  of	  the	  final	  product	  	  As	   shown	   in	   section	   1.4.5	   of	   the	   introduction	   there	   are	   a	   large	   number	   of	  candidates	   which	   meet	   the	   requirements.	   In	   fact	   before	   beginning	   any	  experimental	   work	   the	   fingolimod	   analogue	   shown	   in	   figure	   6.1	   below	   was	  considered	  an	  excellent	  candidate	  for	  ProTide	  synthesis	  as	  it	  does	  not	  possess	  the	  free	   OH	   and	   the	   predicted	   problems	   of	   having	   a	   racemic	   mixture	   of	   the	   final	  product.	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hypertension4	   and	   unwanted	   thickening	   of	   the	   heart	   valves	   known	   as	   cardiac	  fibriosis.5	   The	   available	   literature	  was	   extensively	   searched	   to	   find	   S1P	   receptor	  modulators	   which	   possess	   favourable	   S1P1	   to	   S1P3	   selectivity,	   a	   synthesis	   of	  relative	  feasibility	  and,	  importantly,	  a	  mono	  alcohol	  functionality.	  	  	  	  Due	   to	   the	   commercial	   success	   of	   FTY720	   a	   large	   amount	   of	   interest	   has	   arisen	  regarding	   the	   development	   of	   novel	   S1P	   receptor	  modulators.	   The	   result	   is	   that	  there	   are	   a	   large	   number	   of	   papers	   that	   detail	   the	   synthesis	   and	   biological	  evaluation	   of	   novel	   S1P	   receptor	   modulators	   developed	   in	   many	   academic	  research	   groups	   and	   private	   companies	   globally.	   A	   large	   proportion	   of	   these	  analogues	   are	   diols	   and,	   as	   previously	   explained	   in	   chapter	   5,	   these	   are	   not	   of	  interest	   to	   the	   research	   described	   herein	   due	   to	   the	   inevitable	   unwanted	  cyclisation	   of	   phosphoramidate	   prodrugs.	   Some	   examples	   of	   S1P	   receptor	  modulator	  diols	  which	  were	  not	  of	  interest	  include	  the	  structures	  shown	  in	  figures	  6.2	  –	  6.4.	  	  
	  
Figure	   6.2	   This	   compound	   has	   reported	   favourable	   biological	   activity6	   but	  was	   not	   selected	   for	  phosphoramidate	  synthesis	  due	  to	  expected	  unwanted	  cyclisation	  issues	  	  
	  

















Figure	   6.4	   This	   compound,	   KRP-­‐203,	   has	   reported	   favourable	   biological	   activity8,3	   but	   was	   not	  selected	  for	  phosphoramidate	  synthesis	  due	  to	  expected	  unwanted	  cyclisation	  issues	  	  Some	  novel	  S1P	  receptor	  modulators	  do	  not	  need	  to	  be	  phosphorylated	  in	  vivo	   in	  order	  to	  be	  pharmacologically	  active.	  The	  application	  of	  ProTide	  technology	  to	  S1P	  receptor	  modulators	  which	  do	  not	  need	  to	  be	  phosphorylated	  in	  vivo	  is	  not,	  at	  least	  based	   on	   current	   understanding,	   likely	   to	   yield	   therapeutically	   useful	   novel	  compounds.	   	   The	   compound	   shown	   in	   figure	   6.5	   is	   one	   such	   example.	   The	  compound	  shown	  in	  figure	  6.5	  contains	  only	  one	  alcohol	  group	  so	  the	  cyclisation	  problem	  should	  not	  arise	  but	  it	  is	  reported	  that	  phosphorylation	  is	  not	  required	  for	  favourable	  therapeutic	  activity	  and	  therefore	  the	  application	  of	  phosphoramidate	  technology	  was	  not	  seriously	  considered.	  	  
	  















Figure	  6.6	  This	  compound	  has	  no	  reported	  favourable	  biological	  activity10	  and	  was	  therefore	  was	  not	  selected	  for	  phosphoramidate	  synthesis	  	  
	  













Figure	  6.8	  This	  compound,	  GSK1842799,	  has	  reported	  favourable	  biological	  activity	  and	  possesses	  the	  desired	  mono	  alcohol	  moiety;	  however	   the	  synthesis	   is	  not	  explained	   in	  great	  detail	   and	  was	  therefore	  was	  not	  selected	  for	  the	  first	  phosphoramidate	  synthesis	  of	  a	  mono	  alcohol	  S1P	  receptor	  modulator13	  	  The	  first	  family	  of	  non-­‐FTY720	  compounds	  that	  was	  selected	  for	  phosphoramidate	  modification	   was	   published	   by	   Takashi	   Tsuji	   et	   al	   in	   2014.17	   The	   family	   of	  structures	  reported	  in	  their	  paper	  are	  colloquially	  referred	  to	  as	  Tsuji	  compounds	  and	  are	  referred	  to	  formally	  as	  benzyl	  ether	  derivative	  (BED)	  compounds.	  The	  BED	  family	  was	  selected	  for	  the	  following	  reasons:	  	   1. Detailed	  organic	  syntheses	  reported	  2. Excellent	  S1P1	  to	  S1P3	  selectivity	  of	  some	  analogues	  3. Mono	  alcohol	  functional	  group	  of	  parent	  compounds	  4. Chiral	  HPLC	  not	  required	  5. Poor	   in	   vivo	   phosphorylation	   rate	   of	   the	   most	   S1P1	   to	   S1P3	   selective	  analogues	   making	   them	   ideal	   candidates	   for	   the	   application	   of	  phosphorus	  prodrug	  technology	  	  The	  compound	  shown	  in	  figure	  6.9	  is	  the	  simplest	  analogue	  in	  the	  BED	  family	  and	  the	  phosphorylated	  version	  is	  reported	  to	  have	  far	  greater	  S1P1	  to	  S1P3	  selectivity	  than	  phosphorylated	  fingolimod	  as	  shown	  in	  table	  6.1.17	  	  	  
	  
























FTY720-­‐p	   N/A	   7.0	   2.0	   0.29	  BED(a)-­‐p	   H	   7.0	   200	   29	  BED(b)-­‐p	   2-­‐Me	   3.0	   180	   60	  BED(c)-­‐p	   3-­‐Me	   19.0	   >20,000	   >1052	  BED(d)-­‐p	   2-­‐F	   2.8	   60	   21	  BED(e)-­‐p	   2-­‐Cl	   4.0	   220	   55	  BED(f)-­‐p	   2-­‐Et	   2.3	   12,000	   5217	  BED(g)-­‐p	   2,6-­‐Me2	   2.2	   340	   155	  BED(h)-­‐p	   2,5-­‐Me2	   6.5	   >20,000	   >3077	  	  
Table	  6.1	  SAR	  information	  about	  the	  biological	  activity	  and	  S1P1	  to	  S1P3	  selectivity	  of	  fingolimod	  phosphate	  and	  the	  phosphates	  of	  different	  BED	  analogues17	  	  Their	  paper	  states	  that,	  “…compounds	  2f	  and	  2h	  (BED(f)	  and	  BED(h)	  in	  table	  6.1),	  
of	   which	   phosphates	   showed	   high	   selectivity	   to	   S1P1,	   unfortunately	   demonstrated	  
almost	   no	   efficacy	   in	   rat	   HvGR,	   inhibiting	   only	   10%	   and	   11%	   of	   immunoreactions	  
compared	  with	  the	  vehicle	  controlled	  group.	  To	  investigate	  the	  reason	  for	  this	  drastic	  
deactivation,	  we	  measured	  the	  phosphorylation	  rate	  of	  each	  compound	  in	  rat	  whole	  
blood.	  Through	  this	  analysis,	  it	  was	  revealed	  that	  efficacious	  compounds	  2a,	  2b	  and	  
2e	  were	  properly	  converted	   to	   their	  phosphate	  after	   three	  hours	  of	  being	  added	   to	  
rat	   whole	   blood,	   resulting	   in	   39.5%,	   83.8%	   and	   38.4%	   conversion	   from	   parental	  
alcohol	   to	   phosphate,	   respectively,	   while	   ineffective	   compounds	   2f	   and	   2h	   were	  
transformed	   in	   only	   13.9%	  and	   6.0%	  of	   the	   total	   compounds.	  With	   this	   result	   it	   is	  
reasonable	  to	  speculate	  that	  the	  bulkiness	  of	  the	  central	  benzene	  ring	  moiety	  of	  2a	  
largely	   affected	   the	   substrate	   recognition	   of	   the	   responsible	   kinases	  which	   convert	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rate	  in	  the	  compounds	  possessing	  relatively	  bulky	  substituents	  such	  as	  2f	  and	  2h	  was	  
too	   low	  for	   in	  vivo	  efficacy.	   Ineffectiveness	  of	   the	  most	  S1P1	  selective	  compounds	  2f	  
and	  2h	  in	  the	  rate	  HvGR	  model	  regrettably	  forced	  us	  to	  compromise	  on	  the	  point	  of	  
S1P1	   selectivity…”17	   Based	   on	   this	   information	   it	   is	   reasonable	   to	   assume	   that	  BED(f)	   and	   BED(h),	   as	   described	   in	   table	   6.1,	   could	   be	   ideal	   candidates	   for	   the	  application	  of	  ProTide	  and	  other	  monophosphate	  delivery	  prodrug	  technologies.	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6.2	  Synthesis	  of	  BED	  Compounds	  
	  
6.2.1	  Synthesis	  of	  BED(a)	  
	  The	  synthesis	  of	   the	  compounds	   in	   the	  early	  stages	  of	   the	   total	  synthesis	  are	  not	  adequately	   described	   in	   the	   paper17	   and	   some	   further	   literature	   searching	   and	  repeated	   experimentation	   was	   required	   in	   order	   to	   synthesise	   the	   desired	  compounds	  with	  an	  acceptable	  yield.	  
	  After	   multiple	   attempts	   at	   using	   different	   solvents	   (toluene,	   pentane	   and	  methanol),	   temperatures,	   glassware,	   reaction	   times	   and	   purification	  methods	   an	  amalgamation	   of	   synthetic	   procedures	   found	   in	   3	   papers17,18,19	   was	   eventually	  developed	   to	   yield	   the	   compound	   shown	   in	   scheme	   6.1	   in	   acceptable	   yields	  (>80%).	   It	   was	   found	   that	   thorough	   grinding	   of	   the	   L-­‐serine	   methyl	   ester	   HCl	  starting	   material	   improved	   the	   yield.	   As	   the	   starting	   material	   is	   not	   soluble	   in	  toluene,	  thorough	  grinding	  increases	  the	  surface	  area	  of	  the	  amino	  acid	  ester	  when	  in	   suspension	   in	   toluene.	   The	   description	   in	   Seebach’s	   1984	   paper	   that	   the	  experiment	  was	  conducted	  with	  “continuous	  removal	  of	  water”18	  was	  deciphered	  to	  mean	  that	  the	  use	  of	  a	  Dean	  Stark	  trap	  was	  employed	  as	  shown	  in	  figure	  6.11.	  The	  use	  of	  Dean	  Stark	  apparatus	  allows	  the	  selective	  removal	  of	  water	  but	  without	  the	  unwanted	  excessive	  loss	  of	  toluene	  solvent.	  The	  continuous	  loss	  of	  water	  from	  the	  reaction	  system	  may	  help	  to	  drive	  the	  reaction	  further	  to	  completion.	  
	  
	  




















Figure	  6.11	  Diagram	  of	  Dean	  Stark	  apparatus	  set	  up	  in	  a	  fashion	  similar	  to	  that	  used	  to	  successfully	  synthesise	  the	  compounds	  described	  in	  schemes	  6.1	  and	  6.2	  	  The	   synthesis	   of	   the	   following	   intermediate,	   as	   shown	   in	   scheme	   6.2,	   was	  eventually	   tuned	   after	   a	   similar	   process	   of	   experimentation	   using	   different	  solvents	  (toluene,	  THF	  and	  DCM),	  temperatures	  (from	  -­‐78	  °C	  to	  150	  °C),	  glassware,	  reaction	   times	   (2	   h	   to	   72	   h)	   and	   purification	   methods	   and	   a	   combination	   of	  different	  experimental	  procedures	  from	  different	  papers.17,19,20	  In	  one	  paper19	  it	  is	  recommended	  that	  the	  reaction	  is	  done	  below	  5	  °C,	  however	  after	  many	  variations	  of	  the	  synthetic	  procedure	  it	  was	  found	  that	  in	  order	  to	  obtain	  yields	  greater	  than	  80%	  the	  reaction	  should	  be	  heated	  in	  toluene	  at	  150	  °C	  using	  Dean	  Stark	  apparatus	  as	  in	  the	  first	  reaction	  shown	  in	  scheme	  6.1.	  A	  fortunate	  feature	  of	  the	  syntheses	  of	  
Chapter	  6	  
	   	   	  
	  
Confidential	  
the	   first	   two	   intermediates	   is	   that	   the	   reaction	   conditions	   required	   for	   both	  reactions	  are	  very	  similar	  and	  that	  the	  purification	  simply	  requires	  an	  extraction,	  vacuum	  filtration	  and	  removal	  of	  solvent	  under	  vacuum.	  Column	  chromatography	  is	  not	  required	  for	  the	  first	  two	  stages	  of	  BED	  compound	  synthesis	  which	  helps	  to	  improve	  the	  speed	  and	  ease	  with	  which	  the	  synthesis	  can	  be	  achieved.	  	  
	  
Scheme	  6.2	  Synthesis	  of	  (4S)-­‐dimethyl	  2-­‐(tert-­‐butyl)oxazolidine-­‐3,4-­‐dicarboxylate	  
	  The	   synthesis	   of	   the	   third	   intermediate	   in	   BED	   compound	   synthesis	   also	  underwent	  a	  number	  of	  variations	   in	  reagents	  (potassium	  t-­‐butoxide	  and	   lithium	  bis(trimethylsilyl)amide),	   reaction	   time,	   temperature	   and	   purification	   methods	  and	  the	  final	  procedure	  was	  also	  devised	  from	  a	  combination	  of	  procedures	  from	  different	  papers17,21,22	  and	   fine	   tuning	  of	   the	  experimental	   technique.	  An	  unusual	  quirk	  of	  the	  synthesis,	  as	  shown	  in	  scheme	  6.3,	  is	  that	  if	  the	  reaction	  is	  done	  at	  -­‐78	  °C	  the	  whole	  mixture	  congeals	  and	  forms	  a	  hard	  solid	  but	  if	  the	  mixture	  is	  kept	  at	  -­‐74	  °C	  the	  reaction	  is	  very	  effective.	  At	  temperatures	  much	  warmer	  than	  -­‐74	  °C	  the	  yield	   is	   compromised.	   Achieving	   this	   delicate	   balance	   in	   temperature	   was	  eventually	  accomplished	  by	  simply	  conducting	  the	  reaction	  in	  a	  dry	  ice	  bath	  with	  no	  added	  acetone.	  The	  mixture	   is	  quenched	  using	   saturated	  ammonium	  chloride	  solution	  and	  care	  needs	  to	  be	  taken	  to	  add	  it	  slowly	  as	  excessive	  effervescence	  and	  loss	  of	  product	  can	  occur	  if	  the	  ammonium	  chloride	  solution	  is	  added	  too	  rapidly.	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Synthesis	   of	   the	   fourth	   intermediate	   of	   BED	   compound	   synthesis,	   of	   which	   no	  practical	   experimental	   procedure	   is	   detailed	   in	   the	   lead	  paper,	   underwent	   fewer	  variations	   than	   the	   preceding	   three	   compounds.	   The	   synthesis	   was	   developed	  principally	   using	   two	   papers.17,22	   The	   key	   modifications	   made	   to	   the	   original	  procedure	   devised	   were	   an	   increase	   in	   temperature	   to	   45	   °C	   from	   room	  temperature,	   addition	  of	   toluene	   to	   the	   reaction	  mixture	  and	   the	  use	  of	  LiCl	   and	  KBH4	  as	  opposed	  to	  the	  more	  costly	  moisture	  sensitive	  LiBH4.	  	  	  
	  






















Scheme	   6.5	   Synthesis	   of	   (4R)-­‐methyl	   4-­‐(((4-­‐bromobenzyl)oxy)methyl)-­‐2-­‐(tert-­‐butyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	  has	  been	  achieved	  with	  a	  yield	  of	  70%	  (3.415	  g)	  	  	  
	  
Scheme	  6.6	  Synthesis	  of	  the	  Weinreb	  amide	  N-­‐methoxy-­‐N-­‐methyl-­‐4-­‐(p-­‐tolyl)butanamide	  has	  been	  achieved	  with	  a	  yield	  of	  82%	  (5.084	  g)	   	  	  
	  
























































Scheme	  6.8	  Synthesis	  of	  (S)-­‐methyl	  (1-­‐hydroxy-­‐2-­‐methyl-­‐3-­‐((4-­‐(4-­‐(p-­‐tolyl)butanoyl)	  benzyl)	  oxy)	  propan-­‐2-­‐yl)carbamate	  has	  been	  achieved	  with	  a	  yield	  of	  89%	  (2.691	  g)	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paper17	   they	   report	   converting	   the	   final	   compound	   into	   a	   hydrochloride	   salt	   but	  this	  was	  not	  attempted	  as	  it	  was	  deemed	  unnecessary.	  The	  final	  BED(a)	  compound	  synthesised	  was	  analysed	  using	  polarimetry	  to	  measure	  the	  optical	  rotation	  giving	  an	   optical	   rotation	   value	   of	   [α]	   =	   25.12	   	   ([α]D24	   =	   0.5)	   	   suggesting	   that	   the	  enantioselective	   chirality	   of	   the	   starting	   amino	   acid	   ester	   was	   retained	   and	   the	  final	  product	  is	  not	  a	  50/50	  racemic	  mixture.	  	  
6.2.2	  Synthesis	  of	  BED(h)	  	  In	  order	  to	  make	  the	  more	  S1P1	  selective	  analogues,	  as	  described	  in	  table	  6.1,	  more	  complex	  compounds	  than	  4-­‐bromobenzyl	  bromide,	  as	  shown	  in	  scheme	  6.5,	  need	  to	  be	  used.	  In	  the	  lead	  paper17	  the	  syntheses	  of	  BED(h)	  and	  BED(f)	  are	  very	  poorly	  described,	  referring	  to	  experimental	  procedures	  in	  the	  paper	  which	  in	  fact	  do	  not	  exist.	  Even	  if	  one	  were	  to	  correct	  their	  procedural	  numbers	  to	  ones	  which	  do	  exist	  (e.g.	   taking	   procedure	   4.1.4	   to	   mean	   procedure	   5.1.4)	   the	   explanation	   is	   still	  extremely	  limited	  and	  does	  not	  appear	  to	  be	  an	  approach	  which	  has	  a	  particularly	  high	   chance	   of	   success.	   In	   light	   of	   the	   insufficient	   information	   provided	   by	   the	  authors	   with	   regard	   to	   synthesising	   these	   lead	   compounds,	   and	   no	   relevant	  references	   being	   provided,	   novel	   experimentation	   and	   research	   was	   required.	  Based	   on	   the	   successful	   synthesis	   of	   BED(a)	   the	   logical	   reagents	   needed	   for	   the	  syntheses	   of	   BED(f)	   and	   BED(h)	   are	   shown	   in	   figure	   6.12.	   Unfortunately	   the	  reagents	   which	   can	   potentially	   be	   used	   to	   synthesise	   the	   optimal	   target	  compounds	  BED(f)	  and	  BED(h)	  cannot	  be	  readily	  purchased	  at	  an	  acceptable	  price	  and	  must	  therefore	  be	  synthesised	  in	  the	  lab.	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While	  superficially	  appearing	  to	  be	  relatively	  simple	  compounds	  the	  syntheses	  of	  the	  two	  structures	  shown	  in	  figure	  6.12	  pose	  a	  significant	  synthetic	  challenge.	  The	  synthesis	   of	   either	   compound	   is	   not	   explained	   in	   the	   lead	   paper17	   and	   after	   an	  extensive	   literature	   search	   it	  was	  decided	   that	   the	   structure	   that	   can	  be	   used	   to	  synthesise	   BED(h),	   1-­‐bromo-­‐4-­‐(bromomethyl)-­‐2,5-­‐dimethylbenzene,	   would	  probably	   be	   the	   easiest	   of	   the	   two	   compounds	   to	   synthesise.23	   A	   synthesis	   as	  shown	   in	   scheme	   6.10	   was	   attempted	   and	   successfully	   achieved,	   however	   it	  appears	  that	  an	  unwanted	  inseparable	  (due	  to	  identical	  solubility)	  side	  product	  of	  the	  reaction	  is	  2-­‐bromo-­‐3-­‐(bromomethyl)-­‐1,4-­‐dimethylbenzene	  as	  shown	  in	  figure	  6.13.	   After	   looking	   at	   the	   relative	   integrations	   of	   the	   main	   product	   and	   side	  product	  in	  the	  proton	  NMR	  spectrum,	  as	  shown	  in	  figure	  6.14,	  it	  appears	  that	  the	  desired	  product	  and	  undesired	  product	  are	  synthesised	  in	  a	  ratio	  of	  approximately	  2.5	  :	  1	  respectively.	  	  
	  
Scheme	  6.10	  Synthesis	  of	  1-­‐bromo-­‐4-­‐(bromomethyl)-­‐2,5-­‐dimethylbenzene23	  	  
	  




















Figure	   6.14	   The	   area	   of	   the	   1H	   NMR	   spectrum	   of	   the	   product	   of	   the	   synthesis	   of	   1-­‐bromo-­‐4-­‐(bromomethyl)-­‐2,5-­‐dimethylbenzene	  which	  suggests	   the	  presence	  of	   the	  unwanted	  by-­‐product	  2-­‐bromo-­‐3-­‐(bromomethyl)-­‐1,4-­‐dimethylbenzene	   (the	   peak	   at	   around	   7.3	   ppm	   is	   the	   CDCl3	   solvent	  peak)	  	  A	   further	   complication	   was	   encountered	   in	   the	   synthesis	   of	   BED(h)	   when	   the	  Weinreb	  amide	  coupling	  was	  unsuccessfully	  attempted	  as	  shown	  in	  scheme	  6.11.	  After	   some	   discussion	   it	   was	   suggested	   that	   the	   butyl	   lithium	   reagent	   may	   be	  deprotonating	   the	   adjacent	   ortho	  methyl	   group	   on	   the	   bromo	   benzene	   ring	   and	  that	  perhaps	  a	  weaker	  base	  such	  as	  methyl	   lithium	  may	  yield	  better	   results.	  The	  same	  reaction	  was	  attempted	  using	  methyl	  lithium	  and	  it	  appears	  that	  that	  attempt	  was	   also	  unsuccessful	   as	   shown	   in	   scheme	  6.12.	   Initially	   it	  was	   thought	   that	   the	  synthesis	   was	   successful	   but	   the	   product	   was	   challenging	   to	   separate	   from	   the	  starting	   reagent	   due	   to	   similar	   solubility,	   leading	   to	   a	   similar	   Rf	   value.	   But	   after	  some	   further	   analysis	   and	  experimentation	   it	   became	  apparent	   that	   the	   reaction	  had	   not	   been	   successful	   and	   an	   unwanted	   adduct	   was	   the	   principal	   product	   as	  shown	  in	  scheme	  6.13.	  There	  is	  precedent	  for	  this	  type	  of	  unwanted	  by-­‐product	  in	  Weinreb	  amide	  coupling	  reactions	  as	  previous	  publications	  suggest.24	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Scheme	   6.11	   Unsuccessful	   synthesis	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)-­‐4-­‐(((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butanoyl)benzyl)oxy)methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	  using	  BuLi	  	  
	  
Scheme	   6.12	   Unsuccessful	   synthesis	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)-­‐4-­‐(((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butanoyl)benzyl)oxy)methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	  using	  MeLi	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surprisingly	  poor	  results	  suggesting	  that	  the	  BuLi	  reagent	  may	  have	  degraded	  over	  time.	  	  	  
	  
Scheme	  6.14	  Successful	  synthesis	  of	  1-­‐iodo-­‐4-­‐(bromomethyl)-­‐2,5-­‐dimethylbenzene	  	  
	  
Figure	  6.15	  This	  unwanted	  by-­‐product	  is	  present	  in	  a	  similar	  ratio	  to	  that	  seen	  in	  figure	  6.14	  	  
	  







































Scheme	  6.16	  A	  possible	  route	  for	  the	  synthesis	  of	  (4R)-­‐methyl	  2-­‐(tert-­‐butyl)-­‐4-­‐(((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butanoyl)benzyl)oxy)methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	   using	   Friedel-­‐Crafts	  acylation	  	  
	  



























Scheme	   6.17	   Successful	   synthesis	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)-­‐4-­‐(((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butanoyl)benzyl)oxy)methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	   using	   iPrMgCl	   with	   a	   yield	  of	  42%	  (5.855	  g)	  	  	  The	   next	   stage	   of	   the	   BED(h)	   synthesis	   was	   successfully	   achieved	   on	   the	   first	  attempt	  and	  the	  same	  procedure	  was	  used	  as	  for	  the	  equivalent	  step	  in	  the	  BED(a)	  synthesis	  as	  shown	   in	  scheme	  6.8.	  The	  only	  difference	  was	   that	   the	  reaction	  was	  conducted	  over	  24	  h	  to	  try	  to	  maximise	  the	  yield.	  The	  yield	  was	  a	  very	  satisfying	  yield	  of	  97%	  (271	  mg)	  on	  the	  first	  attempt.	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Finally,	   the	   synthesis	   of	   BED(h)	   was	   successfully	   accomplished	   as	   shown	   in	  scheme	  6.19.	  The	   first	   time	   the	  BED(h)	   synthesis	  was	   conducted	   the	  yield	  was	  a	  low	  yield	  of	  just	  a	  few	  milligrams	  and	  purification	  proved	  challenging.	  The	  desired	  product	  was	  detected	  by	  mass	  spectrometry	  with	  a	  peak	  in	  positive	  mode	  detected	  as	   384.17	   m/z	   [M+H+].	   The	   second	   time	   the	   total	   synthesis	   of	   BED(h)	   was	  attempted	  a	  satisfying	  yield	  of	  2.09	  g	  was	  achieved.	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6.3	  Synthesis	  of	  Phosphorus	  Prodrug	  BED	  Compounds	  
	  As	   well	   as	   phosphoramidate	   prodrugs,	   alternative	   phosphate	   delivery	   prodrug	  moieties	   such	   as	   aryl	   SATE	   were	   considered.	   Non-­‐ProTide	   prodrugs	   of	   S1P	  receptor	  modulators	   have	   never	   been	   synthesised	   and	   tested	   by	   other	   research	  groups	   so	   it	   is	   possible	   that	   other	   prodrug	   moieties	   besides	   phosphoramidates	  may	  yield	  better	  results.	  	  
6.3.1	  Synthesis	  of	  ProTide	  BED	  Analogues	  	  Synthesis	   of	  ProTide	  BED(a)	  was	   attempted	  using	   the	  method	  developed	   for	   the	  synthesis	  of	  ProTide	  fingolimod.	  It	  was	  unknown	  whether	  the	  loss	  of	  the	  additional	  OH	   of	   the	   diol	   functionality	  would	   lead	   to	   reduced	   steric	   hindrance	   causing	   the	  phosphorochloridate	  to	  bind	  to	  the	  free	  amine	  as	  shown	  in	  figure	  6.17.	  In	  order	  to	  mitigate	  this	  problem	  if	  it	  arose	  a	  synthetic	  strategy	  was	  devised	  that	  makes	  use	  of	  some	  of	  the	  synthetic	  procedures	  developed	  in	  the	  chiral	  synthesis.	  Fortunately	  it	  was	  not	  necessary	  to	  resort	  to	  a	  synthetic	  procedure	  of	  the	  type	  shown	  in	  scheme	  6.20.	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Scheme	   6.23	   Successful	   application	   of	   the	   ProTide	   fingolimod	   synthesis	   procedure	   to	   the	   BED	  family	   of	   compounds	   to	   yield	   (2S)-­‐isopropyl	   2-­‐((((R)-­‐2-­‐amino-­‐2-­‐methyl-­‐3-­‐((4-­‐(4-­‐(p-­‐tolyl)	  butanoyl)	  benzyl)	  oxy)	  propoxy)	  (phenoxy)	  phosphoryl)	  amino)	  propanoate	  (14)	  or	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  with	  a	  yield	  of	  50%	  (234	  mg)	  	  	  
Compound	   Ar	   AA	   R	   %	  Yield	   31P	  NMR	  δ 	  (ppm)	  
12	   Ph	   L-­‐Ala	   Me	   44%	   2.55,	  2.52,	  2.47,	  2.17	  
13	   Ph	   L-­‐Ala	   Bzl	   65%	   3.14,	  2.67,	  2.26	  

















































































Scheme	   6.26	   Successful	   application	   of	   the	   ProTide	   fingolimod	   synthesis	   procedure	   to	   the	   BED	  family	   of	   compounds	   to	   yield	   (2S)-­‐isopropyl	   2-­‐((((R)-­‐2-­‐amino-­‐3-­‐((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)	  butanoyl)	  benzyl)	  oxy)-­‐2-­‐methylpropoxy)	   (phenoxy)	  phosphoryl)	  amino)	  propanoate	   (17)	  or	  Ph-­‐LAla-­‐OiPr-­‐BED(h)	  with	  a	  yield	  of	  15%	  (129	  mg)	  	  	  
Compound	   Ar	   AA	   R	   %	  Yield	   31P	  NMR	  δ 	  (ppm)	  
15	   Ph	   L-­‐Ala	   Me	   99%	   3.72,	  3.37,	  3.30	  
16	   Ph	   L-­‐Ala	   Bzl	   87%	   3.60,	  3.51,	  3.08,	  3.05	  
17	   Ph	   L-­‐Ala	   iPr	   15%	   2.58,	  2.52,	  2.29,	  2.27	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6.3.2	  CycloSal	  BED	  	  The	  synthesis	  of	  CycloSal	  BED(a)	  was	  attempted	  as	  shown	  in	  scheme	  6.27	  but	  was	  not	   successfully	  achieved.25,26	   It	   appears	   that	   the	  main	  product	  of	   the	   reaction	   is	  the	  unwanted	  salt	  as	  shown	  in	  figure	  6.18.	  The	  1H	  NMR	  of	  the	  product	  appears	  to	  have	  the	  right	  chemical	  shifts	  and	  relative	  integrations,	  however	  the	  key	  pieces	  of	  evidence	  which	  suggest	  that	  the	  unwanted	  salt	  was	  formed	  include:	  	   1. No	  mass	   peak	   corresponding	   to	   the	   desired	   product.	   The	  major	   peak	  being	  that	  which	  corresponds	  to	  the	  parent	  BED(a)	  2. No	  obvious	  coupling	  in	  the	  13C	  NMR	  spectrum	  of	  the	  carbon	  adjacent	  to	  the	  alcohol	  group	  with	  a	  phosphorus	  atom	  3. Poor	   solubility	   in	   CHCl3	   and	   other	   conventional	   solvents	   apart	   from	  methanol	  	  4. Solid	   salt-­‐like	   appearance	   unlike	   the	   usual	   oil	   type	   appearance	   of	  previously	  synthesised	  phosphorus	  prodrugs	  5. Very	   large	  NH3+	  peak	   in	   the	   1H	  NMR	  similar	   to	   that	  of	   fingolimod	  HCl	   	  	  
	  

























Figure	  6.18	  Likely	  undesired	  product	  of	  the	  attempted	  CycloSal	  BED(a)	  synthesis	  	  The	  unsuccessful	  synthesis	  of	  CycloSal	  BED(a)	  is	  not	  a	  great	  cause	  for	  concern	  as	  no	   CycloSal	   analogue	   has	   reached	   clinical	   trials	   and	   there	   is	   little	   precedent	   for	  CycloSal	   phosphate	   delivery	   prodrugs	   to	   be	   particularly	   effective	   therapeutic	  agents.25	  	  
6.3.3	  HepDirect	  BED	  


























































Scheme	  6.29	  Unsuccessful	  synthesis	  HepDirect	  BED(a)	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6.3.4	  Aryl	  SATE	  BED(a)	  and	  Fingolimod	  
	  The	   synthesis	   of	   aryl	   SATE	   BED(a)	   was	   attempted	   and	   appears	   to	   have	   been	  successfully	   achieved.25,29,30	   The	   purification	   of	   the	   final	   step	   (scheme	   6.31)	  was	  unusually	   challenging,	   taking	  2	  days,	  and	   the	   final	  yield	  was	  a	  very	  poor	  3%	  (14	  mg).	   The	   1H	   NMR,	   13C	   NMR	   and	   31P	   NMR	   data	   suggest	   that	   the	   synthesis	   was	  successful	  although	  a	  mass	  fragment	  ion	  corresponding	  to	  the	  desired	  product	  was	  not	  detected	  using	  mass	  spectrometry.	  However,	  masses	  of	  674.29	  m/z	  and	  696.28	  m/z	   were	   detected	   in	   the	   positive	   mode	   which	   are	   likely	   to	   correspond	   to	  [M+H2O+H+]	  and	   [M+H2O+Na+]	   respectively.	  Likewise	  a	  mass	  of	  672.39	  m/z	  was	  detected	   in	   negative	  mode	  which	   is	   likely	   to	   correspond	   to	   [M+H2O-­‐H].	   The	  +18	  masses	   detected	   in	   both	   positive	   and	   negative	  mode	   are	   very	   likely	   due	   to	   H2O	  being	  added	  to	  the	  parent	  mass	  and	  it	  can	  be	  argued	  that	  this	  is	  most	  likely	  to	  be	  an	  artifact	  of	  the	  mass	  spectrometric	  analysis	  rather	  than	  the	  aryl	  SATE	  BED(a)	  has	  gained	  2	  hydrogen	  atoms	  and	  an	  oxygen	  during	  the	  synthetic	  procedure.	  	  
	  	  
	  






















































Scheme	  6.32	  Synthesis	  of	  SATE	  fingolimod	  giving	  a	  poor	  yield	  of	  9%	  (76	  mg)	  	  	  As	   the	   synthesis	   of	   aryl	   SATE	   phosphate	   delivery	   prodrugs	   of	   S1P	   receptor	  modulators	  was	  comparatively	  challenging	  and	   there	   is	   little	  precedent	   for	  SATE	  compounds	  to	  be	  particularly	  effective	  therapeutics	  the	  synthesis	  of	  further	  SATE	  analogues	   was	   not	   seriously	   considered.25	   The	   synthesis	   of	   SATE	   analogues	   of	  fingolimod	  still	  has	  the	  same	  problem	  of	  unwanted	  diastereoisomers	  as	  previously	  encountered	  with	  the	  synthesis	  of	  ProTide	  fingolimod	  analogues.	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Chapter	   7	   –	   Biochemical	   Processing	   and	   Analysis	   of	  
ProTide	  BED	  Compounds	  
	  
7.1	  Enzymatic	  and	  Cell	  Lysate	  Assays	  
	  
7.1.1	  Ph-­LAla-­OMe-­BED(a)	  Carboxypeptidase	  Experiment	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2	  weeks	  with	  occasional	  shaking	  of	  the	  NMR	  tube	  to	  ensure	  effective	  mixing	  of	  the	  reagents.	  	  	  
	  
Figure	  7.1	  Stacked	  31P	  NMR	  spectra	  showing	  carboxypeptidase	  processing	  of	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  over	  2	  weeks	  	  The	   intermediary	   compound	   shown	   in	   figure	   7.1	   in	   which	   the	   ester	   has	   been	  cleaved	  leaving	  a	  free	  carboxylic	  acid	  group	  is	  likely	  to	  be	  the	  structure	  shown	  as	  the	  peak	  has	  clearly	  2	  signals,	  which	  suggests	  that	  the	  chirality	  of	  the	  molecule	  has	  been	  maintained.	  	  Mass	  spectrometric	  analysis	  was	  conducted	  on	  the	  mixture	  after	  2	  weeks	  and	  the	  3	  most	  significant	  mass	  signals	  in	  the	  negative	  mode	  analysis	  were:	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• 595.27	  m/z	  
• 434.16	  m/z	  	  The	   peaks	   of	   631.25	   m/z	   [M+Cl-­‐]	   and	   595.27	   m/z	   	   [M-­‐H-­‐]	   correspond	   to	   the	  starting	  material	  whereas	  the	  peak	  of	  434.16	  m/z	  [M-­‐H]	  is	  likely	  to	  correspond	  to	  the	   desired	   monophosphate	   as	   it	   has	   a	   predicted	   mass	   of	   435.18	   g/mol.	   The	  positive	  mode	  analysis	  also	  provided	  a	  significant	  peak	  of	  437.17	  m/z	  which	  very	  likely	  corresponds	  to	  the	  monophosphate.	  It	  is	  probable	  that	  the	  437.17	  m/z	  signal	  has	   a	  mass	   +1	   than	  would	   be	   typically	   expected	   due	   to	   the	   fact	   that	   the	   sample	  submitted	   for	  mass	   spectrometric	   analysis	  was	  highly	   concentrated	   and	   it	   is	   the	  C13	   isotope	   that	   is	   detected.	   The	   mass	   spectrometer	   used	   had	   also	   consistently	  been	   giving	   results	   in	   the	   positive	   mode	   analysis	   of	   mass	   +1	   than	   would	   be	  expected	  for	  a	  range	  of	  compounds.	  	  
	  
Figure	  7.2	  Monophosphate	  BED(a)	  has	  a	  predicted	  mass	  of	  435.18	  g/mol	  	  It	   can	   be	   concluded	   that:	   removal	   of	   the	   adjacent	   free	   alcohol	   from	  ProTide	  
analogues	  of	  S1P	  receptor	  modulators	  such	  as	  fingolimod	  and	  KRP-­203	  leads	  
to:	  
	  
1. Greatly	  improved	  stability	  
2. Desired	   enzymatic	   processing	   by	   carboxypeptidase	   to	   the	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7.1.2	  Ph-­LAla-­OMe-­BED(a)	  Neuronal	  Cell	  Lysate	  Experiment	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7.1.3	  Ph-­LAla-­OBzl-­BED(a)	  Neuronal	  Cell	  Lysate	  Experiment	  	  
	  
	  


























Figure	  7.4	  Stacked	  31P	  NMR	  spectra	  of	  Ph-­‐LAla-­‐OBzl-­‐BED(a)	  processing	  in	  cell	  lysate	  over	  4	  days	  
	  
	  
Figure	  7.5	  Exact	  mass:	  582.25	  g/mol,	  observed	  mass	  in	  negative	  mode:	  581.46	  m/z	  [M-­‐H]	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7.1.4	  Ph-­LAla-­OMe-­BED(h)	  Carboxypeptidase	  Experiment	  
	  
	  
Scheme	  7.4	  Processing	  of	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  to	  the	  monophosphate	  by	  carboxypeptidase	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7.2	  Stability	  Assays	  Part	  1	   	  
7.2.1	  Ph-­LAla-­OMe-­BED(h)	  Base	  Stability	  Experiment	  
	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  was	  subjected	  to	  a	  pH	  8	  stability	  experiment	  as	  described	  in	  section	  5.1.2.	   Interestingly	   there	  appears	   to	  have	  been	   some	   instant	  degradation	  on	   adding	   the	   base	   but	   then	   the	   compound	   was	   not	   degraded	   further	   over	   13	  hours.	  What	  may	  have	  happened	  is	  that	  some	  impurity	  in	  the	  starting	  material	  may	  have	   degraded	   in	   the	   presence	   of	   base	   but	   the	   parent	   Ph-­‐LAla-­‐OMe-­‐BED(h)	  compound	  has	  not	  degraded.	  Certainly	  it	  appears	  that	  ProTide	  BED	  analogues	  are	  more	  stable	  in	  basic	  conditions	  than	  ProTide	  fingolimod	  analogues.	  	  	  
	  
Figure	  7.8	  31P	  NMR	  spectrum	  of	  blank	  containing	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  dissolved	  in	  MeOD	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7.2.2	  Ph-­LAla-­OiPr-­BED(a)	  Base	  Stability	  Experiment	  
	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  was	  subjected	  to	  a	  pH	  8	  stability	  experiment	  as	  described	  in	  section	   5.1.2.	   Interestingly	   it	   appears	   to	   have	   rapidly	   degraded	   in	   part	   and	   then	  remained	   constant	   as	   with	   the	   same	   experiment	   conducted	   with	   Ph-­‐LAla-­‐OMe-­‐BED(h)	  as	  shown	  in	  figure	  7.10.	  	  
	  
	  























Figure	  7.11	  Mass	  spectrometry	  experiment	  of	  base	  induced	  Ph-­‐LAla-­‐OiPr-­‐BED(h)	  degradation	  	  	  
	  
Figure	  7.12	  Exact	  mass:	  506.22	  g/mol,	  observed	  mass	  in	  positive	  mode	  507.23	  m/z	  [M+H]	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7.2.3	  Ph-­LAla-­OMe-­BED(h)	  Acid	  Stability	  Experiment	  
	  The	  acid	  stability	  experiment	  involving	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  in	  pH	  1.5	  buffer	  over	  13	  h	  gave	  similar	  results	  to	  the	  base	  stability	  experiments.	  Small	  new	  peaks	  appear	  but	  the	  main	  parent	  peaks	  did	  not	  decrease	  in	  intensity.	  It	  appears	  likely	  that	  in	  the	  base	  experiments	  figures	  7.9	  and	  7.10	  and	  the	  acid	  stability	  experiment	  shown	  in	  figure	  7.13	  impurities	  have	  been	  degraded	  but	  the	  compound	  being	  tested	  has	  not	  degraded.	  
	  
	  





























7.3.1	  Analytical	  HPLC	  
	  In	   order	   to	   confirm	   the	   hypothesis	   that	   the	   compounds	   being	   tested	   were	   not	  sufficiently	  pure	  and	  that	  it	  is	  impurities	  that	  are	  being	  degraded	  and	  detected	  by	  phosphorus	  NMR,	  analytical	  HPLC	  was	  conducted	  on	  the	  ProTide	  BED	  analogues.	  	  The	  HPLC	  method	  used	  20%	  ACN	  and	  80%	  0.1%	  TFA	   in	  H2O	   increasing	   to	  ACN	  100%	  over	  34	  minutes.3	  The	  UV	  detector	  was	  set	  to	  220	  nm	  and	  263	  nm.	  	  
	  
	  
Figure	  7.14	  Analytical	  HPLC	  method	  information	  for	  BED	  analogues	  
	  
	  
Figure	  7.15	  Analytical	  HPLC	  method	  information	  for	  BED	  analogues	  
	  Figures	  7.17	  and	  7.18	  show	  the	  data	   for	   the	  analytical	  HPLC	  experiments	   for	   the	  two	   ProTide	   BED	   analogues	   previously	   tested	   in	   base	   and	   acid	   stability	  experiments.	  As	  can	  be	  seen,	  the	  analogues	  tested	  are	  not	  sufficiently	  pure	  to	  rule	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out	   the	   possibility	   that	   the	   new	   peaks	   seen	   in	   the	   base	   and	   acid	   stability	  experiments	  are	  degraded	  impurities.	  With	  purities	  of	  around:	  	  
• 87%	  for	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  
• 82%	  for	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  	  It	  was	  decided	  that,	  in	  order	  to	  be	  able	  to	  progress	  with	  the	  stability	  experiments,	  preparative	  HPLC	  needed	  to	  be	  conducted	  on	  the	  ProTide	  BED	  analogues	  in	  order	  to	  be	  able	  to	  rule	  out	  impurities	  as	  an	  explanation	  for	  any	  further	  data	  of	  the	  type	  previously	   seen	   in	   the	   base	   and	   acid	   stability	   experiments	   for	   BED	   analogues.	  Typically	   purities	   of	   around	   95%	   or	   more	   are	   more	   acceptable	   for	   biological	  testing	  and	  publication	  standard	  data.	  	  
	  
Figure	  7.16	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  
	  
Figure	  7.17	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  	  A	  similar	  level	  of	  purity	  was	  observed	  in	  all	  6	  ProTide	  BED	  analogues	  synthesised	  and	  purified	  by	  column	  chromatography.	  Parent	  BED(a)	  and	  BED(h)	  were	  both	  a	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more	  acceptable	  94%	  and	  95%	  pure	  respectively	  after	  column	  chromatography	  as	  shown	  in	  figures	  7.19	  and	  7.20.	  	  
	  
Figure	  7.18	  Analytical	  HPLC	  chromatograph	  of	  BED(a)	  	  
	  
Figure	  7.19	  Analytical	  HPLC	  chromatograph	  of	  BED(h)	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Figure	  7.21	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  	  	  
	  
Figure	  7.22	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OBzl-­‐BED(a)	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Figure	  7.23	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OiPr-­‐BED(h)	  
	  
7.3.2	  Preparative	  HPLC	  
	   	  Preparative	   HPLC	   was	   conducted	   on	   the	   ProTide	   BED	   analogues	   and	   then	   the	  purified	   compounds	   were	   checked	   for	   purity	   again	   using	   analytical	   HPLC.	   The	  solvent	  system	  used	  for	  the	  preparative	  method	  was	  the	  same	  as	  the	  analytical	  but	  on	  a	  larger	  scale.	  The	  UV	  detector	  was	  set	  to	  220	  nm	  and	  245	  nm	  /	  263	  nm.	  
	  
	  
Figure	  7.24	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  after	  preparative	  HPLC	  
	  
	  
Figure	  7.25	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OBzl-­‐BED(a)	  after	  preparative	  HPLC	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Figure	  7.26	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  after	  preparative	  HPLC	  
	  
	  
Figure	  7.27	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  after	  preparative	  HPLC	  
	  
	  
Figure	  7.28	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OBzl-­‐BED(h)	  after	  preparative	  HPLC	  
	  
Figure	  7.29	  Analytical	  HPLC	  chromatograph	  of	  Ph-­‐LAla-­‐OiPr-­‐BED(h)	  after	  preparative	  HPLC	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7.4	  Stability	  Assays	  Part	  2	  
	  
7.4.1	  Ph-­LAla-­OiPr-­BED(h)	  Acid	  Stability	  Experiment	  
	  An	   acid	   stability	   experiment	   involving	   preparative	   HPLC	   purified	   Ph-­‐LAla-­‐OiPr-­‐BED(h)	  in	  pH	  1.5	  buffer	  over	  13	  h	  gave	  much	  better	  results	  than	  in	  figure	  7.13.	  As	  can	  be	  seen	  below	  in	  figure	  7.30	  there	  was	  no	  discernable	  change	  over	  13	  hours	  at	  pH	   1.5	   suggesting	   that	   ProTide	   BED	   analogues	   are	   able	   to	   withstand	   the	   acidic	  conditions	  of	   the	   stomach	  and	   that	   the	  previously	  observed	  peaks	   seen	   in	   figure	  7.13	  are	  in	  fact	  degraded	  compounds	  of	  impurities.	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7.4.2	  Ph-­LAla-­OMe-­BED(a)	  Base	  Stability	  Experiment	  
	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  was	  subjected	  to	  a	  pH	  8	  stability	  experiment	  as	  described	  in	  sections	  7.2.1	  and	  7.2.2.	  This	   time,	  however,	   the	  expected	  results	  were	  observed.	  No	  degradation	  is	  discernable	  in	  the	  NMR	  spectra	  confirming	  that:	  	  
• ProTide	  BED	  analogues	   are	  more	   stable	   in	  basic	   conditions	   than	  ProTide	  fingolimod	  analogues	  
• The	  previously	  observed	  unexpected	  degradations	  seen	  in	  figures	  7.9	  and	  7.10	  are	  the	  result	  of	  impurities	  in	  the	  compound	  degrading	  as	  opposed	  to	  the	  desired	  ProTide	  BED	  analogues	  themselves	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7.4.3	  Ph-­LAla-­OMe-­BED(h)	  Base	  Stability	  Experiment	  
	  Ph-­‐LAla-­‐OMe-­‐BED(h)	   was	   subjected	   to	   a	   pH	   8	   stability	   experiment	   of	   the	   same	  type	   as	   described	   in	   section	   7.2.1.	   This	   time,	   however,	   no	   small	   peak	   appeared.	  This	   confirms	  beyond	   any	   reasonable	  doubt	   that	   the	  previously	   seen	   small	   peak	  that	  was	  observed	  was	  due	  to	  an	   impurity	  rather	   than	  degradation	  of	   the	  parent	  compound	  itself.	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7.4.4	  Ph-­LAla-­OMe-­BED(a)	  Human	  Serum	  Experiment	  	  
	  



























Figure	  7.33	  Stacked	  31P	  NMR	  spectra	  of	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  processing	  in	  human	  serum	  over	  12	  hours	  at	  37	  °C	  

























	   	   	  
	  
Confidential	  
7.4.5	  Ph-­LAla-­OiPr-­BED(a)	  Human	  Serum	  Experiment	  
	  A	  stability	  study	  of	  Ph-­‐LAla-­‐OiPr-­‐BED(a)	  in	  human	  serum	  as	  37	  °C	  was	  conducted	  over	  5	  days.	  The	   sample	   tube	  was	  kept	  warm	  during	   the	  5	  day	  experiment	   time	  period	  using	  a	  water	  bath	  set	  to	  37°C.	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7.4.6	  Ph-­LAla-­OMe-­BED(h)	  Human	  Serum	  Experiment	  
	  A	  stability	  study	  of	  Ph-­‐LAla-­‐OMe-­‐BED(h)	  in	  human	  serum	  as	  37	  °C	  was	  conducted	  over	  5	  days.	  The	   sample	   tube	  was	  kept	  warm	  during	   the	  5	  day	  experiment	   time	  period	  using	  a	  water	  bath	  set	  to	  37°C.	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7.5	  Potential	  for	  Therapeutic	  Viability	  and	  FDA	  Approval	  
	  
7.5.1	  ProTide	  Moiety	  Stability	  and	  Processing	  
	  ProTide	  BED	  analogues	  have	  proven	  to	  be	  far	  more	  stable	  than	  ProTide	  fingolimod	  analogues	  and	  have	  been	  observed	  to	  be	  processed	  to	  the	  desired	  monophosphate	  in	  various	  processing	  experiments.	  Certainly	  with	  regards	  to	  stability	  and	  proof-­‐of-­‐concept	   experiments	   these	   compounds	   appear	   to	   show	  more	   potential	   as	   viable	  therapeutics	  when	  compared	  with	  ProTide	  fingolimod.	  However,	   there	  are	  a	  vast	  range	  of	  other	  key	  factors	  which	  influence	  a	  compound’s	  oral	  bioavailability,	  CNS	  penetration	   properties	   and	   ultimate	   chances	   of	   being	   approved	   by	   the	   FDA	   and	  EMA.	  	  
7.5.2	  CNS	  Transfer	  Properties	  	  A	  paper	  published	  by	  Pajouhesh	  et	   al	  suggests	   that	   the	   ideal	   logP	   range	   for	  CNS	  acting	  drugs	   is	   1.5-­‐2.7.4	   ProTide	  BED	   compounds	  have	  much	  higher	   lipophilicity	  e.g.	  5.24	  for	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  (calculated	  using	  a	  website5).	  A	  possible	  way	  of	  mediating	   this	   unwanted	   lipophilicity	   could	   be	   to	   change	   the	   amino	   acid	   of	   the	  ProTide	   to	   tune	   the	   polarity	   to	   help	   CNS	   absorption.	  However,	   fingolimod	   has	   a	  logP	   of	   4.72,	   according	   to	   the	   same	   site,	   suggesting	   that	   it	   is	   possible	   for	   a	  compound	   to	   have	   a	   higher	   logP	   than	   the	  published	   ideal	   1.5-­‐2.7	   range	   and	   still	  cross	  the	  BBB.	  	  	  The	  same	  paper	  says	  the	  polar	  surface	  area	  (PSA)	  of	  CNS	  therapeutics	  is	  typically	  60-­‐70	  Å	  with	  an	  upper	  limit	  of	  90	  Å.	  Another	  website6	  has	  been	  used	  to	  calculate	  that	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  has	  a	  PSA	  of	  126.18	  Å,	   further	  suggesting	   that	  ProTide	  BED	  analogues	  are	  not	  likely	  to	  cross	  the	  BBB.4	  The	  monophosphate	  of	  BED(a)	  has	  a	  calculated	  PSA	  of	  119.08	  Å	  which	  again	  is	  too	  large	  according	  to	  Pajouhesh	  et	  al’s	  paper.	   Fingolimod	   has	   a	   calculated	   PSA	   of	   66.48	   Å	  which	   fits	  with	   the	   reported	  range	  of	  appropriate	  values.	  	  The	  Pajouhesh	  paper	  also	  reports	  that	  the	  mean	  value	  of	  molecular	  weight	  for	  CNS	  active	   therapeutics	   is	   310	   g/mol.	   Fingolimod	   has	   a	   molecular	   weight	   of	   307.5	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g/mol	   which	   correlates	   very	   well	   with	   the	   published	   value	   for	   ideal	   molecular	  weight.	  ProTide	  BED	  compounds	  have	  a	  much	  larger	  molecular	  weight	  (e.g.	  596.3	  g/mol	   for	   Ph-­‐LAla-­‐OMe-­‐BED(a))	   which	   further	   suggests	   that	   ProTide	   BED	  analogues	  are	  less	  likely	  to	  cross	  the	  BBB	  than	  fingolimod.4	  	  A	  possible	  way	  around	  the	  likely	  inability	  for	  ProTide	  BED	  compounds	  to	  cross	  the	  BBB	  via	  passive	  diffusion	  is	  to	  use	  an	  amino	  acid	  moiety	  similar	  to	  one	  used	  in	  the	  commercially	   successful	   drug	   gabapentin	   (figure	   7.39)	   or	   the	   natural	  endogenously	  occurring	  dopamine	  precursor	  L-­‐DOPA	  (figure	  7.37).	  Potentially	  this	  would	   increase	   the	   likelihood	   of	   active	   transport	   across	   the	   BBB	   by	   the	   LAT1	  transporter7	  although	  this	  would	  dramatically	  increase	  the	  molecular	  weight	  even	  further	   and	   potentially	   reduce	   the	   efficacy	   of	   ProTide	   activation	   by	   the	   host	  enzymes.	  A	  cursory	  look	  at	  a	  paper8	  detailing	  approaches	  for	  CNS	  delivery	  suggests	  that	   the	   possible	   CNS	   infiltration	   moiety	   suggested	   in	   figure	   7.40	   is	   arguably	  unlikely	   to	   be	   effective	   as	   it	   lacks	   the	   reportedly	   essential	   components	   for	   LAT1	  transport	   of	   a	   negatively	   charged	   carboxyl	   group	   and	   positively	   charged	   amino	  group	  as	  present	  in	  the	  CNS-­‐acting	  drugs	  melphalan	  (figure	  7.38)	  and	  gabapentin.	  Interestingly	   the	   amino	   and	   alcohol	   functionalities	   of	   fingolimod	   are	   very	  reminiscent	   of	   the	   carboxyl	   and	   amino	   functional	   groups	   in	   melphalan	   and	  gabapentin	  and	  this	  may	  aid	  fingolimod’s	  transport	  across	  the	  BBB.	  	  
	  
Figure	  7.37	  Naturally	  occurring	  endogenous	  metabolic	  precursor	  of	  dopamine-­‐	  L-­‐DOPA	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  



















Figure	  7.40	  ProTide	  BED(a)	  analogue	  containing	  the	  same	  amino	  acid	  moiety	  present	   in	  L-­‐DOPA	  which	   could	   possibly	   lead	   to	   enhanced	   penetration	   of	   the	   BBB	   via	   active	   transport	   by	   the	   LAT1	  transporter5	  	  An	   alternative	  possibility	   to	   aid	   transport	   across	   the	  BBB	   could	  be	   to	   synthesise	  analogues	   which	   possess	   a	   C6-­‐glucose	   functional	   group	   to	   aid	   transport	   via	   the	  GLUT1	   transporter.	   This	   has	   been	   previously	   performed8	   as	   with	   D-­‐glucose	  conjugates	   of	   7-­‐chlorokynurenic	   acid.9	   However,	   the	   synthesis	   of	   D-­‐glucose	  ProTide	   analogues	   would	   increase	   the	   molecular	   mass	   of	   the	   compound	   even	  further	   and	   it	   is	   unknown	  whether	  D-­‐glucose	   ProTide	   analogues	   are	   capable	   of	  being	  processed	  to	  the	  monophosphate.	  It	  is	  possible	  that	  an	  unwanted	  cyclisation	  would	  result	  of	  a	  type	  similar	  to	  that	  as	  previously	  described	  in	  Chapter	  5.	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7.5.3	  Discussion	  of	  ProTide	  Processing	  in	  Human	  Serum	  	  Human	   serum	   experiments,	   such	   as	   in	   section	   7.4.4,	   suggest	   that	   ProTide	   BED	  analogues	  can	  be	  processed	  to	  the	  monophosphate	  in	  the	  blood	  with	  Ph-­‐LAla-­‐OMe-­‐BED(a)	  having	  a	  half-­‐life	  of	  around	  14	  h.	  Typically	  with	  ProTide	  therapeutics	  this	  would	   be	   considered	   as	   a	   negative	   outcome	   as	   the	   monophosphate	   does	   not	  readily	   transfer	  across	   the	   cell	  membrane	  and	   the	  monophosphate	   is	  only	  active	  intracellularly.	  However,	  it	  is	  possible	  that	  in	  the	  case	  of	  S1P	  receptor	  modulators	  this	  may	   not	   be	   such	   negative	   result.	   There	   are	   potentially	   2	   reasons	   as	   to	  why	  processing	   of	   ProTide	   S1P	   receptor	   modulators	   to	   the	   monophosphate	   in	   the	  serum	  may	   not	   be	   such	   an	   unwanted	   result	   as	   with	   typical	   ProTide	   nucleoside	  drugs:	  	  
• Possible	   diffusion	   across	   the	   BBB	   in	   the	   style	   of	   psilocybin	   which	   also	  possesses	  a	  phosphate	  and	  amine	  group	  
• S1P	  receptors	  are	  reported	  as	  being	  on	  the	  outside	  of	  the	  cell	  membrane	  as	  opposed	  to	  in	  the	  intracellular	  matrix10,11	  	  
	  
Figure	  7.42	  Putative	  mode	  of	  activation	  of	  fingolimod	  in	  vivo11	  	  The	   mode	   of	   activation	   of	   fingolimod,	   as	   shown	   in	   figure	   7.42,	   suggests	   that	  processing	  of	  ProTide	  S1P	  receptor	  modulators	   to	   the	  monophosphate	   in	  human	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serum	  may	  not	  be	  as	  negative	  a	  consequence	  as	   is	  typical	   for	  ProTide	  nucleoside	  analogues.	   ProTide	   nucleosides	   are	   typically	   incorporated	   into	   the	   host	   DNA	   or	  RNA	   and	   therefore	   need	   to	   be	   activated	   intracellularly.12	   However,	   as	   S1P	  receptors	   are	   G	   protein–coupled	   receptors10	   and	   are	   therefore	   located	   on	   the	  outside	  of	   the	  cell11	  processing	  of	  ProTide	  BED	  analogues	   to	   the	  monophosphate	  may	  in	  fact	  be	  a	  positive	  outcome.	  	  
7.5.4	  Metabolic	  Stability	  	  According	   to	   Tsuji	   et	   al’s	   paper13	   the	   compounds	   they	   produced	   have	   a	   poorer	  metabolic	  stability	  profile	   than	  fingolimod	  and	  phospho-­‐fingolimod.	  For	  example,	  fingolimod	  has	  a	  metabolic	  stability	  percentage	  (of	  the	  remaining	  compounds	  after	  30	  min	   incubation	   at	   37	   °C	  with	   rat	   hepatic	  microsomes)	   of	   97%	   and	   phospho-­‐fingolimod	   has	   a	   metabolic	   stability	   of	   >100%-­‐	   this	   is	   in	   contrast	   to	   51%	   for	  BED(a)	  and	  92%	  for	  phospho-­‐BED(a).	  The	  ether	  functional	  group	  present	  in	  all	  the	  BED	  compounds	   is	  potentially	   the	   region	  of	   the	  molecule	  which	   is	  most	   liable	   to	  metabolism	  catalysed	  degradation.	  This	  poorer	  metabolic	  stability	  is	  also	  another	  contributory	   factor	   which	   leads	   to	   the	   conclusion	   that	   phosphorus	   prodrugs	   of	  BED	  compounds	  are	  not	  likely	  to	  be	  preferable	  to	  parent	  fingolimod.	  	  
7.5.5	  Toxicity	  	  ProTide	   BED	   analogues	   were	   exposed	   to	   mouse	   embryonic	   stem	   cell-­‐derived	  neurons	   at	   10	   nM,	   100	   nM	   and	   1	   μM	   concentrations	   for	   3	   weeks.	   ProTide	   BED	  analogues	  were	  found	  to	  not	  be	  toxic	  at	  10	  nM	  and	  100	  nM	  but	  were	  toxic	  at	  1	  μM	  concentration.	   Crucially,	   phospho-­‐fingolimod	  was	   also	   found	   to	   be	   toxic	   at	   1	   μM	  concentration,	   suggesting	   that	   ProTide	   BED	   analogues	   are	   not	   more	   toxic	   to	  neurons	   than	   the	   pharmacologically	   active	   monophosphate	   of	   the	   commercially	  available	   fingolimod.	  The	  toxicity	   testing	  was	  conducted	  by	  Katharina	  Säuberli	   in	  the	  School	  of	  Biosciences.	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Figure	  7.43	  Day	  2	  culture	  of	  neurons	  derived	  from	  mouse	  embryonic	  stem	  cells	  (Image	  courtesy	  of	  Katharina	  Säuberli)	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Chapter	  8	  –	  Molecular	  Modelling	  Studies	  
	  
	  
8.1	  S1P1	  Selectivity	  	  While	   the	   improved	   stability	   and	   biochemical	   processing	   of	   ProTide	   BED	  compounds	   over	   ProTide	   fingolimod	   is	   indicative	   that	   making	   phosphorus	  prodrugs	   of	   mono	   alcohol	   S1P	   receptor	   modulators	   is	   more	   likely	   to	   lead	   to	   a	  viable	   therapeutic,	   some	  of	   the	   other	   characteristics	   of	   ProTide	  BED	   compounds	  such	   as	   published	  metabolic	   stability,1	   logP	   and	   polar	   surface	   area	   suggest	   that	  ProTide	   BED	   analogues	   are	   not	   likely	   to	   be	   more	   effective	   therapeutics	   than	  fingolimod.	  The	  next	  logical	  stage	  in	  the	  development	  of	  the	  project	  is	  arguably	  to	  try	   to	   incorporate	   the	   most	   favourable	   aspects	   of	   the	   BED	   compounds	   and	  fingolimod	  while	  eliminating	  the	  less	  favourable	  aspects	  of	  both.	  	  
	  
Figure	  8.1	  BED(a)	  and	  BED(h)	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1α	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2α	  	  	  
Figure	   8.2	   Mono-­‐alcohol	   fingolimod	   analogue	   (1α)	   and	   hypothetically	   more	   S1P1	   selective	  analogue	  (R)-­‐2-­‐amino-­‐4-­‐(2,5-­‐dimethyl-­‐4-­‐octylphenyl)-­‐2-­‐methylbutan-­‐1-­‐ol	  (2α)	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According	  to	  Tsuji	  et	  al	  BED(h),	  as	  shown	  in	  figure	  8.1,	  is	  more	  S1P1	  selective	  over	  S1P3	   than	   BED(a)	   and	   this	   selectivity	   seems	   a	   consequence	   of	   the	   2,5-­‐dimethyl	  groups	   in	   the	   central	   aromatic	   ring.	   Starting	   from	   this	   finding,	   the	   2,5-­‐dimethyl	  groups	   could	   be	   added	   to	   the	   aryl	   moiety	   of	   the	   mono-­‐alcohol	   analogues	   of	  fingolimod,	  potentially	  leading	  to	  greater	  S1P1	  selectivity	  compared	  to	  fingolimod.	  Greater	  S1P1	  selectivity	  could	  potentially	  lead	  to	  fewer	  unwanted	  side	  effects.	  	  	  Different	  molecular	  modelling	   techniques	  were	   to	  be	  exploited	   in	  order	   to	  verify	  the	  potential	  selectivity	  of	  the	  newly	  designed	  molecules.	  Initially	  the	  structure	  of	  the	   S1P1	   receptor	   was	   deduced	   by	   a	   comparison	   of	   computational	   models	   with	  other	  receptors	  such	  as	  the	  X-­‐ray	  crystal	  structure	  of	  bovine	  rhodopsin.2	  In	  2012	  the	   crystal	   structure	   of	   the	   S1P1	   receptor	   fused	   to	  T4-­‐lysozyme	   in	   complex	  with	  the	   antagonist	   sphingolipid	  mimic	  ML056	  was	   published.3	   X-­‐ray	   crystallography	  was	  used	  to	  determine	  the	  3D	  structure	  of	  the	  transmembrane	  GPCR	  S1P1	  receptor	  as	  shown	  in	  figures	  8.4	  and	  8.5.4	  
	  
Figure	  8.4	  Structure	   of	   the	   S1P1	   receptor	   and	   its	   4	   primary	   regions	  with	   the	  position	  of	   the	   cell	  membrane	  shown	  with	  white	  spheres4	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Figure	  8.5	  A:	  S1P1	  receptor	  in	  magenta	  fused	  to	  the	  T4	  lysozyme	  in	  yellow	  with	  ML056	  antagonist	  in	  complex	  with	  the	  active	  site.	  B:	  Water-­‐mediated	  ligand-­‐receptor	  interactions5	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8.2	  Homology	  Modelling	  
	  As	   no	   human	   S1P3	   protein	   crystal	   structure	   is	   available	   a	   homology	  model	   was	  prepared	   using	   the	   crystal	   structure	   of	   the	   human	   sphingosine	   1-­‐phosphate	  receptor	   1	   (S1P1)	   fused	   to	   T4-­‐lysozyme	   (PDB	   ID:	   3V2Y)	   in	   complex	   with	   an	  antagonist	  sphingolipid	  mimic	  (ML056),	  having	  a	  sequence	  similarity	  of	  53%	  with	  S1P3.	   After	   removing	   the	   T4-­‐lysozyme	   portion,	   the	   model	   was	   prepared	   using	  MOE2015.10	   homology	   tool	   using	   a	   previously	   reported	   procedure.6	   The	  antagonist’s	   atoms	  were	   included	   in	   the	   environment	   for	   induced	   fit	   in	   order	   to	  shape	   the	   active	   site	   of	   the	   new	  model.	   The	   final	   model	   was	   energy	  minimised	  using	  AMBER99	  force	  field.	  	  
8.2.1	  Molecular	  Docking	  
	  According	   to	   Hanson	   et	   al.3,4	   	   the	   antagonist	   conformation	   of	   the	   available	   S1P1	  crystal	   structure	   cannot	   accommodate	   a	   long	   lateral	   chain,	   which	   is	   a	   common	  feature	  in	  the	  fingolimod,	  the	  natural	  substrate	  sphingosine-­‐1-­‐phosphate	  and	  other	  S1P1	  agonists.	  The	  necessary	  space	   to	  accommodate	  a	   lateral	   chain	  of	  an	  agonist	  could	  be	  obtained	  by	  performing	  an	  induced	  fit	  docking	  of	  an	  agonist	   in	  the	  S1P1	  antagonist	  conformation.	   Induced	  fit	  docking	   is	  a	   technique	  that	   takes	   in	  account	  the	  potential	  side-­‐chain	  or	  backbone	  movements	  of	  a	  protein	  upon	  ligand	  binding,	  whereas	  standard	  virtual	  docking	  studies	  consider	  the	  ligand	  free	  to	  move	  but	  the	  protein	  is	  held	  rigid.	   	  Following	  previously	  published	  work,3,4	   induced	  fit	  docking	  of	   the	   natural	   substrate	   sphingosine-­‐1-­‐phosphate	   and	   phospho-­‐fingolimod	   was	  performed	   on	   the	   S1P1	   crystal	   structure.	   As	   reported,	   the	   induced	   fit	   docking	  allows	   a	   better	   accommodation	   of	   the	   lateral	   chain	   in	   the	   hydrophobic	   pocket,	  inducing	   residue	   conformation	   changes	   in	   that	   area	   of	   the	   protein.	   Moreover,	  ∆Gbinding	   energy	   and	   ligand	   strain	   (LS)	   energy	   calculations	   of	   the	   ligand-­‐protein	  complex	  after	  standard	  docking	  and	  induced	  fit	  docking	  show	  a	  drop	  in	  both	  values	  in	  the	  case	  of	  the	  induced	  fit,	  confirming	  that	  the	  induced	  agonist	  conformation	  is	  the	   optimal	   protein	   conformation	   for	   a	   potential	   agonist	   molecular	   modelling	  evaluation.	   The	   study	   was	   performed	   in	   both	   S1P1	   crystal	   and	   S1P3	   homology	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models.	  The	  results	  are	  shown	  in	  tables	  8.1	  and	  8.2	  and	  are	  in	  accordance	  with	  the	  work	  reported	  for	  other	  agonists	  by	  Hanson	  et	  al.3,4	  	  
Sphingosine-­1-­phosphate	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  S1P1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  S1P3	  	   Docking	   Induced	  Fit	   Docking	   Induced	  Fit	  ∆G	  =	   -­‐86.95	   -­‐122.428	   -­‐66.783	   -­‐149.51	  LS	  =	   24.427	   7.204	   13.917	   10.458	  
	  
Table	   8.1	  Docking	   study	   data	   of	   sphingosine-­‐1-­‐phosphate	   in	   the	   S1P1	   and	   S1P3	   receptors.	   The	  ∆Gbinding	  energy	  and	  ligand	  strain	  (LS)	  energy	  values	  are	  in	  (kcal/mol).	  	  	  
Phospho-­fingolimod	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  S1P1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  S1P3	  	   Docking	   Induced	  Fit	   Docking	   Induced	  Fit	  ∆G	  =	   -­‐94.383	   -­‐109.154	   -­‐76.028	   -­‐135.124	  LS	  =	   22.065	   12.960	   20.591	   12.424	  
	  
Table	  8.2	  Docking	  study	  data	  of	  phospho-­‐fingolimod	  in	  the	  S1P1	  and	  S1P3	  receptors.	  The	  ∆Gbinding	  energy	  and	  ligand	  strain	  (LS)	  energy	  values	  are	  in	  (kcal/mol).	  	  
	  Considering	   these	   data,	   the	   proteins	   obtained	   from	   induced	   fit	   docking	   were	  therefore	  selected	  to	  be	  used	  in	  the	  following	  standard	  docking	  studies.	  According	  to	   the	  data	  above,	  phospho-­‐fingolimod	   fits	   slightly	  more	  comfortably	   in	   the	  S1P3	  receptor	  than	  the	  S1P1	  receptor.	  This	  correlates	  well	  with	  much	  of	   the	  published	  data	  which	   suggest	   that	  phospho-­‐fingolimod	  has	   a	   comparable	  or	   slightly	  higher	  affinity	  for	  the	  S1P3	  receptor	  than	  the	  S1P1	  receptor.1,7	  	  In	  the	  case	  of	  S1P1,	  the	  protein	  coming	  from	  the	  induced	  fit	  docking	  of	  BED(h),	  the	  most	  active	  S1P1	  agonist	  according	  to	  Tsuji	  et	  al,1	  was	  chosen,	  whereas	  in	  the	  case	  of	   S1P3	   the	   protein	   obtained	   after	   the	   phospho-­‐fingolimod,	   the	  most	   active	   S1P3	  agonist	  according	   to	  Tsuji	  et	  al,1	   induced	  docking	  was	  selected.	  The	   two	  proteins	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were	  used	   to	  perform	  a	  Glide	  SP	  docking	  of	   the	  proposed	  new	  agonists	   together	  with	  the	  reported	  BED(a)	  and	  BED(h)	  derivatives	  as	  controls.	  	  	  	  
	  
Figure	  8.7	  Phospho-­‐fingolimod	  in	  S1P1	  	  
	  
Figure	  8.8	  Phospho-­‐fingolimod	  in	  S1P3	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Figure	  8.9	  Phospho-­‐BED(a)	  in	  S1P1	  	  	  
	  
Figure	  8.10	  Phospho-­‐BED(h)	  in	  S1P3	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Figure	  8.11	  Proposed	  phospho-­‐dimethyl	  fingolimod	  (2α)	  in	  S1P1	  	  	  
	  
Figure	  8.12	  Proposed	  phospho-­‐dimethyl	  fingolimod	  (2α)	  in	  S1P3	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After	   the	   homology	   modelling	   induced	   fit	   docking	   studies	   provided	   data	   which	  suggest	  that	  the	  initially	  proposed	  aryl	  dimethyl	  fingolimod	  analogue	  2α	  shown	  in	  figure	  8.2	  was	  unlikely	  to	  be	  particularly	  more	  S1P1	  selective	  than	  fingolimod	  (see	  section	   8.2.3)	   the	   structures	   shown	   in	   figures	   8.13	   and	   8.14	   were	   chosen	   for	  investigation.	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1β	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2β	  
Figure	  8.13	  (R)-­‐2-­‐amino-­‐2-­‐methyl-­‐4-­‐(4-­‐(4-­‐(p-­‐tolyl)butyl)phenyl)butan-­‐1-­‐ol	  (1β)	  and	  (R)-­‐2-­‐amino-­‐4-­‐(2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butyl)phenyl)-­‐2-­‐methylbutan-­‐1-­‐ol	   (2β)	   structures	   for	  S1P1	  and	  S1P3	  receptor	  selectivity	  investigation	  	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1γ	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2γ	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8.2.2	  S1P1	  Docking	  
	  All	   the	   derivatives,	   including	   sphingosine-­‐1-­‐phosphate	   and	   phospho-­‐fingolimod,	  occupy	  the	  S1P1	  binding	  site	  in	  a	  similar	  manner	  with	  the	  phosphate	  head	  mainly	  interacting	   with	   Tyr29,	   Lys34	   and	   Arg120,	   all	   amino	   acids	   reported	   to	   be	  important	   for	   the	   interaction	   with	   the	   phosphate	   head1,3,4	   and	   the	   rest	   of	   the	  molecule	   points	   to	   the	   active	   site	   towards	   the	   area	   defined	   by	   Val194,	   Phe125,	  Cys206,	   Leu276.	   An	   example	   of	   the	   interaction	   with	   the	   active	   site	   is	   shown	   in	  figure	  8.15.	  The	  results	  suggest	   that	   the	  phosphates	  of	  all	   the	  novel	  structures	   in	  figures	  8.2,	  8.12	  and	  8.13,	  can	  bind	  as	  effectively	  as	  phospho-­‐fingolimod.	  	  
	  
Figure	   8.15	  Phospho-­‐(R)-­‐1-­‐(4-­‐(3-­‐amino-­‐4-­‐hydroxy-­‐3-­‐methylbutyl)phenyl)-­‐4-­‐(p-­‐tolyl)butan-­‐1-­‐one	  (1γ)	  in	  S1P1	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8.2.3	  S1P3	  Docking	  	  Sphingosine-­‐1-­‐phosphate	   and	   phospho-­‐fingolimod	   occupy	   the	   S1P3	   binding	   site	  with	   the	   phosphate	   head	   interacting	  with	   Tyr22,	   Lys27,	   Arg31	   and	   Arg114	   (see	  figure	  8.15).	  The	  rest	  of	  the	  molecule	  is	  inserted	  in	  the	  active	  pocket	  pointing	  to	  the	  area	  delimited	  by	  Phe119,	   Ile188	   (corresponding	   to	   the	  Val194	   in	  S1P1),	  Cys200	  and	  Phe263	  (corresponding	  to	  the	  Leu276	  in	  S1P1).	  	  
	  
Figure	  8.16	  Phospho-­‐fingolimod	  in	  S1P3	  	  It	   is	  evident	  that	  the	  presence	  of	  Ile188	  (Val194	  in	  S1P1)	  and	  Phe263	  (Leu276	  in	  S1P1)	  narrows	  the	  S1P3	  binding	  site	  when	  compared	  to	  S1P1.	  Particularly,	  Phe263	  in	  the	  S1P3	  receptor	  together	  with	  Phe119	  and	  Phe260	  form	  a	  phenylalanine	  area	  which	  can	  easily	  accommodate	  the	  linear	  lateral	  chain	  of	  the	  phospho-­‐fingolimod	  but	  it	  does	  not	  easily	  allow	  the	  positioning	  of	  the	  extra	  benzene	  ring	  present	  in	  the	  lateral	  chain	  of	  BED(h).	  Figure	  8.17	  shows	  the	  docking	  of	  phospho-­‐BED(h)	  in	  S1P3	  and	   the	  potential	   clashes,	   represented	  as	   surface	   contacts,	  between	   the	  aromatic	  ring	  in	  the	  lateral	  chain	  and	  the	  phenylalanine	  area.	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Figure	  8.17	  Phospho-­‐BED(h)	  in	  S1P3	  showing	  clashes	  between	  Phe263	  and	  the	  benzene	  ring	  in	  the	  lateral	  chain	  	  The	  presence	  of	   the	   rigid	  ketone	  group	   in	  phospho-­‐BED(h)	  and	   the	  2,5-­‐dimethyl	  substituent	   in	   the	   central	  benzene	   ring	   in	  phospho-­‐BED(h)	   (figure	  8.17)	   seem	   to	  force	   the	   lateral	   chain	   into	  a	  conformation	   that	   is	  not	  optimal	   for	   the	   interaction	  with	   the	   receptor,	   due	   to	   the	  presence	  of	   additional	   steric	  hindrance	   induced	  by	  Ile188.	   These	   findings,	   together	   with	   the	   clashes	   with	   Phe263,	   could	   justify	   the	  large	   loss	  of	   S1P3	  activity	   reported	   for	  BED(h)	  and	  BED(a)	  when	  compared	  with	  fingolimod,	   making	   these	   two	  molecules	   unlikely	   to	   have	   a	   high	   affinity	   for	   the	  S1P3	  receptor.	  	  	  Docking	  studies	  of	  the	  newly	  designed	  derivatives	  were	  in	  line	  with	  these	  results.	  The	   structure	   of	   the	   monophosphate	   of	   2α,	   shown	   in	   figure	   8.2,	   obtained	   by	  combining	  the	  structure	  of	  BED(h)	  and	  fingolimod,	  perfectly	  occupies	  the	  binding	  site,	  with	  the	  phosphate	  head	  interacting	  with	  the	  relevant	  amino	  acids,	  the	  linear	  lateral	   chain	   pointing	   toward	   the	   inner	   part	   of	   the	   active	   site	   with	   no	   clashes	  observed.	   In	   this	  case,	   it	   seems	   that	   the	  presence	  of	   the	  2,5-­‐dimethyl	  substituent	  does	  not	   influence	  in	  a	  negative	  manner	  the	  binding	  of	  the	  molecule,	  making	  this	  compound	  a	  potential	  agonist	  for	  S1P3	  (see	  figure	  8.18).	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Figure	  8.18	  Proposed	  phospho-­‐dimethyl	  fingolimod	  (2α)	  in	  S1P3	  	  However,	   compounds	   1β,	   2β,	   1γ	   and	   2γ	   in	   figures	   8.13	   and	   8.14,	   with	   much	  greater	   structural	   similarity	   to	   parent	   BED	   compounds,	   give	   similar	   results	   to	  BED(h)	  with	  the	  extra	  aromatic	  portion	  leading	  to	  clashes	  with	  the	  phenylalanine	  area	  influencing	  in	  a	  negative	  way	  the	  interaction	  with	  the	  receptor.	  Moreover,	  the	  combination	  of	  the	  extra	  aromatic	  ring,	  together	  with	  the	  2,5-­‐dimethyl	  substituent	  and	   the	   lateral	   ketone	   in	   2γ	   (as	   shown	   in	   figure	   8.19)	   causes	   a	   completely	  unfavourable	  binding	  of	  the	  molecule,	  especially	  in	  the	  phosphate	  head	  area.	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Figure	   8.19	   Phospho-­‐(R)-­‐1-­‐(4-­‐(3-­‐amino-­‐4-­‐hydroxy-­‐3-­‐methylbutyl)-­‐2,5-­‐dimethylphenyl)-­‐4-­‐(p-­‐tolyl)butan-­‐1-­‐one	  (2γ)	  	  in	  S1P3	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  After	  preparing	  a	   reliable	  S1P3	  homology	  model,	   a	   series	  of	  molecular	  modelling	  studies	  were	  performed	   in	  order	   to	  predict	   the	  potential	   selectivity	  of	   the	  newly	  designed	  compounds.	  All	  the	  new	  derivatives	  bind	  to	  the	  S1P1	  receptor	  in	  a	  similar	  manner	   to	   phospho-­‐fingolimod	   and	   they	   can	  be	   considered	  potential	   agonists	   of	  this	  receptor.	  	  Different	  results	  were	  obtained	   for	   the	  S1P3	  protein.	  The	  compounds	  1α	  and	  2α,	  reported	  in	  figure	  8.2,	  seem	  to	  perfectly	  dock	  in	  the	  binding	  pocket	  and	  therefore	  they	  are	  potential	  S1P3	  agonists	  lacking	  the	  desired	  S1P1	  selectivity.	  On	  the	  other	  hand,	   the	  binding	  of	  derivatives	  1β,	  2β,	  1γ,	   and	  2γ,	   reported	   in	   figures	  8.13	  and	  8.14,	  due	  to	  the	  addition	  of	  an	  extra	  aromatic	  ring	  and	  the	  combination	  of	  the	  2,5-­‐dimethyl	   substituent	   in	   2β	   and	   2γ	   and	   the	   lateral	   ketone	   in	   1γ	   and	   2γ,	   is	  characterised	   by	   different	   clashes	   with	   the	   protein	   amino	   acids.	   It	   can	   be	  speculated	  that	  this	  unfavourable	  binding	  could	  lead	  to	  an	  absence	  of	  S1P3	  activity	  and	  therefore	  can	  lead	  to	  potential	  S1P1	  selectivity	  over	  S1P3.	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Chapter	  9	  –	  Experimental	  
	  
	  
9.1	  General	  Experimental	  Details	  
	  
Solvents	  and	  Reagents	  
	  The	   following	  anhydrous	  solvents	  and	  reagents	  were	  bought	   from	  Sigma-­‐Aldrich	  with	   a	   suba-­‐seal	   stopper:	   dichloromethane	   (DCM),	   N,N-­‐dimethyl-­‐formamide	  (DMF),	  tetrahydrofuran	  (THF),	  triethylamine	  (TEA)	  and	  N-­‐methylimidazole	  (NMI).	  All	   commercially	   available	   reagents	   and	   solvents	   were	   used	   without	   further	  purification.	  	  
Thin	  Layer	  Chromatography	  
	  Pre-­‐coated,	   aluminium	   backed	   plates	   supplied	   by	   Merck	   (60	   F254,	   0.2	   mm	  thickness)	  were	  visualised	  under	  both	  short	  and	   long	  wave	  ultraviolet	   light	   (254	  nm	   and	   366	   nm),	   or	   by	   burning	   using	   TLC	   indicators	   such	   as	   vanillin	   and	  potassium	  permanganate	  solution.	  	  
Flash	  Column	  Chromatography	  
	  Column	  chromatography	  was	  carried	  out	  using	  silica	  gel	  supplied	  by	  Fisher	  (60A,	  35-­‐70	  μm).	  Glass	   columns	  were	   slurry	  packed	  using	   the	   appropriate	   eluent	  with	  the	   sample	   being	   loaded	   pre-­‐adsorbed	   onto	   silica	   gel.	   Fractions	   containing	   the	  desired	   product	   were	   identified	   by	   TLC,	   combined	   and	   the	   solvent	   removed	   in	  
vacuo.	  
	  
High	  Performance	  Liquid	  Chromatography	  
	  Analytical	   and	   preparative	   HPLC	   were	   conducted	   by	   Varian	   Prostar	   (LC	   Work	  Station-­‐	   Varian	   Prostar	   335	   LC	   detector,	   Varian	   fraction	   collector	   (model	   701),	  Prostar	  210	  solvent	  delivery	  system,	  using	  Agilent	  Eclipse	  Plus	  C18	  (5	  μm)	  as	  an	  
Chapter	  9	  
	   	   	  
	  
Confidential	  
analytical	   column	   and	   a	   Varian	   Pursuit	   XRs	   5	   C18	   (150	   x	   21.2	  mm)	  model	   as	   a	  preparative	  column.	  The	  software	  used	  was	  Galaxie	  Chromatography	  Data	  System.	  
	  
Nuclear	  Magnetic	  Resonance	  Spectroscopy	  	  
	  1H	  NMR	  (500	  MHz),	  13C	  NMR	  (125	  MHz),	  31P	  NMR	  (202	  MHz)	  were	  recorded	  on	  a	  Bruker	   Avance	   500	   MHz	   spectrometer	   at	   25	   °C.	   Spectra	   were	   calibrated	   to	   the	  deuterated	   solvent	   used.	   Chemical	   shifts	   are	   detailed	   in	   parts	   per	  million	   (ppm)	  downfield	   from	   tetramethylsilane.	   For	   31P	  NMR	   experiments,	   chemical	   shifts	   are	  quoted	   in	   parts	   per	   million	   relative	   to	   an	   external	   phosphoric	   acid	   standard.	  Coupling	  constants	  are	  described	  in	  Hertz	  (J).	  	  The	  following	  abbreviations	  are	  used	  in	  the	  assignment	  of	  NMR	  signals:	  s	  (singlet),	  d	   (doublet),	   t	   (triplet),	   q	   (quartet),	   quin	   (quintet),	   sep	   (septet),	   b	   (broad),	   m	  (multiplet)	  and	  dd	  (doublet	  of	  doublets).	  The	  ratio	  of	  diastereoisomers	  was	  based	  on	  31P	  NMR.	  The	  assignment	  of	  signals	  in	  1H	  NMR	  and	  13C	  NMR	  was	  done	  based	  on	  the	   analysis	   of	   coupling	   constants	   and	   additional	   two-­‐dimensional	   experiments	  (COSY,	  HSQC,	  PENDANT).	  
	  
Mass	  Spectrometry	  
	  Low	  resolution	  mass	  spectrometry	  was	  performed	  using	  a	  Bruker	  Daltonics	  device	  (atmospheric	   pressure	   ionisation,	   electrospray	   mass	   spectrometer)	   in	   either	  positive	  and/or	  negative	  mode.	  	  	  
Purity	  of	  Final	  Compounds	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9.2	  Standard	  Procedures	  	  
Phosphorochloridate	  Synthesis	  Standard	  Procedure	  	  To	   a	   stirred	   solution	   of	   the	   appropriate	   amino	   acid	   ester	   salt	   (1	   eq)	   and	   the	  appropriate	  aryl	  dichlorophosphate	  (1	  eq)	  in	  anhydrous	  DCM	  was	  added	  dropwise	  at	  	  -­‐78	  °C	  anhydrous	  TEA	  (2	  eq).	  Following	  the	  addition,	  the	  reaction	  mixture	  was	  stirred	  at	  -­‐78	  °C	  for	  30	  min	  and	  then	  at	  room	  temperature	  for	  1	  h.	  Formation	  of	  the	  desired	   compound	  was	  monitored	   by	   31PNMR.	  After	   this	   period	   the	   solvent	  was	  removed	   under	   reduced	   pressure	   to	   give	   an	   oil.	   Most	   of	   the	   aryl	  phosphorochloridates	  synthesised	  were	  purified	  by	  flash	  column	  chromatography	  (eluting	  with	  hexane	  -­‐	  ethyl	  acetate	  70:30	  v/v).	  	  
Phosphoramidate	  Synthesis	  Using	  tBuMgCl	  Standard	  Procedure	  
	  tBuMgCl	   (1	   eq)	   was	   added	   dropwise	   to	   a	   solution	   of	   primary	   alcohol	   (e.g.	  fingolimod	   hydrochloride	   /	   (S)-­‐1-­‐(4-­‐((2-­‐amino-­‐3-­‐hydroxy-­‐2-­‐methylpropoxy)methyl)phenyl)-­‐4-­‐(p-­‐tolyl)butan-­‐1-­‐one)	   (1	   eq)	   in	   anhydrous	  THF	  (7	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  the	  phosphorochloridate	  (1	  eq)	  in	  anhydrous	  THF	  (2	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	  left	  to	  stir	  for	  24	  hours.	  After	  24	  hours	  the	  solvent	  was	  removed	  in	  vacuo	  and	  the	  desired	  product	   was	   dry-­‐loaded	   to	   a	   column	   and	   isolated	   using	   flash	   chromatography	  (eluting	  with	  methanol	  –	  dichloromethane	  0:100	  v/v	  increasing	  to	  10:90	  v/v).	  
	  
Carboxypeptidase	  Y	  Enzymatic	  Processing	  Experiment	  Standard	  Procedure	  
	  The	  experiment	  was	  carried	  out	  by	  dissolving	  phosphoramidate	  compound	  (3	  mg)	  in	  acetone-­‐d6	  (0.15	  ml)	  and	  adding	  0.3	  ml	  of	  Trizma	  buffer	  (pH	  7.6).	  After	  the	  31P	  NMR	   data	   were	   recorded	   at	   25	   °C	   as	   a	   control,	   a	   previously	   defrosted	  carboxypeptidase	   Y	   (0.1	   mg	   dissolved	   in	   0.15	   ml	   of	   Trizma)	   was	   added	   to	   the	  sample.	  Next,	  the	  sample	  was	  submitted	  to	  31P	  NMR	  experiments	  (at	  25	  °C)	  and	  the	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spectra	   were	   recorded	   every	   7	   min	   over	   13	   h.	   31P	   NMR	   recorded	   data	   were	  processed	  and	  analysed	  with	  the	  Bruker	  Topspin	  2.1	  program.1	  	  
pH	  1.5	  Stability	  Assay	  Standard	  Procedure	  
	  The	  stability	  assay	  toward	  hydrolysis	  by	  aqueous	  buffer	  at	  pH	  1.5	  was	  conducted	  using	   in	   situ	   31P	  NMR	   (202	  MHz).	   The	   experiment	  was	   carried	   out	   by	   dissolving	  test	  compound	  (e.g.	  phosphoramidate	  fingolimod)	  (3	  mg)	  in	  methanol-­‐d4	  (0.1	  ml)	  and	   then	  adding	  buffer	  of	  pH	  1.5	   (prepared	   from	  HCl	  and	  KCl).	  Next,	   the	   sample	  was	   subjected	   to	   31P	   NMR	   experiments	   at	   25	   °C	   and	   the	   spectra	  were	   recorded	  every	  12	  min	  over	  13	  h.	  	  
pH	  8	  Stability	  Assay	  Standard	  Procedure	  
	  The	   stability	   assay	   toward	   hydrolysis	   by	   aqueous	   buffer	   at	   pH	   8	  was	   conducted	  using	   in	   situ	   31P	  NMR	   (202	  MHz).	   The	   experiment	  was	   carried	   out	   by	   dissolving	  test	  compound	  (e.g.	  phosphoramidate	  fingolimod)	  (3	  mg)	  in	  methanol-­‐d4	  (0.1	  ml)	  and	   then	  adding	  buffer,	  pH	  8	   (prepared	   from	   tris(hydroxymethyl)aminomethane	  and	  HCl).	  Next,	  the	  sample	  was	  subjected	  to	  31P	  NMR	  experiments	  at	  25	  °C	  and	  the	  spectra	  were	  recorded	  every	  12	  min	  over	  13	  h.	  	  
Human	  Serum	  Assay	  Standard	  Procedure	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Porcine	  Liver	  Esterase	  Processing	  Experiment	  Standard	  Procedure	  
	  Test	  compound	  (e.g.	  phosphoramidate	   fingolimod)	  (30	  mg)	  was	  added	  to	  Trizma	  solution	  (1	  ml)	  and	  acetone	  (2	  ml)	  and	  stirred	  at	  37	  °C	  for	  24	  h	  with	  monitoring	  by	  TLC.	   After	   24	   h	   the	   acetone	   was	   removed	   in	   vacuo	   and	   the	   remaining	   aqueous	  mixture	  was	  extracted	  with	  DCM.	  The	  organic	  layer	  was	  collected	  and	  the	  solvent	  removed	   under	   vacuum	   yielding	   the	   mixture	   of	   products	   and	   starting	   material	  which	  was	  then	  analysed	  by	  NMR	  and	  mass	  spectrometry.	  
	  
Cell	  Lysate	  Processing	  Experiment	  Standard	  Procedure	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9.3	  Phosphorochloridate	  Syntheses	  
	  
Synthesis	  of	  (S)-­1-­(benzyloxy)-­1-­oxopropan-­2-­aminium	  chloride	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SO O C13H21NO5S	  MW:	  303.11	  
Chapter	  9	  
	   	   	  
	  
Confidential	  
Synthesis	  of	  Phenyl-­(benzyloxy-­L-­alaninyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(methoxy-­L-­alaninyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(benzyloxy-­glycinyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(benzyloxy-­L-­leucinyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(benzyloxy-­L-­prolinyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(ethoxy-­L-­alaninyl)	  phosphorochloridate	  	  





O C11H15ClNO4P	  MW:	  291.0	  
Chapter	  9	  
	   	   	  
	  
Confidential	  
Synthesis	  of	  1-­Naphthyl	  dichlorophosphate	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Synthesis	  of	  1-­Naphthyl-­(ethoxy-­L-­alaninyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(methoxy-­glycinyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(ethoxy-­glycinyl)	  phosphorochloridate	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Synthesis	  of	  Phenyl-­(isopropyloxy-­L-­alaninyl)	  phosphorochloridate	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9.4	  Non-­S1P	  Receptor	  Modulator	  Phosphoramidate	  Syntheses	  	  
Synthesis	   of	   (2S)-­benzyl	   2-­((((3-­hydroxypropyl)	   amino)	   (phenoxy)	  
phosphoryl)	  amino)	  propanoate	  using	  NaH	  	  
	  	  3-­‐amino1-­‐propanol	   (0.3	  ml,	   4	  mmol,	   1	   eq)	  was	   added	   dropwise	   to	   a	   solution	   of	  phosphorochloridate	  (2.89	  g,	  8.5	  mmol,	  2.25	  eq)	  in	  anhydrous	  DCM	  (20	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  NaH	  (96	  mg,	  4	  mmol,	  1	  eq)	  was	  added	  and	  the	  mixture	  was	  left	  to	  stir	   for	   3	   days.	   After	   3	   days	   the	   solvent	   was	   removed	   in	   vacuo	   and	   the	   desired	  product	  was	  isolated	  using	  flash	  chromatography	  (petroleum	  ether	  –	  ethyl	  acetate	  90:10	  v/v	   increasing	  to	  70:30	  v/v)	  giving	  the	  desired	  oil	  product	  as	  mixture	  of	  2	  diastereoisomers.	  31P	  NMR	  (MeOD,	  202	  MHz):	  δ	  12.04,	  11.70.	  1H	  NMR	  (MeOD,	  500	  MHz):	  δ	  7.36	  (7H,	  m,	  ArH),	  7.20	  (3H,	  m,	  ArH),	  5.17	  (1H,	  s,	  OCH2Ph),	  5.16	  (1H,	  s,	  OCH2Ph),	  4.02	  (1H,	  q,	  







O C19H25N2O5P	  MW:	  392.1	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Synthesis	   of	   (2S)-­benzyl	   2-­((((3-­hydroxypropyl)	   amino)	   (phenoxy)	  
phosphoryl)	  amino)	  propanoate	  using	  NMI	  	  
	  	  1-­‐methylimidazole	  (0.39	  ml,	  4.9	  mmol,	  4.9	  eq)	  was	  added	  dropwise	  to	  a	  solution	  of	  3-­‐amino-­‐1-­‐propanol	   (0.075	  ml,	   1	  mmol,	   1	   eq)	   in	   anhydrous	   THF	   (10	  ml)	   under	  anhydrous	  conditions	  at	  0	  °C.	  The	  mixture	  was	  stirred	  at	  0	  °C	  for	  30	  min.	  After	  30	  min	  the	  phosphorochloridate	  (500	  mg,	  1.4	  mmol,	  1.4	  eq)	  in	  anhydrous	  THF	  (8	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  Following	   the	  addition,	   the	  reaction	   mixture	   was	   stirred	   at	   0	   °C	   for	   a	   further	   30	   min	   and	   then	   at	   room	  temperature	   for	  3	  days.	  After	  3	  days	   the	  solvent	  was	  removed	   in	  vacuo	   to	  give	  a	  residue	  that	  was	  redissolved	  in	  DCM	  and	  washed	  twice	  with	  0.5	  M	  HCl	  (2	  x	  5	  ml).	  The	   organic	   phase	   was	   purified	   by	   column	   chromatography	   (methanol	   –	  dichloromethane	   2:98	   v/v)	   giving	   the	   desired	   oil	   product	   as	   mixture	   of	   2	  diastereoisomers	  (62%,	  0.23	  g).	  	  31P	  NMR	  (CDCl3,	  202	  MHz):	  δ	  10.86,	  10.63.	  1H	  NMR	  (MeOD,	  500	  MHz):	  δ	  7.36	  (7H,	  m,	  ArH),	  7.20	  (3H,	  m,	  ArH),	  5.17	  (1H,	  s,	  OCH2Ph),	  5.16	  (1H,	  s,	  OCH2Ph),	  4.02	  (1H,	  q,	  







O C19H25N2O5P	  MW:	  392.1	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Synthesis	   of	   (2S)-­benzyl	   2-­((((3-­hydroxypropyl)	   amino)	   (phenoxy)	  
phosphoryl)	  amino)	  propanoate	  using	  NaOMe	  	  
	  	  Phosphorochloridate	  (500	  mg,	  1.41	  mmol)	  was	  added	  dropwise	  to	  a	  solution	  of	  3-­‐amino1-­‐propanol	  (0.11	  ml,	  1.41	  mmol)	  in	  anhydrous	  DCM	  (5	  ml)	  under	  anhydrous	  conditions.	  The	  temperature	  of	  the	  mixture	  was	  then	  lowered	  to	  -­‐78	  °C.	  After	  one	  hour	   NaOMe	   (25%	   in	   MeOH)	   (0.32	   ml,	   1.41	   mmol)	   was	   added.	   Following	   the	  addition,	   the	  reaction	  mixture	  was	  stirred	  at	   -­‐78	  °C	  for	  30	  min	  and	  then	  at	  room	  temperature	  for	  1	  h.	  After	  1	  h	  the	  solvent	  was	  removed	   in	  vacuo	  and	  the	  desired	  product	  was	   isolated	  using	   flash	  chromatography	   (methanol	  –	  ethyl	  acetate	  2:98	  v/v)	  giving	  the	  desired	  oil	  product	  as	  mixture	  of	  2	  diastereoisomers	  (56%,	  0.31	  g).	  	  31P	  NMR	  (MeOD,	  202	  MHz):	  δ	  12.04,	  11.70.	  1H	  NMR	  (MeOD,	  500	  MHz):	  δ	  7.36	  (7H,	  m,	  ArH),	  7.20	  (3H,	  m,	  ArH),	  5.17	  (1H,	  s,	  OCH2Ph),	  5.16	  (1H,	  s,	  OCH2Ph),	  4.02	  (1H,	  q,	  











O C19H25N2O5P	  MW:	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Synthesis	   of	   (2S)-­benzyl	   2-­(((3-­(((((S)-­1-­(benzyloxy)-­1-­oxopropan-­2-­yl)	  
amino)	   (phenoxy)	   phosphoryl)	   amino)	   propoxy)	   (phenoxy)	   phosphoryl)	  
amino)	  propanoate	  using	  tBuMgCl	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38.51	   (d,	   2JC-­‐P	   =	   4.9	   Hz,	   CH2NHP),	   38.43	   (d,	   2JC-­‐P	   =	   5.6	   Hz,	   CH2NHP),	   33.28	  (CH2CH2CH2),	   33.24	   (CH2CH2CH2),	   33.18	   (CH2CH2CH2),	   20.97	   (CHCH3),	   20.81	  (CHCH3),	  20.77	   (CHCH3),	  20.57	   (CHCH3),	  20.51	   (CHCH3).	  MS	  MS	   (ES+)	  m/z	  710.3	  (MH+).	  	  	  
Synthesis	   of	   (2S)-­methyl	   2-­(((2-­amino-­2-­methylpropoxy)	   (phenoxy)	  
phosphoryl)	  amino)	  propanoate	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9.5	  Syntheses	  of	  Fingolimod	  Derived	  Phosphoramidates	  
	  
Synthesis	  of	  Phenyl-­(methyloxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (1)	  
	  
	   	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (7	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(methyloxy-­‐L-­‐alaninyl)	  phosphorochloridate	  (403	  mg,	  1.45	  mmol)	  in	  anhydrous	  THF	  (2.6	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(benzyloxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (2)	  	  
	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (7	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(benzyloxy-­‐L-­‐alaninyl)	  phosphorochloridate	  (513	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (1.5	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(benzyloxy-­glycinyl)	  phosphoramidate	  fingolimod	  (3)	  	  
	   	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (7	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   phenyl-­‐(benzyloxy-­‐glycinyl)	   phosphorochloridate	   (493	   mg,	   1.45	   mmol)	   in	  anhydrous	  THF	  (2.75	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(benzyloxy-­L-­leucinyl)	  phosphoramidate	  fingolimod	  (4)	  	  
	   	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (5	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(benzyloxy-­‐L-­‐leucinyl)	  phosphorochloridate	   (574	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (3.2	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(benzyloxy-­L-­prolinyl)	  phosphoramidate	  fingolimod	  (5)	  	  
	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (5	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(benzyloxy-­‐L-­‐prolinyl)	  phosphorochloridate	  (551	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (4.5	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(ethoxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (6)	  
	  
	   	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (5	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   phenyl-­‐(ethoxy-­‐L-­‐alaninyl)	   phosphorochloridate	   (423	   mg,	   1.45	   mmol)	   in	  anhydrous	  THF	  (2.8	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	  








O C30H47N2O6P	  MW:	  562.3	  
Chapter	  9	  
	   	   	  
	  
Confidential	  
Synthesis	  of	  Naphthyl-­(ethoxy-­L-­alaninyl)	  phosphoramidate	  fingolimod	  (7)	  
	  
	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	   1.45	  mmol)	   in	   anhydrous	   THF	   (5	  ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   naphthyl-­‐(ethoxy-­‐L-­‐alaninyl)	   phosphorochloridate	   (496	  mg,	   1.45	   mmol)	   in	  anhydrous	  THF	  (2.2	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(methoxy-­glycinyl)	  phosphoramidate	  fingolimod	  (8)	  	  
	  	  tBuMgCl	   (1.76	   ml,	   1.76	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (607	  mg,	  1.76	  mmol)	   in	  anhydrous	  THF	  (10	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   phenyl-­‐(methoxy-­‐glycinyl)	   phosphorochloridate	   (516	   mg,	   1.76	   mmol)	   in	  anhydrous	  THF	  (7	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(ethoxy-­glycinyl)	  phosphoramidate	  fingolimod	  (9)	  
	  
	  	  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (20	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   phenyl-­‐(ethoxy-­‐glycinyl)	   phosphorochloridate	   (403	   mg,	   1.45	   mmol)	   in	  anhydrous	  THF	  (4	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	  
vacuo	  and	  the	  desired	  product	  was	  isolated	  using	  flash	  chromatography	  (methanol	  –	   dichloromethane	   0:100	   v/v	   increasing	   to	   10:90	   v/v)	   giving	   the	   desired	  colourless	  oil	  compound	  as	  a	  mixture	  of	  4	  diastereoisomers	  (39%,	  0.313	  g).	  	  31P	  NMR	  (CDCl3,	  202	  MHz):	  δ	  4.48.	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  8.37	  (2H,	  b,	  CNH2),	  7.17-­‐6.89	  (9H,	  m,	  ArH),	  5.29	  (1H,	  m,	  CHNH),	  4.48	  (0.5H,	  m,	  HOCH2C),	  4.34	  (0.5H,	  m,	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  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (20	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(pentoxy-­‐L-­‐phenylalanyl)	  phosphorochloridate	  (593	  mg,	  1.45	  mmol)	  in	  anhydrous	  THF	  (5	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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  tBuMgCl	   (1.45	   ml,	   1.45	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   fingolimod	  hydrochloride	   (500	  mg,	  1.45	  mmol)	   in	  anhydrous	  THF	  (20	  ml)	  under	  anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(methoxy-­‐L-­‐isoleucinyl)	  phosphorochloridate	  (464	  mg,	  1.45	  mmol)	  in	  anhydrous	  THF	  (4	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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9.6	   Chiral	   Phosphoramidate	   Fingolimod	   Synthesis	   and	  
Intermediates	  
	  
Synthesis	  of	  2-­amino-­2-­(hydroxymethyl)-­4-­(4-­octylphenyl)butyl	  acetate	  	  
	  
	  A	  mixture	  of	  fingolimod	  HCl	  (500	  ml,	  1.454	  mmol)	  and	  acetic	  anhydride	  (0.165	  ml,	  1.744	  mmol)	  in	  CHCl3	  (40	  ml)	  and	  saturated	  NaHCO3	  (25	  ml)	  was	  stirred	  at	  room	  temperature	  for	  3	  h.	  After	  3	  h	  the	  mixture	  was	  extracted	  with	  brine	  and	  CHCl3.	  The	  organic	   layer	  was	   dried	   over	  MgS04,	   vacuum	   filtered	   and	   the	   remaining	   solvent	  was	  removed	  in	  vacuo	  yielding	  a	  white	  residue	  (49%,	  0.24	  g).	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.03	  (4H,	  s,	  ArH),	  6.18	  (1H,	  s,	  OH),	  4.43	  (2H,	  b,	  NH2),	  3.71	   (2H,	   d,	   J	  =	   10.5	  Hz,	   HOCH2),	   3.51	   (2H,	   d,	   J	  =	   10.5	  Hz,	   HOCH2),	   2.55	   (2H,	  m,	  CH2CH2Ph),	  2.49	   (2H,	  m,	  CH2CH2Ph),	  1.86	   (3H,	   s,	  COCH3),	  1.85	   (2H,	  m,	  CCH2CH2),	  1.51	  (2H,	  quin,	  J	  =	  7.5	  Hz,	  CH2CH2CH2),	  1.25-­‐1.16	  (10H,	  m,	  CH2CH2CH2),	  0.81	  (3H,	  t,	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Synthesis	  of	  Freebase	  Fingolimod	  from	  Fingolimod	  HCl	  
	  
	  
	  KOH	  solution	  (226	  mg	  in	  25	  ml	  H2O)	  was	  added	  to	  fingolimod	  HCl	  (500	  mg,	  1.45	  mmol)	  in	  DCM	  (25	  ml).	  The	  mixture	  was	  thoroughly	  stirred	  for	  24	  h.	  After	  24	  h	  the	  mixture	   was	   extracted	   with	   additional	   water	   and	   DCM.	   The	   organic	   layer	   was	  collected	  and	  solvent	  removed	   in	  vacuo	  yielding	  freebase	  fingolimod	  (100%,	  0.46	  g).	  	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.03	  (4H,	  s,	  ArH),	  3.54	  (2H,	  d,	  J	  =	  11	  Hz,	  HOCH2),	  3.44	  (2H,	   d,	   J	   =	   11	   Hz,	   HOCH2),	   2.55	   (2H,	   m,	   CH2CH2Ph),	   2.49	   (2H,	   t,	   J	   =	   7.5	   Hz,	  CH2CH2Ph),	   1.87	   (2H,	   b,	   NH2),	   1.62	   (2H,	   m,	   CCH2CH2),	   1.51	   (2H,	   quin,	   J	   =	   8	   Hz,	  CH2CH2CH2),	  1.25-­‐1.16	  (10H,	  m,	  CH2CH2CH2),	  0.81	  (3H,	  t,	  J	  =	  7	  Hz,	  CH2CH3).	  	  
	  
Synthesis	  of	  benzyl	  (3-­(((benzyloxy)carbonyl)oxy)propyl)carbamate	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Synthesis	   of	   (R)-­2-­(((benzyloxy)carbonyl)	   amino)-­2-­(hydroxymethyl)-­4-­(4-­
octylphenyl)	  butyl	  acetate	  	  
	  
	  To	   benzyl	   (1-­‐hydroxy-­‐2-­‐(hydroxymethyl)-­‐4-­‐(4-­‐octylphenyl)butan-­‐2-­‐yl)carbamate	  (638	  mg,	  1.45	  mmol)	  in	  anhydrous	  THF	  (36	  ml)	  was	  added	  vinyl	  acetate	  (1.34	  ml,	  14.5	  mmol)	  and	  Immobilized	  Lipase	  (640	  mg)	  and	  then	  stirred	  at	  25	  °C	  for	  24	  h.	  After	  24	  h	  the	  mixture	  was	  vacuum	  filtered	  to	  remove	  the	  enzyme	  and	  the	  desired	  product	   was	   isolated	   by	   removing	   the	   solvent	   in	   vacuo	   giving	   the	   desired	   oil	  product	  (78%,	  0.561	  g).	  1H	   NMR	   (CDCl3,	   500	  MHz):	   δ	   7.25	   (5H,	  m,	   ArH),	   6.98	   (4H,	  m,	   ArH),	   5.14	   (1H,	   s,	  CNH),	  4.98	  (2H,	  s,	  PhCH2),	  4.24	  (1H,	  d,	  J	  =	  11.5	  Hz,	  CO2CH2C),	  4.10	  (1H,	  d,	  J	  =	  11.5	  Hz,	   CO2CH2C),	   3.65	   (2H,	   m,	   HOCH2C),	   3.61	   (1H,	   s,	   HOCH2C),	   2.46	   (2H,	   m,	  CH2CH2Ph),	  2.45	  (2H,	  m,	  CH2CH2Ph),	  2.02	  (2H,	  m,	  CCH2CH2),	  1.96	  (3H,	  s,	  CH3CO2),	  1.49	  (2H,	  quin,	  J	  =	  7.5	  Hz,	  CH2CH2CH2),	  1.21-­‐1.18	  (10H,	  m,	  CH2CH2CH2),	  0.80	  (3H,	  t,	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Synthesis	   of	   (2S)-­benzyl	   2-­((((S)-­2-­(acetoxymethyl)-­	   2-­(((benzyloxy)	  
carbonyl)	   amino)-­4-­(4-­octylphenyl)	   butoxy)	   (phenoxy)	   phosphoryl)	   amino)	  
propanoate	  
	  
	  	  tBuMgCl	   (1.13	   ml,	   1.13	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   (R)-­‐2-­‐(((benzyloxy)carbonyl)	   amino)-­‐2-­‐(hydroxymethyl)-­‐4-­‐(4-­‐octylphenyl)	   butyl	  acetate	   (544	   mg,	   1.13	   mmol)	   in	   anhydrous	   THF	   (10	   ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	  phenyl-­‐(benzyloxy-­‐L-­‐alaninyl)	  phosphorochloridate	  (399	  mg,	  1.13	  mmol)	   in	  anhydrous	  THF	  (6	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  benzyl	  vinyl	  carbonate	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Synthesis	  of	  (R)-­benzyl	  (1-­(((benzyloxy)carbonyl)oxy)-­2-­(hydroxymethyl)-­4-­
(4-­octylphenyl)	  butan-­2-­yl)	  carbamate	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Synthesis	   of	   methyl	   2-­((((S)-­2-­(((benzyloxy)	   carbonyl)	   amino)-­2-­
((((benzyloxy)	   carbonyl)	   oxy)	   methyl)-­4-­(4-­octylphenyl)	   butoxy)(phenoxy)	  
phosphoryl)	  amino)	  acetate	  
	  
	  
	  tBuMgCl	  (1.01	  ml,	  1.01	  mmol)	  was	  added	  dropwise	  to	  a	  solution	  of	  (R)-­‐benzyl	  (1-­‐(((benzyloxy)carbonyl)oxy)-­‐2-­‐(hydroxymethyl)-­‐4-­‐(4-­‐octylphenyl)	   butan-­‐2-­‐yl)	  carbamate	   (583	   mg,	   1.01	   mmol)	   in	   anhydrous	   THF	   (40	   ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   phenyl-­‐(methoxy-­‐glycinyl)	   phosphorochloridate	   (296	   mg,	   1.01	   mmol)	   in	  anhydrous	  THF	  (6	  ml)	  was	  added	  dropwise	   to	   the	  stirring	   reaction	  mixture.	  The	  reaction	  was	   left	   to	  stir	   for	  24	  hours.	  After	  24	  hours	   the	  solvent	  was	  removed	   in	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Synthesis	  of	  Phenyl-­(methoxy-­glycinyl)	  phosphoramidate	  fingolimod	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9.7	  Syntheses	  of	  BED	  Compounds	  	  
Synthesis	  of	  (4S)-­methyl	  2-­(tert-­butyl)oxazolidine-­4-­carboxylate	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Synthesis	  of	  (4S)-­dimethyl	  2-­(tert-­butyl)oxazolidine-­3,4-­dicarboxylate	  	  
	  
	  Triethylamine	   (13.35	  ml,	   95.78	  mmol)	  was	   added	   slowly	   to	   a	  mixture	   of	  methyl	  chloroformate	   (7.4	  ml,	  95.78	  mmol)	   and	   (4S)-­‐methyl	  2-­‐(tert-­‐butyl)oxazolidine-­‐4-­‐carboxylate	  (8.961	  g,	  47.89	  mmol)	  in	  toluene	  (200	  ml).	  The	  reaction	  mixture	  was	  attached	  to	  a	  Dean	  Stark	  trap	  and	  stirred	  at	  150	  °C	  for	  24	  h.	  After	  24	  h	  the	  mixture	  extracted	  with	  1M	  HCl	  and	  AcOEt	  and	  washed	  with	  brine.	  The	  organic	   layer	  was	  dried	  over	  MgSO4	  and	  vacuum	  filtered.	  The	  solvent	  was	  removed	   in	  vacuo	  giving	  the	  desired	  dark	  brown	  oil	  product	  (77%,	  9.025	  g).	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  5.01	  (1H,	  s,	  OCH),	  4.68	  (1H,	  m,	  CHCH2O),	  4.29	  (1H,	  m,	  CHCH2O),	  4.02	   (1H,	   t,	   J	  =	  8	  Hz,	  CH2CHCO),	  3.70	   (3H,	   s,	  OCH3),	  3.68	   (3H,	   s,	  OCH3),	  0.86	  (9H,	  s,	  CCH3).	  13C	  NMR	  (CDCl3,	  125	  MHz):	  δ	  170.67	  (C=O),	  156.65	  (C=O),	  97.89	  (NCHC),	   68.21	   (NCHCH2O),	   59.65	   (NCHCH2O),	   53.18	   (OCH3),	   52.50	   (OCH3),	   37.48	  (C(CH3)3),	  25.57	  (C(CH3)3).	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  Lithium	  bis(trimethylsilyl)	  amide	  solution	  (73.64	  ml,	  73.64	  mmol,	  1M	  in	  THF)	  was	  added	   to	   a	   mixture	   of	   (4S)-­‐dimethyl	   2-­‐(tert-­‐butyl)oxazolidine-­‐3,4-­‐dicarboxylate	  (9.025	   g,	   36.82	  mmol),	  methyl	   iodide	   (9.17	  ml,	   147.28	  mmol)	   and	   1,3-­‐dimethyl-­‐3,4,5,6-­‐tetrahydro-­‐2(1H)-­‐pyrimidinone	   (15	  ml)	   in	  a	  THF	  (30	  ml)	  and	  hexane	   (15	  ml)	  mixture	  stirring	  at	   -­‐74	  °C.	  After	  1	  h	   the	  reaction	  mixture	  was	  quenched	  with	  saturated	  ammonium	  chloride	   solution	  and	  extracted	  with	  AcOEt	   and	  brine.	  The	  organic	  layer	  was	  dried	  over	  MgSO4	  and	  vacuum	  filtered.	  The	  solvent	  was	  removed	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  (4S)-­‐dimethyl	   2-­‐(tert-­‐butyl)-­‐4-­‐methyloxazolidine-­‐3,4-­‐dicarboxylate	   (8.153	   g,	  31.46	   mmol)	   dissolved	   in	   35	   ml	   toluene	   was	   added	   to	   a	   mixture	   of	   potassium	  borohydride	  (3.394	  g,	  62.92	  mmol)	  and	  lithium	  chloride	  (2.667	  g,	  62.92	  mmol)	  in	  THF	  (100	  ml).	  The	  mixture	  was	  heated	  at	  45	  °C	  for	  24	  h.	  After	  24	  h	   the	  reaction	  mixture	   was	   slowly	   quenched	   with	   saturated	   ammonium	   chloride	   solution	   and	  extracted	   with	   AcOEt	   and	   water.	   The	   organic	   layer	   was	   dried	   over	   MgSO4	   and	  vacuum	  filtered.	  The	  solvent	  was	  removed	   in	  vacuo	  and	  the	  desired	  product	  was	  isolated	  using	  flash	  chromatography	  (hexane	  –	  ethyl	  acetate	  60:40	  v/v	  increasing	  to	  50:50	  v/v)	  giving	  the	  desired	  white	  solid	  product	  (80%,	  5.802	  g).	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  5.15	  (1H,	  s,	  OCH),	  4.54	  (1H,	  b,	  OH),	  3.90	  (1H,	  d,	  J	  =	  8	  Hz,	   CH2OH),	   3.84	   (1H,	   m,	   CCH2O),	   3.76	   (1H,	   d,	   J	   =	   8.5	   Hz,	   CH2OH),	   3.73	   (3H,	   s,	  OCH3),	  3.57	  (1H,	  m,	  CCH2O),	  1.44	  (3H,	  s,	  CCH3),	  0.95	  (9H,	  s,	  CCH3).	  13C	  NMR	  (CDCl3,	  125	   MHz):	   δ	   156.94	   (C=O),	   97.39	   (NCHC),	   75.85	   (CH2O),	   67.26	   (NCCH3),	   60.42	  (CH2OH),	  52.63	  (OCH3),	  38.70	  (C(CH3)3),	  26.52	  (C(CH3)3),	  19.56	  (NCCH3).	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Synthesis	  of	  (4R)-­methyl	  4-­(((4-­bromobenzyl)	  oxy)	  methyl)-­2-­(tert-­butyl)-­4-­
methyloxazolidine-­3-­carboxylate	  
	  
	  Sodium	  hydride	  (60%,	  0.752	  g,	  18.8	  mmol)	  was	  added	  to	  a	  solution	  of	  (4R)-­‐methyl	  2-­‐(tert-­‐butyl)-­‐4-­‐(hydroxymethyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	   (2.822	   g,	  12.21	  mmol)	  in	  DMF	  (30	  ml)	  at	  0	  °C.	  The	  reaction	  mixture	  was	  stirred	  for	  10	  min,	  at	   which	   time	   4-­‐bromobenzyl	   bromide	   (4.699	   g,	   18.8	   mmol)	   was	   added.	   The	  resultant	  mixture	  was	  warmed	   to	  ambient	   temperature	  and	   then	   stirred	   for	  2	  h.	  After	  2	  h	  the	  reaction	  mixture	  was	  quenched	  with	  saturated	  ammonium	  chloride	  solution	  and	  extracted	  with	  AcOEt	  and	  water	  and	  washed	  with	  brine.	  The	  organic	  layer	   was	   dried	   over	   MgSO4	   and	   vacuum	   filtered.	   The	   solvent	   was	   removed	   in	  
vacuo	  and	  the	  desired	  product	  was	  isolated	  using	  flash	  chromatography	  (hexane	  –	  ethyl	   acetate	   70:30	   v/v	   increasing	   to	   60:40	   v/v)	   giving	   the	   desired	   oil	   product	  (70%,	  3.415	  g).	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.28	  (2H,	  d,	  J	  =	  8.5	  Hz,	  ArH),	  7.03	  (2H,	  d,	  J	  =	  8	  Hz,	  ArH),	  5.01	  (1H,	  s,	  OCH),	  4.32	  (2H,	  m,	  PhCH2O),	  4.04	  (1H,	  d,	  J	  =	  9	  Hz,	  CCH2O),	  3.73	  (1H,	  d,	  J	  =	  9	  Hz,	  CCH2O),	  3.60	  (1H,	  d,	  J	  =	  8.5	  Hz,	  CCH2O),	  3.55	  (1H,	  d,	  J	  =	  8.5	  Hz,	  CCH2O),	  3.51	  (3H,	  s,	  OCH3),	  1.28	  (3H,	  s,	  CCH3),	  0.80	  (9H,	  s,	  CCH3).	  13C	  NMR	  (CDCl3,	  125	  MHz):	  δ	  137.28	  (C=O),	  131.29	  (CH-­‐Ar),	  129.01	  (CH-­‐Ar),	  129.01	  (C-­‐Ar),	  97.03	  (OCHC(CH3)3),	  	  76.78	   (OCH2C),	   74.57	   (OCH2C),	   72.46	   (OCH2Ph),	   63.18	   (NCCH3),	   51.76	   (OCH3),	  38.43	   (C(CH3)3),	  26.48	   (C(CH3)3),	  20.43	   (NCCH3).	  MS	   (ES+)	  m/z	  400.1	   (MH+)	  and	  422.1	  (MNa+).	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Synthesis	  of	  N-­methoxy-­N-­methyl-­4-­(p-­tolyl)	  butanamide	  	  	  
	  	  To	   a	   solution	   of	   4-­‐(p-­‐tolyl)butanoic	   acid	   (5	   g,	   28	  mmol)	   in	   DCM	   (130	  ml)	  were	  added	   N,O-­‐dimethylhydroxylamine	   hydrochloride	   (3.3	   g,	   34	   mmol)	   and	   1-­‐(3-­‐dimethylaminopropyl)-­‐3-­‐ethyl-­‐carbodiimide	  hydrochloride	   (6.5	  g,	  34	  mmol).	  The	  solution	  was	  stirred	  for	  10	  min	  at	  ambient	  temperature.	  The	  mixture	  was	  cooled	  to	  0	   °C	   and	   N-­‐methylmorpholine	   (9.3	   ml,	   84	   mmol)	   was	   added	   dropwise	   to	   the	  solution.	  The	  reaction	  mixture	  was	  warmed	  to	  room	  temperature	  and	  stirred	   for	  24	  h.	  After	  quenching	  with	  1M	  HCl	   (100	  ml)	   the	  resulting	  mixture	  was	  extracted	  with	   DCM	   and	  water	   and	  washed	  with	   brine.	   The	   organic	   layer	   was	   dried	   over	  MgSO4	   and	   vacuum	   filtered.	   The	   solvent	  was	   removed	   in	   vacuo	   and	   the	   desired	  product	  was	   isolated	   using	   flash	   chromatography	   (hexane	   –	   ethyl	   acetate	   50:50	  v/v	  increasing	  to	  40:60	  v/v)	  giving	  the	  desired	  colourless	  oil	  product	  (82%,	  5.084	  g).	  1H	   NMR	   (CDCl3,	   500	  MHz):	   δ	   7.13	   (4H,	   s,	   ArH),	   3.66	   (3H,	   s,	   OCH3),	   3.21	   (3H,	   s,	  NCH3),	  2.68	  (2H,	  t,	  J	  =	  7.5	  Hz,	  PhCH2CH2),	  2.48	  (2H,	  t,	  J	  =	  7	  Hz,	  COCH2),	  2.35	  (3H,	  s,	  PhCH3),	   2.00	   (2H,	   quin,	   J	   =	   7.5	   Hz,	   CH2CH2CH2).	   13C	   NMR	   (CDCl3,	   125	   MHz):	   δ	  175.80	   (C=O),	   138.70	   (C-­‐Ar),	   135.31	   (C-­‐Ar),	   129.22	   (CH-­‐Ar),	   129.05	   (CH-­‐Ar),	  128.72	   (CH-­‐Ar),	   129.61	   (CH-­‐Ar),	   61.16	   (CH3ON),	   34.90	   (PhCH2),	   32.19	   (CH3N),	  31.21	  (CH2CH2CH2),	  27.20	  (COCH2),	  21.33	  (PhCH3).	  	  	   	  	  	  	  	  	  	  
C13H19NO2	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Synthesis	   of	   (4R)-­methyl	   2-­(tert-­butyl)-­4-­methyl-­4-­(((4-­(4-­(p-­tolyl)	  
butanoyl)	  benzyl)	  oxy)	  methyl)	  oxazolidine-­3-­carboxylate	  
	  
	  To	   a	   solution	   of	   (4R)-­‐methyl	   4-­‐(((4-­‐bromobenzyl)oxy)methyl)-­‐2-­‐(tert-­‐butyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	  (7.618	  g,	  19.09	  mmol)	  in	  THF	  (60	  ml)	  was	  slowly	  added	   n-­‐BuLi	   (1.6	  M	   n-­‐hexane	   solution,	   18.01	  ml,	   28.64	  mmol)	   at	   -­‐78	   °C	   under	  argon.	  The	  mixture	  was	  stirred	  for	  30	  min	  at	  the	  same	  temperature.	  A	  solution	  of	  
N-­‐methoxy-­‐N-­‐methyl-­‐4-­‐(p-­‐tolyl)butanamide	  (8.443	  g,	  38.18	  mmol)	  in	  THF	  (10	  ml)	  was	   added	   to	   the	   solution	   and	   the	   reaction	   mixture	   was	   gradually	   warmed	   to	  ambient	   temperature	   and	   then	   stirred	   for	   2	   h.	   After	   quenching	   with	   saturated	  ammonium	   chloride	   solution	   the	   resulting	   mixture	   was	   poured	   into	   water	   and	  extracted	   with	   AcOEt.	   The	   combined	   organic	   layer	   was	   washed	   with	   water	   and	  brine,	  dried	  over	  MgSO4	  and	  vacuum	   filtered.	  The	  solvent	  was	   removed	   in	   vacuo	  and	  the	  desired	  product	  was	  isolated	  using	  flash	  chromatography	  (hexane	  –	  ethyl	  acetate	  100:0	   v/v	   increasing	   to	  50:50	   v/v)	   giving	   the	  desired	  brown	  oil	   product	  (38%,	  3.518	  g).	  	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.78	  (2H,	  d,	   J	  =	  8.5	  Hz,	  ArH),	  7.25	  (2H,	  d,	   J	  =	  8.5	  Hz,	  ArH),	  6.97	  (4H,	  s,	  ArH),	  5.02	  (1H,	  s,	  OCH),	  4.45	  (2H,	  m,	  PhCH2O),	  4.07	  (1H,	  d,	  J	  =	  9	  Hz,	  CCH2O),	  3.76	  (1H,	  d,	  J	  =	  8	  Hz,	  CCH2O),	  3.64	  (1H,	  d,	  J	  =	  8.5	  Hz,	  CCH2O),	  3.57	  (1H,	  d,	  J	  =	  8.5	  Hz,	  CCH2O),	  3.54	  (3H,	  s,	  OCH3),	  2.83	  (2H,	  t,	  J	  =	  7	  Hz,	  COCH2),	  2.56	  (2H,	  t,	  J	  =	  7.5	  Hz,	  PhCH2CH2),	  2.19	  (3H,	  s,	  PhCH3),	  1.93	  (2H,	  quin,	  J	  =	  7.5	  Hz,	  CH2CH2CH2),	  1.31	  (3H,	   s,	   CCH3),	   0.80	   (9H,	   s,	   CCH3).	   13C	   NMR	   (CDCl3,	   125	   MHz):	   δ	   199.81	   (C=O),	  143.51	  (C=O,	  ester),	  138.57	  (C-­‐Ar),	  136.35	  (C-­‐Ar),	  135.40	  (C-­‐Ar),	  129.09	  (CH-­‐Ar),	  128.72	  (CH-­‐Ar),	  128.40	  (CH-­‐Ar),	  128.35	  (CH-­‐Ar),	  128.29	  (CH-­‐Ar),	  128.29	  (CH-­‐Ar),	  128.19	   (CH-­‐Ar),	   127.54	   (CH-­‐Ar),	   127.23	   (CH-­‐Ar),	   97.27	   (OCHC(CH3)3),	   75.34	  (OCH2C),	   73.17	   (OCH2C),	   63.35	   (PhCH2O),	   52.04	   (OCH3,	   ester),	   48.59	   (COCH2),	  37.75	   (C(CH3)3),	   34.76	   (PhCH2),	   29.37	   (C(CH3)3),	   26.37	   (CH2CH2CH2),	   21.01	  (PhCH3),	  14.13	  (NCCH3).	  MS	  (ES+)	  m/z	  482.3	  (MH+)	  and	  520.3	  (MNa+).	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Synthesis	   of	   (S)-­methyl	   (1-­hydroxy-­2-­methyl-­3-­((4-­(4-­(p-­tolyl)	   butanoyl)	  
benzyl)	  oxy)	  propan-­2-­yl)	  carbamate	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Synthesis	  of	  1-­bromo-­4-­(bromomethyl)-­2,5-­dimethylbenzene	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Synthesis	  of	  1-­(bromomethyl)-­4-­iodo-­2,5-­dimethylbenzene	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  Sodium	   hydride	   (60%,	   1.793	   g,	   44.83	   mmol)	   was	   added	   to	   a	   solution	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)-­‐4-­‐(hydroxymethyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	  (8.298	  g,	  35.9	  mmol)	  in	  DMF	  (50	  ml)	  at	  0	  °C.	  The	  reaction	  mixture	  was	  stirred	  for	  25	   min,	   at	   which	   time	   1-­‐(bromomethyl)-­‐4-­‐iodo-­‐2,5-­‐dimethylbenzene	   (14.522	   g,	  44.83	  mmol)	  in	  DMF	  (40	  ml)	  was	  added.	  The	  resultant	  mixture	  was	  stirred	  at	  0	  °C	  for	   20	   min	   and	   then	   warmed	   to	   ambient	   temperature	   for	   24	   h.	   After	   24	   h	   the	  reaction	   mixture	   was	   quenched	   slowly	   with	   saturated	   ammonium	   chloride	  solution	  and	  extracted	  with	  AcOEt	  and	  water	  and	  washed	  with	  brine.	  The	  organic	  layer	   was	   dried	   over	   MgSO4	   and	   vacuum	   filtered.	   The	   solvent	   was	   removed	   in	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Synthesis	   of	   (4R)-­methyl	   2-­(tert-­butyl)	   -­4-­(((2,5-­dimethyl-­4-­(4-­(p-­tolyl)	  
butanoyl)	  benzyl)	  oxy)	  methyl)-­4-­methyloxazolidine-­3-­carboxylate	  
	  
	  
	  To	   a	   solution	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)-­‐4-­‐(((4-­‐iodo-­‐2,5-­‐dimethylbenzyl)oxy)methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	   (13.172	   g,	   27.72	  mmol)	  in	  THF	  (30	  ml)	  was	  slowly	  added	  iPrMgCl	  (27.72	  ml,	  55.44	  mmol)	  at	  -­‐78	  °C	  under	   argon.	   The	   mixture	   was	   stirred	   for	   30	   min	   at	   the	   same	   temperature.	   A	  solution	   of	  N-­‐methoxy-­‐N-­‐methyl-­‐4-­‐(p-­‐tolyl)butanamide	   (12.26	   g,	   55.44	  mmol)	   in	  THF	  (30	  ml)	  was	  added	  to	  the	  solution	  and	  the	  reaction	  mixture	  was	  stirred	  at	  	  -­‐78	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34.75	  (PhCH2),	  26.53	  (C(CH3)3),	  25.99	  (CH2CH2CH2),	  21.01	  (PhCH3),	  20.82	  (PhCH3),	  18.31	  (NCCH3).	  	  	  




	  To	   a	   solution	   of	   (4R)-­‐methyl	   2-­‐(tert-­‐butyl)	   -­‐4-­‐(((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)	  butanoyl)	  benzyl)	  oxy)	  methyl)-­‐4-­‐methyloxazolidine-­‐3-­‐carboxylate	   (5.855	  g,	   11.5	  mmol)	  in	  MeOH	  (200	  ml)	  was	  added	  p-­‐toluenesulfonic	  acid	  monohydrate	  (4.375	  g,	  23	  mmol).	  The	  mixture	  was	  stirred	  for	  24	  h	  at	  50	  °C.	  The	  solvent	  was	  removed	  in	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  To	   a	   solution	   of	   (S)-­‐methyl	   (1-­‐((2,5-­‐dimethyl-­‐4-­‐(4-­‐(p-­‐tolyl)butanoyl)benzyl)oxy)-­‐3-­‐hydroxy-­‐2-­‐methylpropan-­‐2-­‐yl)carbamate	  (4.32	  g,	  9.79	  mmol)	   in	  EtOH	  (200	  ml)	  was	  added	  KOH	  solution	  (8	  M,	  61.19	  ml,	  489.5	  mmol).	  Mixture	  heated	  under	  reflux	  at	  90	  °C	  for	  24	  h.	  The	  solvent	  was	  removed	  in	  vacuo	  and	  the	  resulting	  mixture	  was	  extracted	  with	  brine	  and	  DCM,	  dried	  over	  MgSO4	  and	  vacuum	  filtered.	  The	  solvent	  was	   removed	   in	   vacuo	   and	   the	   desired	   product	   was	   isolated	   using	   flash	  chromatography	  (methanol	  –	  dichloromethane	  0:100	  v/v	  increasing	  to	  10:90	  v/v)	  giving	  the	  desired	  brown	  oil	  product	  (56%,	  2.09	  g).	  	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.24	   (H,	   s,	  ArH),	  7.10	   (H,	   s,	  ArH),	  7.01	   (4H,	   s,	  ArH),	  4.43	  (2H,	  s,	  PhCH2O),	  3.87	  (2H,	  b,	  NH2),	  3.54	  (1H,	  d,	  J	  =	  11	  Hz,	  CCH2OH),	  3.43	  (1H,	  d,	  







NH2 C24H33NO3	  MW:	  383.25	  
Chapter	  9	  
	   	   	  
	  
Confidential	  
9.8	  Syntheses	  of	  BED	  Compound	  Derived	  Phosphoramidates	  
	  
Synthesis	   of	   (2S)-­methyl	   2-­((((R)-­2-­amino-­2-­methyl-­3-­((4-­(4-­(p-­tolyl)	  
butanoyl)	  benzyl)	  oxy)	  propoxy)	  (phenoxy)	  phosphoryl)	  amino)	  propanoate	  
(12)	  	  
	  	  tBuMgCl	   (0.72	  ml,	  0.72	  mmol)	  was	  added	  dropwise	   to	  a	   solution	  of	   (S)-­‐1-­‐(4-­‐((2-­‐amino-­‐3-­‐hydroxy-­‐2-­‐methylpropoxy)methyl)phenyl)-­‐4-­‐(p-­‐tolyl)butan-­‐1-­‐one	   	   (254	  mg,	   0.72	   mmol)	   in	   anhydrous	   THF	   (20	   ml)	   under	   anhydrous	   conditions.	   The	  mixture	   was	   stirred	   at	   room	   temperature	   for	   one	   hour.	   After	   one	   hour	   the	  phosphorochloridate	   (199	  mg,	   0.72	  mmol)	   in	   anhydrous	   THF	   (3	  ml)	  was	   added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	  left	  to	  stir	  for	  24	  hours.	  After	   24	   hours	   the	   solvent	   was	   removed	   in	   vacuo	   and	   the	   desired	   product	   was	  isolated	   using	   flash	   chromatography	   (methanol	   –	   ethyl	   acetate	   0:100	   v/v	  increasing	   to	   10:90	   v/v)	   giving	   the	   desired	   oil	   product	   as	   a	   mixture	   of	   2	  diastereoisomers	   (44%,	   0.188	   g).	   The	   resulting	   oil	   was	   further	   purified	   using	  preparative	  reverse-­‐phase	  HPLC	  (0.1%	  TFA	  in	  H2O	  –	  ACN	  20:80	  v/v	  increasing	  to	  100:0	  v/v	  in	  35	  min)	  giving	  the	  desired	  product	  (6%,	  0.026	  g).	  	  31P	  NMR	  (MeOD,	  202	  MHz):	  δ	  3.74,	  3.37,	  3.30.	   1H	  NMR	  (MeOD,	  500	  MHz):	  δ	  7.84	  (2H,	  m,	  ArH),	  7.41	  (2H,	  m,	  ArH),	  7.27	  (2H,	  t,	  J	  =	  8.5	  Hz,	  ArH),	  7.12	  (3H,	  m,	  ArH),	  6.97	  (4H,	  s,	  ArH),	  4.57	  (2H,	  m,	  PhCH2O),	  4.09	  (2H,	  m,	  CH2OP),	  3.88	  (1H,	  m,	  CH3CH),	  3.56	  (3H,	  m,	  OCH3),	  3.46	   (2H,	  m,	  CCH2O),	  2.90	   (2H,	  m,	  COCH2),	  2.55	   (2H,	   t,	   J	  =	  7.5	  Hz,	  PhCH2),	   2.19	   (3H,	   s,	   PhCH3),	   1.88	   (2H,	   quin,	   J	  =	   7	   Hz,	   CH2CH2CH2),	   1.24	   (3H,	  m,	  CHCH3),	   1.21	   (3H,	  m,	  CCH3).	   13C	  NMR	  (MeOD,	  125	  MHz):	  δ	   200.62	   (C=O),	  175.04	  (C=O),	  142.74	  (2d,	   2JC-­‐P	  =	  3.3	  Hz,	  POC-­‐Ar),	  138.57	  (C-­‐Ar),	  136.51	  (C-­‐Ar),	  136.0	  (C-­‐Ar),	  129.52	  (CH-­‐Ar),	  128.64	  (CH-­‐Ar),	  128.02	  (CH-­‐Ar),	  127.59	  (CH-­‐Ar),	  127.57	  (CH-­‐
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Ar),	  125.08	  (CH-­‐Ar),	  120.03	  (2d,	  3JC-­‐P	  =	  4.9	  Hz,	  CH-­‐Ar),	  72.55	  (OCH2C),	  70.81	  (d,	  2JC-­‐P	  =	   3.6	   Hz,	   CH2OP),	   70.66	   (PhCH2O),	   51.50	   (OCH3),	   50.11	   (CHCH3),	   41.71	   (NH2C),	  37.31	   (COCH2),	   34.30	   (PhCH2),	   25.94	   (CH2CH2CH2),	   19.69	   (PhCH3),	   19.04	   (m,	  
CH3C),	  17.14	  (CHCH3).	  MS	  (ES+)	  m/z	  597.3	  (MH+).	  Reverse-­‐phase	  analytical	  HPLC	  (0.1%	  TFA	  in	  H2O	  –	  ACN	  20:80	  v/v	  increasing	  to	  0:100	  v/v	  in	  35	  min),	  1	  ml/min,	  λ	  =	  263	  nm	  showed	  a	  peak	  with	  a	  tR	  =	  14.84	  min	  (99.1%).	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Synthesis	   of	   (2S)-­benzyl	   2-­((((R)-­2-­amino-­2-­methyl-­3-­((4-­(4-­(p-­tolyl)	  
butanoyl)	  benzyl)	  oxy)	  propoxy)	  (phenoxy)	  phosphoryl)	  amino)	  propanoate	  
(13)	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CH2OP),	   71.40	   (PhCH2O),	   67.18	   (PhCH2O),	   60.43	   (NH2C),	   50.33	   (CHCH3),	   37.76	  (COCH2),	   34.79	   (PhCH2),	   25.85	   (CH2CH2CH2),	   21.05	   (PhCH3),	   20.85	   (CH3C),	   14.26	  (CHCH3).	  MS	   (ES+)	  m/z	  673.3	   (MH+)	  and	  695.3	   (MNa+).	  Reverse-­‐phase	  analytical	  HPLC	   (0.1%	  TFA	   in	  H2O	   –	  ACN	  20:80	   v/v	   increasing	   to	   0:100	   v/v	   in	   35	  min),	   1	  ml/min,	  λ	  =	  263	  nm	  showed	  a	  peak	  with	  a	  tR	  =	  17.67	  min	  (99.2%).	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Synthesis	   of	   (2S)-­isopropyl	   2-­((((R)-­2-­amino-­2-­methyl-­3-­((4-­(4-­(p-­tolyl)	  
butanoyl)	  benzyl)	  oxy)	  propoxy)(phenoxy)	  phosphoryl)	  amino)	  propanoate	  
(14)	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(PhCH2O),	   70.61	   (d,	   2JC-­‐P	   =	   1.63	   Hz,	   CH2OP),	   68.98	   (OCH(CH3)2),	   56.21	   (NH2C),	  50.54	   (CHCH3),	   37.31	   (COCH2),	   34.30	   (PhCH2),	   25.94	   (CH2CH2CH2),	   20.60	  (OCHCH3),	   20.52	   (OCHCH3),	   19.72	   (PhCH3),	   19.14	   (m,	   CH3C),	   17.11	   (CHCH3).	  MS	  (ES+)	  m/z	  625.3	   (MH+)	   and	  647.3	   (MNa+).	   Reverse-­‐phase	   analytical	  HPLC	   (0.1%	  TFA	  in	  H2O	  –	  ACN	  20:80	  v/v	  increasing	  to	  0:100	  v/v	  in	  35	  min),	  1	  ml/min,	  λ	  =	  263	  nm	  showed	  a	  peak	  with	  a	  tR	  =	  17.30	  min	  (95.5%).	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Synthesis	   of	   (2S)-­methyl	   2-­((((R)-­2-­amino-­3-­((2,5-­dimethyl-­4-­(4-­(p-­tolyl)	  
butanoyl)	   benzyl)	   oxy)-­2-­methylpropoxy)	   (phenoxy)	   phosphoryl)	   amino)	  
propanoate	  (15)	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70.72	  (d,	  2JC-­‐P	  =	  2.6	  Hz,	  CH2OP),	  70.57	  (PhCH2O),	  56.18	  (NH2C),	  51.50	  (OCH3),	  50.34	  (CHCH3),	  40.31	  (COCH2),	  34.25	  (PhCH2),	  26.00	  (CH2CH2CH2),	  19.73	  (PhCH3),	  19.44	  (PhCH3),	  19.06	  (PhCH3),	  18.87	  (CH3C),	  17.12	  (CHCH3).	  MS	  (ES+)	  m/z	  625.3	  (MH+)	  and	  647.3	  (MNa+).	  Reverse-­‐phase	  analytical	  HPLC	  (0.1%	  TFA	  in	  H2O	  –	  ACN	  20:80	  v/v	  increasing	  to	  0:100	  v/v	  in	  35	  min),	  1	  ml/min,	  λ	  =	  245	  nm	  showed	  a	  peak	  with	  a	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Synthesis	   of	   (2S)-­benzyl	   2-­((((R)-­2-­amino-­3-­((2,5-­dimethyl-­4-­(4-­(p-­tolyl)	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Ar),	  129.94	  (CH-­‐Ar),	  129.86	  (CH-­‐Ar),	  129.84	  (CH-­‐Ar),	  127.08	  (CH-­‐Ar),	  127.03	  (CH-­‐Ar),	  122.11	  (2d,	  3JC-­‐P	  =	  4.63	  Hz,	  CH-­‐Ar),	  73.17	  (OCH2C),	  72.70	  (PhCH2O),	  69.50	  (d,	  2JC-­‐P	   =	   5.38	   Hz,	   CH2OP),	   68.68	   (PhCH2O),	   58.23	   (NH2C),	   50.50	   (CHCH3),	   42.29	  (COCH2),	  36.24	  (PhCH2),	  27.98	  (CH2CH2CH2),	  21.73	  (PhCH3),	  21.45	  (PhCH3),	  21.05	  (PhCH3),	   20.85	   (CH3C),	   19.13	   (CHCH3).	   MS	   (ES+)	   m/z	   701.5	   (MH+)	   and	   723.4	  (MNa+).	   Reverse-­‐phase	   analytical	   HPLC	   (0.1%	   TFA	   in	   H2O	   –	   ACN	   20:80	   v/v	  increasing	  to	  0:100	  v/v	  in	  35	  min),	  1	  ml/min,	  λ	  =	  245	  nm	  showed	  a	  peak	  with	  a	  tR	  =	  19.88	  min	  (97.3%).	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Synthesis	   of	   (2S)-­isopropyl	   2-­((((R)-­2-­amino-­3-­((2,5-­dimethyl-­4-­(4-­(p-­tolyl)	  




	  tBuMgCl	   (1.3	   ml,	   1.3	   mmol)	   was	   added	   dropwise	   to	   a	   solution	   of	   (S)-­‐1-­‐(4-­‐((2-­‐amino-­‐3-­‐hydroxy-­‐2-­‐methylpropoxy)	   methyl)	   -­‐2,5-­‐dimethylphenyl)-­‐4-­‐(p-­‐tolyl)	  butan-­‐1-­‐one	   (499	   mg,	   1.3	   mmol)	   in	   anhydrous	   THF	   (25	   ml)	   under	   anhydrous	  conditions.	  The	  mixture	  was	  stirred	  at	  room	  temperature	  for	  one	  hour.	  After	  one	  hour	   the	  phosphorochloridate	  (397	  mg,	  1.3	  mmol)	   in	  anhydrous	  THF	  (6	  ml)	  was	  added	  dropwise	  to	  the	  stirring	  reaction	  mixture.	  The	  reaction	  was	  left	  to	  stir	  for	  24	  hours.	  After	  24	  hours	  the	  solvent	  was	  removed	   in	  vacuo	  and	  the	  desired	  product	  was	  isolated	  using	  flash	  chromatography	  (methanol	  –	  dichloromethane	  0:100	  v/v	  increasing	   to	   10:90	   v/v)	   giving	   the	   desired	   oil	   product	   as	   a	   mixture	   of	   2	  diastereoisomers	   (15%,	   0.129	   g).	   The	   resulting	   oil	   was	   further	   purified	   using	  preparative	  reverse-­‐phase	  HPLC	  (0.1%	  TFA	  in	  H2O	  –	  ACN	  20:80	  v/v	  increasing	  to	  100:0	  v/v	  in	  35	  min)	  giving	  the	  desired	  product	  (8%,	  0.065	  g).	  31P	  NMR	  (MeOD,	  202	  MHz):	  δ	  3.78,	  3.51,	  3.43.	   1H	  NMR	  (MeOD,	  500	  MHz):	  δ	  7.31	  (1H,	  d,	   J	  =	  3.5	  Hz,	  ArH),	  7.26	  (2H,	  m,	  ArH),	  7.15	  (1H,	  m,	  ArH),	  7.12	  (3H,	  m,	  ArH),	  6.96	   (4H,	   s,	   ArH),	   4.85	   (1H,	   m,	   CH(CH3)2),	   	   4.51	   (2H,	   m,	   PhCH2O),	   4.13	   (2H,	   m,	  CH2OP),	  3.80	  (1H,	  m,	  CHCH3),	  3.51	  (1H,	  m,	  CCH2O),	  3.47	  (1H,	  m,	  CCH2O),	  2.78	  (2H,	  t,	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9.9	  SATE	  Phosphorus	  Prodrugs	  
	  
Synthesis	  of	  2,2-­Dimethyl-­thiopropionic	  acid	  S-­(2-­hydroxy-­ethyl)	  ester	  
	  
	   	  	  Pivaloyl	   chloride	   (2.5	   ml,	   20.3	   mmol)	   was	   added	   to	   a	   stirred	   solution	   of	   2-­‐mercaptoethanol	  (1.42	  ml,	  20.3	  mmol)	  and	  triethylamine	  (2.83	  ml,	  20.3	  mmol)	  in	  DCM,	   cooled	   at	   -­‐78	   °C.	   The	  mixture	  was	   stirred	   at	   -­‐78	   °C	   for	   1	   h.	   After	   1	   h	   the	  mixture	  was	   extracted	  with	  water	   and	   DCM	   (3	   x	   20	  ml).	   The	   combined	   organic	  extracts	  were	  dried	  over	  MgSO4	  and	  concentrated	   in	  vacuo.	  The	  oily	  residue	  was	  purified	   by	   flash	   column	   chromatography	   (eluting	   with	   hexane	   -­‐	   ethyl	   acetate	  80:20	  v/v	  increasing	  to	  70:30	  v/v)	  giving	  the	  desired	  compound	  (75%,	  2.481	  g).	  	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  3.98	  (2H,	  m,	  HOCH2),	  3.03	  (2H,	  m,	  SCH2),	  2.85	  (1H,	  b,	  OH),	  1.23	  (9H,	  s,	  CCH3).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
S
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Synthesis	   of	   2,2-­Dimethyl-­thiopropionic	   acid	   S-­(chloro-­phenoxy-­
phosphoryloxy)-­ethyl	  ester	  	  
	  	  Phenyl	  dichlorophosphate	  (2.29ml,	  15.31	  mmol)	  was	  added	  dropwise	  into	  a	  cooled	  solution	   at	   -­‐78	   °C	   of	   2,2-­‐Dimethyl-­‐thiopropionic	   acid	   S-­‐(2-­‐hydroxy-­‐ethyl)	   ester	  (2.481	  g,	   15.31	  mmol)	   and	   triethylamine	   (2.13	  ml,	   15.31	  mmol)	   in	  THF	   (20	  ml).	  The	   reaction	   was	   left	   to	   warm	   to	   room	   temperature	   and	   stirred	   overnight.	   The	  white	  precipitate	  was	  filtered	  off	  and	  the	  solution	  was	  concentrated	  in	  vacuo.	  The	  crude	  oil	  was	  used	  for	  the	  next	  step	  without	  further	  purification.	  	  31P	  NMR	  (CDCl3,	  202	  MHz):	  δ	  -­‐0.69.	  1H	  NMR	  (CDCl3,	  500	  MHz):	  δ	  7.31	  (2H,	  m,	  ArH),	  7.18	   (3H,	  m,	  ArH),	  4.28	   (2H,	  m,	  OCH2),	  3.15	   (2H,	   t,	   J	  =	  6.5	  Hz,	  SCH2),	  1.17	   (9H,	   s,	  CCH3).	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Synthesis	   of	   S-­(2-­(((2-­amino-­2-­(hydroxymethyl)-­4-­(4-­octylphenyl)	   butoxy)	  
(phenoxy)	  phosphoryl)oxy)	  ethyl)	  2,2-­dimethylpropanethioate	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Synthesis	   of	   S-­(2-­((((R)-­2-­amino-­2-­methyl-­3-­((4-­(4-­(p-­tolyl)	   butanoyl)	  
benzyl)	   oxy)	   propoxy)	   (phenoxy)phosphoryl)	   oxy)	   ethyl)	   2,2-­
dimethylpropanethioate	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9.10	  HepDirect	  Phosphorus	  Prodrugs	  
	  
Synthesis	  of	  ethyl	  3-­(3-­chlorophenyl)-­3-­hydroxypropanoate	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Synthesis	  of	  1-­(3-­chlorophenyl)	  propane-­1,3-­diol	  
	  
	  	  Crude	   ethyl	   3-­‐(3-­‐chlorophenyl)-­‐3-­‐hydroxypropanoate	   (<	   17.8	   mmol)	   was	  dissolved	  in	  diethyl	  ether	  (40	  ml)	  and	  cooled	  to	  0	  °C.	  A	  solution	  of	  LiAlH4	  (1M	  in	  THF,	   52.5	  ml,	   52.5	  mmol)	  was	   added	   slowly	   and	   the	  mixture	  was	   left	   to	   slowly	  warm	   to	   ambient	   temperature	  overnight.	   The	  mixture	  was	   cooled	   in	   an	   ice	  bath	  and	  the	  reaction	  was	  quenched	  slowly	  with	  AcOEt	  and	  treated	  with	  0.5	  M	  HCl.	  The	  mixture	   was	   stirred	   vigorously	   and	   then	   extracted	   with	   AcOEt.	   The	   combined	  organic	   extracts	   were	   dried	   over	   MgSO4	   and	   concentrated	   in	   vacuo.	   The	   crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (eluting	  with	  hexane	  -­‐	  ethyl	  acetate	   75:25	   v/v	   increasing	   to	   50:50	   v/v)	   giving	   the	   desired	   compound	   (15%,	  0.503	  g).	  	  1H	   NMR	   (CDCl3,	   500	  MHz):	   δ	   7.39	   (1H,	   s,	   ArH),	   7.27	   (3H,	  m,	   ArH),	   4.95	   (1H,	  m,	  CHOH),	  3.87	  (2H,	  m,	  CH2OH),	  3.44	  (1H,	  b,	  CHOH),	  2.63	  (1H,	  b,	  CH2OH),	  1.95	  (2H,	  m,	  CHCH2CH2).	  	  	  	  	  	  	  	  	  	  	  	  	  
OH OH
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Synthesis	  of	  4-­(3-­chlorophenyl)-­2-­(4-­nitrophenoxy)-­1,3,2-­dioxaphosphinane	  
2-­oxide	  
	  
	  	  To	   a	   solution	   of	   4-­‐nitrophenyl	   phosphorodichloridate	   (760	   mg,	   2.97	   mmol),	  triethylamine	   (1.5	  ml,	  10.8	  mmol)	   in	  THF	   (12	  ml)	  was	  added	  1-­‐(3-­‐chlorophenyl)	  propane-­‐1,3-­‐diol	  	  (503	  mg,	  2.7	  mmol)	  at	  0	  °C.	  After	  1	  h	  4-­‐nitrophenol	  (1.5	  g,	  10.8	  mmol)	   in	  THF	   (6	  ml)	  was	   added	   followed	  by	   triethylamine	   (1.5	  ml,	   10.8	  mmol).	  The	  mixture	  was	   then	   allowed	   to	  warm	   to	   ambient	   temperature	   overnight.	   The	  solvent	   was	   then	   removed	   in	   vacuo	   and	   the	   crude	   product	   was	   extracted	   with	  AcOEt	  and	  water.	  The	  organic	  phase	  was	  then	  washed	  with	  0.4	  M	  NaOH	  solution,	  brine,	  water	  and	  then	  dried	  over	  MgSO4.	  The	  crude	  product	  was	  then	  concentrated	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